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Summary
This study investigates 5HT receptor and a -adrenoceptor
2
subtypes. The principal technique used is radioligand 
binding. Where possible, functional correlates for the 
binding sites were examined. Once characterised the 5HT 
binding assays were used to examine the effect of 
cerebral ischaemia on 5HT neuropharmacology. Finally, 
preliminary investigations of a possible interaction of 5HT 
with -adrenoceptors were undertaken.
1. Under carefully defined conditions, 5HT binding sites
1
were identified on rat and gerbil brain membranes, using
[ H]-5HT as radioligand. 5HT and 5HT binding sites were
1A IB
characterised by 8 compounds that showed selectivity for
the two subtypes (5HT, 5CT, 8-OH-DPAT, RU24969, buspirone,
spiperone, mianserin and pindolol). 5CT and RU24969 yielded
triphasic concentration response curves in the rat but not
the gerbil cortex, providing evidence that [ H]-5HT labels
three distinct 5HT sites in these membranes. High affinity 
3 1
[ H]-5HT binding to an uptake site or 5HT1D binding site,
was absent in the rat cortex. However, preliminary studies
3
indicated that a fourth, distinct [ H]-5HT binding site was 
present on bovine cortex.
2. More selective radioligands led to better definition
of heterogeneity of 5HT binding sites. [ H]-8-OH-DPAT and 
3 1 . . .
r HI-WB4101 were found to label 5HT binding sites,
1A
predominantly in the hippocampus, characterised by high
affinity for 5HT, 8-OH-DPAT and buspirone. The binding of 
3
r HI-8-OH-DPAT was sensitive to GTP, suggesting the ligand
125
may act as an agonist. [ I]-CYP (in the presence of 30mM 
isoprenaline) was found to label the 5HT1B subtype showing 
high affinity for 5HT, cyanopindolol, and RU24969.
3. The pharmacological profile of 5HT sites in the rat
and gerbil appeared to be similar. Unlike human or pig, a
5HT site was present on gerbil brain membranes, which was 
IB
similar to the rat. A 5HT binding site in the gerbil was
1C
not evident from these studies.
14
4. The 5HT1a binding site in the hippocampus was
significantly down-regulated following chronic dosing with
an antidepressant, which suggests a possible role for this
subtype in the aetiology of depression. 5HT release studies
suggest the autoreceptor is likely to be a 5HT subtype as
1
showed by high affinity for 5HT and 5CT whereas the 5HT
2
ligand mianserin and the 5HT ligand MDL 72222 were 
inactive.
5. In peripheral tissue, a high affinity, low capacity 
[ H]-5HT binding site was identified on rat parenchymal 
lung membranes, which showed high affinity for 5HT and 5CT. 
This binding site was distinct from the 5HT uptake site as 
it showed only low affinity for imipramine and desipramine. 
No specific [ H]-5HT binding was found on guinea-pig or 
rabbit atrial membranes.
6. The kinetic and pharmacological characteristics of the
3 3 125
binding of [ H]-ketanserin, [ H]-mianserin and [ I]-LSD
to brain membranes from rat and/or gerbil were studied. All
three ligands labelled sites with the characteristics of
the 5HT binding site, showing high affinity for 5HT2
antagonists and low affinity for 5HT.
3
7. r H]-LSD was found to label a 5HT receptor on human
2
platelet membranes, the affinity of drugs to inhibit this 
binding correlated well with their ability to inhibit 5HT- 
induced platelet aggregation.
8. High affinity, saturable, reversible binding, which 
could be inhibited by 5HT antagonists, was identified in 
homb%enates of gig coronary and human umbilical arteries, 
labelled by [ I]-LSD. This binding site correlated well 
with the receptor mediating the response to 5HT in the 
isolated PCA.
15
9. A reliable, rapid and highly predictive method for 
selection of stroke-prone gerbils was developed, using a 
microscopic examination of the anastomosis between the 
anterior cerebral arteries in the circulus arteriosus. 
Isoelectric EEG recordings also proved useful for 
identifing stroke-prone animals.
10. Global unilateral ischaemia (up to 3h) and brief 
bilateral ischaemia with recovery was found to have 
pronounced effects upon the level of 5HT in two areas of 
the gerbil brain, frontal cortex and corpus striatum.
11. Unilateral cerebral ischaemia (3h) caused a 
significant ipsilateral decrease in the number of 5HT
2
binding sites in the gerbil frontal cortex, labelled by 
[ H]-ketanserin, with no significant effect on the
affinity. However, unlike 3h postmortem tissue, the 
remaining binding sites showed high affinity for 
antagonists, and therefore were still viable.
12. Bilateral ischaemia (5min) with 72h recovery also 
caused a significant decrease in the number of 5HT^ binding 
sites. Quipazine-induced head shakes, mediated via a 5HT2 
receptor, were observed in the gerbil. However, no 
significant decrease in head shakes was seen in animals 24 
or 72h following 5min bilateral ischaemia.
13. Preliminary studies were undertaken to localise 5HT^ 
binding sites in the gerbil brain using autoradiographic 
techniques. The [ I]-LSD binding was assessed to be
specific as it could be displaced by 2/xM methysergide.
14. Cerebral ischaemia (lOmin bilateral and 2h
reperfusion or 5min bilateral and 72h recovery) was found 
to cause a significant increase in the number of 5HT
1A
binding sites in the gerbil hippocampus labelled by
3 3 3
[ H]-8-OH-DPAT, [ H]-WB4101 or [ H]-5HT without an apparent
change in affinity.
16
15. A number of 5HT1A ligands (8-OH-DPAT, RU24969, 
methysergide and buspirone) showed higher affinity for the 
the -adrenoceptor on rat hippocampus compared with rat 
cortex. The displacement curves had low Hill slopes.
16. No evidence of an interaction between a -adrenoceptor
and 5HT receptors could be found in the hippocampus. 5HT 
1A 3
had no direct effect on the binding of [ H]-yohimbine at
-4
concentrations up to 1x10 M and it had no modulatory 
effects at concentrations of 1 or lOnM.
17. Chemical modification experiments indicated that the
amino acids, arginine and cysteine are essential for the
3
binding of [ H]-yohimbine to rat cortex and hippocampus 
a^-adrenoceptors.
3
18. [ H]-Yohimbine was found to label two binding sites in
rat cortex and hippocampus, shown by the biphasic curves
for prazosin, oxymetazoline, 8-OH-DPAT, methysergide and
RU24969. Both binding sites appeared to be a
3 2
-adrenoceptor-like. [ H]-Idazoxan was found to label a
subpopulation of the [ H]-yohimbine sites, equivalent to
the site with low affinity for prazosin (site B).
3
19. [ H]-Yohimbine labelled only one site on human
platelet membranes which showed some species differences to
the rat brain a -adrenoceptor binding sites.
2
This study verifies and adds to the current knowledge of
5HT receptors, and shows that 5HT is implicated in
alterations due to cerebral ischaemia. The study also adds
to the increasing literature evidence for subtypes of
a -adrenoceptors.
2
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Chapter 1: INTRODUCTION
1. INTRODUCTION
1.1. General introduction on 5HT
1.1.1 Discovery and identification of 5HT
5HT was first identified as a vasoconstrictor agent 
present in clotted blood (Rapport et al, 1948). Originally 
termed serotonin, it is now generally referred to as 
5-hydroxytryptamine (5HT;fig. 1.1) (Rapport, 1949).
Fig. 1.1 The chemical structure of 5HT
 nCHXH N H.
In mammals the main source of 5HT present in the body 
(about 90%) is found in the gastro-intestinal tract, where 
it was originally called enteramine (Erspamer and 
Asero, 1952? Stacey, 1966a). Although considerable amounts 
of 5HT are found in normal diet, the high level of 5HT in 
enterochromaffin celis does not arise as a consequence of 
5HT uptake from the intestine but by "in situ" synthesis 
from tryptophan (Douglas, 1980). 5HT is continually 
released from enterochromaffin cells out into the gut lumen 
or into the portal circulation. The release into the 
circulation can be increased by either mechanical 
stimulation of the intestine or by pharmacological 
interventions, i.e. through the activation of serosal 
muscarinic receptors (for refs, see Forsberg and Miller, 
1982) .
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1.1.2 Peripheral 5HT
Virtually all of the 5HT in the blood is contained in 
the thrombocytes (Stacey, 1966b). It has been estimated 
that 10 platelets circulating in a 70 kg adult contain in 
total approximately 500/zg of 5HT (Fozard, 1981) . The total 
quantity of 5HT in an adult is approximately lOmg (Douglas,
1980). The quantity of 5HT in the blood represents only 5% 
of the total available 5HT. In addition to 5HT associated 
with thrombocytes, plasma also contains some free 5HT. This 
fraction has been calculated to account for 3-45/ig/L 
(Crawford, 1963). Platelets do not synthesise 5HT but 
possess a high affinity uptake system, which allows a rapid 
and effective accumulation of 5HT from the surrounding 
plasma (Coppen et al, 1978; Pletscher, 1978).
The function of 5HT in platelets is obscure; one view is 
that platelets may simply remove the 5HT escaping from the 
enterochromaffin cells (Douglas, 1980). 5HT is released 
from platelets as a result of aggregation and promotes 
"platelet shape change" without inducing the "release 
reaction" (Douglas, 1980). The effect is small and 
reversible (Born, 1970 ; Graf and Pletscher, 1979) and is 
due to activation of specific receptors on the platelet
surface (5HT ) (Drummond and Gordon, 1975).
2
In addition to being in platelets and enterochromaffin 
cells 5HT is also present in the pineal gland, where it is 
mainly the percursor of melatonin. 5HT neurons have been 
identified in the peripheral nervous system, notably in 
plexuses innervating the gut. These neurons seem to have 
metabolic properties very similar to those observed in 
central 5HT neurons (Gershon, 1981).
1.1.3 Central nervous system
Considerable evidence exists to indicate that 5HT acts 
as a neurotransmitter.
1. 5HT is distributed heterogeneously within the brain 
(Dahlstrom and Fuxe, 1964).
2. The effect of iontophoretic injections of 5HT mimics 
the electrical stimulation of neurons containing 5HT
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(Aghajanian et al, 1975).
3. 5HT is released from nerve endings in response to 
electrical stimulation (Gothert, 1982).
4. The monoamine is synthesised in nervous tissue and the 
main enzymes involved with its metabolism have been 
identified (see Green and Grahame-Smith, 1975), see 
fig. 1.2.
Pig, 1,2 5HT formation and metabolism
OpH Cft,CH<pOOH NH,
tryptophan
S-hydroxylas,
CH,CH«|ON d*cTboxyU«« 
101*1.
Tryptophan 3-hydroxytryptophan
or* ^  "OpCHjCOOH
S-hydroxyindolaacatic
acid
5. 5HT is inactivated by a high affinity neuronal uptake 
system (Shaskan and Snyder, 1970).
6. 5HT pathways have been described in the brain? they 
correspond to an organised neuronal system orginating 
principally from neurona in the raphe area and 
projecting to several brain regions (Fuxe et al, 1968; 
Kuhar et al, 1972 and Aghajanian et al, 1973).
The density of 5HT terminals in the CNS is generally 
less than 5% and only a small percentage of these exhibit 
contact with other cells (Beaudet and Descarries, 1981). 
It has been suggested that the anatomical distribution of 
5HT neurons in the CNS would be more consistent with 5HT 
being a neuromodulator than a neurotransmitter (Hamon et 
al, 1984a). Indeed 5HT neurons exert an influence on 
several central functions (appetite, memory,
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thermoregulation, sleep, sexual behaviour, anxiety, 
depression and food consumption) without directly 
participating in the specific neuronal organisation 
responsible for the behaviour.
1.1.4 5HT pathways in the CMS
5HT is selectively contained in neurons with cell bodies 
mainly located in the midline area of the brainstem and 
terminals diffusely distributed throughout the CNS. The 
cell bodies of 5HT neurons supplying mainly the spinal cord 
are found in the posterior raphe nuclei, nucleus raphe 
obscurus, pallidus and magnus; whereas the projections 
innervating the forebrain regions. i.e. striatum, 
hippocampus, hypothalamus, amygdala and cerebral cortex, 
belong to the anterior raphe nuclei, nucleus raphe dorsalis 
(DRN), centralis superior and linearis rosralis. A 
schematic representation of 5HT pathways is shown in fig. 
1.3.
Fig. 1.3 5HT pathways in the rat brain
Corpus Callosum
Hippocampus
Cerebral Cor Dorsal RaphaT Nucleus 
/  Cerebellum
Stria
Terminals
/  Pons
Median Raphe' 
Nucleus Medulla
Aghajanian et al, (1970) identified pacemaker cells in 
the DRN with a slow, 1-2 spikes/sec, and highly regular
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discharge pattern which could be completely suppressed by 
systemic administration of low doses (10/xg/kg) of lysergic 
acid diethylamine (LSD) (a 5HT ligand; Gaddum, 1953). This 
suggested that the slow regular firing cells were 
serotonergic, since this type of activity was encountered 
only in areas of the brain known to contain 5HT cells.
5HT neurons in the DRN are autoactive as they are not 
influenced by the forebrain or hindbrain but controlled by 
local homeostatic responses, i.e. negative feedback. 
Adrenergic neurons have been shown to provide a tonic 
excitatory input to 5HT neurons in the DRN, whereas other 
neurotransmitters GABA, histamine, glycine and 5HT itself 
are inhibitory.
5HT, in order to produce its diverse effects on a number 
of physiological functions, is thought to bind to a 
number of specific receptors on the plasma membrane of the 
cell. The following section describes the present 
classification of 5HT receptors but first outlines the 
origins of receptor theory and the role played by ligand 
binding assays in determining receptor classification.
1.2. Receptor classification
1.2.1 The origin of the receptor concept
The concept of biological active substances 
(neurotransmitter, hormone, drug, etc) producing an action 
on an effector cell through an interaction with a specific 
protein (receptor) located on or within the cell has become 
widely accepted since the turn of the century. This 
concept is generally attributed to the work of Paul Ehrlich 
(1854-1915) and J.N. Langley (1852-1926). However, the 
French physiologist Claude Bernard (1813-1878), although 
not using the terminology of receptors "per se", was the 
first to demonstrate that functional efficacy of a drug 
depends on its access to a particular location. While 
studying the action of curare he postulated that the site 
of action was positioned between the nerve endings and the
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muscle cell. Later Langley studying the action of curare 
and nicotine on striated muscle concluded that these 
compounds acted directly on the muscle cell through a 
receptor ("receptive substance"). He furthermore stated 
that the occurrence of receptors was widespread and that it 
was through this site located within the effector cell that 
most compounds exerted their physiological actions. 
Erhlich, who concentrated on selectivity of 
chemotherapeutic agents concluded with his dictum "Corpora 
non agunt nisi fixata" (Agents cannot act unless they are 
bound).
Therefore early evidence indicated that receptors are 
specific for particular drugs or endogenous substances and 
that through this selectivity various biological systems 
are controlled. By 1970, using classical pharmacological 
techniques and neurophysiological methods the existence of 
specific receptors for a variety of endogenous 
compounds, including.neurotransmitters, was established.
Chemical neurotransmission depends upon synaptic 
communication mediated via neurotransmitters acting at 
specific receptor sites. The study of neurotransmitters 
was greatly advanced during the mid 1950's by the 
introduction of sensitive and specific assays for biogenic 
amines and the availability of radiolabelled biogenic 
amines and their precursors. Biochemical studies 
characterised mechanisms for neurotransmitter biosynthesis, 
storage, release and inactivation. By 1970 considerable 
experimental data on the catabolism and pharmacological 
profiles of various neurotransmitters was available yet 
still very little was known about neurotransmission at the 
molecular level in relation to its interaction with its 
receptor.
Classical pharmacological methods adopted for 
determining the affinity of agonists and antagonists were 
indirect and plagued by numerous experimental and 
analytical artefacts. However, during the 1960's it was 
shown that radiolabelled compounds could be used to 
directly label and define receptor binding sites. These 
binding sites exhibited the same pharmacological profile as
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that observed for specific receptors in interactive 
studies (Jensen and Jacobson, 1962; Paton and Rang, 1965). 
This ability to determine directly the affinity of agonists 
and antagonists of the receptor has established ligand 
binding as a useful additional technique in the process of 
receptor classification.
1.2.2 Receptor binding assays
Paton and Rang (1965) pioneered the first attempts to
study a neurotransmitter receptor at the biochemical level.
To measure direct binding to slices of guinea-pig ileum
[ H]-atropine was used. Unfortunately because of the low
3
specific activity of the [ H]-atropine and the high levels
of non-specific binding, the binding site was not
characterised in great detail. The application of binding
techniques to the nicotinic cholinergic receptor also
provided early success. [ H]-Muscarone was shown to bind to
nicotinic cholinergic receptors in electric organs of the
electric fish using centrifugation (O'Brian et al, 1969)
and equilibrium dialysis (O'Brian et al, 1974) separation
techniques. Shortly afterwards several groups successfully
12 5
demonstrated specific binding of [ I]-alpha-bungarotoxin 
to nicotinic receptors on membranes of the electric organ.
In the early studies virtually all drug binding involved 
non-specific sites and not pharmacologically relevant 
receptors. To detect specific binding and minimise 
non-specific binding required technical innovations; 
including the development of high affinity ligands, 
labelled to high specific activity which favours binding to 
receptors rather than to non-specific sites, improved 
membrane preparations and vacuum filtration methods for 
separating bound from free radioactivity. Vacuum filtration 
permits extensive but rapid washing of the membrane to 
remove free radioactivity and radioactive drug loosely 
bound to non-specific sites while retaining tighter bound 
drug-receptor complexes.
In vitro binding assays have in the last fifteen years 
been established for many neurotransmitter receptor systems 
and are the most direct way to characterise a receptor.
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The specificity of the receptor system is achieved if 
binding sites are saturable, reversible and show the same 
pharmacological characterisation as the receptor, and are 
stereoselective. Assays can be designed to make 
quantitative as well as qualitative assessment of the 
binding site and the use of radioligands also makes it 
possible to study ligand-receptor kinetics. Receptor 
binding assays have been used to study the receptor during 
solu bilisation, purification and reconstitution and more 
recently, as appropriate radioligands become available, to 
label membrane receptors on intact cells and to study 
receptor internalisation and other regulatory processes. 
Ultimately these experiments may lead to better 
understanding of how receptor occupation leads to the 
observed biochemical and physiological response. The 
technique has also been used to successfully label ion 
channels, second messenger systems and specific enzymes.
Direct binding studies can provide an accurate 
measurement of agonist and antagonist affinities but 
considerable caution must be taken to eliminate 
experimental errors and, perhaps more commonly, analytical 
artefacts (see Limbird, 1986). The importance of ensuring 
receptor specificity of the binding assays is emphasised by 
the ever increasing number of reports of^radioligands 
binding to non-receptor material; e.g. [ I]-insulin 
binding to glass tubes and talc (Cuatrecasas and 
Hollenberg, 1975) and specific histamine receptors on
glass fibre filters (Bielkiewicz and Cook, 1985). Therefore 
it is crucial to verify the specificity of the binding site 
by direct comparison with functional studies.
1.3. Classification of 5HT receptors
1.3.1 History
The first studies on 5HT receptors concerned their 
pharmacological characteristics on guinea pig ileum and led 
Gaddum and Picarelli (1957) to postulate the existence of 
two receptor types, M and D, based on their sensitivity to
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morphine (M) and dibenzyline (phenoxybenzamine)(D). In the 
following 20 years or so this proposal remained unchanged 
despite reservations concerning the selectivity of the 
antagonists employed. Phenoxybenzamine has been shown to 
block a-adrenoceptors (Drew, 1976) , histamine and 
acetylcholine responses on smooth muscle and M receptors 
(Day and Vane, 1963).
The introduction of a more diverse approach to the study 
of 5HT mediated responses including ligand binding, 
electrophysiology, behavioural observations as well as 
measurement of smooth muscle contractions, has led to the 
conclusion that several types of 5HT receptors exist in 
the CNS and periphery. With such a diverse experimental 
approach, a number of classifications of 5HT receptors 
have been proposed. This has both aided and hindered our 
understanding of the vast amount of data generated in the 
last 10 years. The origin and relevance of some of these 
classifications, shown in table 1.1, will be discussed 
further.
Table l.l. Proposed classifications of 5HT receptors
1. M and D classification (Gaddum and Picarelli, 1957)
2. 5HT , 5HT binding classification (Peroutka and Snyder,
1 2 
1979)
3. S , S binding classification (Leysen et al, 1981)
1 2  . . .  . .
4. S , S electrophysiology classification (Aghajanian,
1 2 
1981)
5. 5HT subtypes? 5HT , 5HT subtypes (Pedigo et al,
1 1A IB
1981). 5HT subtype (Pazos et al, 1984a). 5HT1D
subtype (Heuring and Peroutka, 1987).
6. 5HT subtypes (Richardson et al, 1985)
3
7. 5HT -like, 5HT and 5HT functional receptor
1 2 3
classification (Bradley et al, 1986)
8. 5HT-ETMIC, 5HT-ETMIF and 5HT-IL subtypes have been 
proposed for the peripheral nervous system (Wallis
1981).
9. A,A',B,C,alpha and beta 5HT receptor types have been 
identified in molluscs (Gerschenfeld and Paupardin 
-Tritsch, 1974).
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1.3.2 Ligand binding assays
Initial attempts to observe 5HT receptors directly by 
binding studies were performed by Marchbanks (1966). 
Several classes of low affinity binding sites were shown tog
exist with association constants in the order of 2x10 M 
5
and 5x10 M. Binding studies continued with equilibrium
dialysis filtration using [ H]-LSD as the radioligand
(Farrow and Van Vunakis, 1972). However, the use .of
[ H]-LSD as a ligand to label 5HT sites was limited by its
lack of selectivity; as it was also found to label dopamine
sites (Burt et al, 1976). Bennett and Aghajanian, (1974),
using rapid filtration techniques for seperating membrane
3
bound and free radioactivity, showed [ H]-LSD binding to
be saturable, reversible and display high affinity (Kd
7.5nM) for a 5HT site in the brain. The binding of
[ H]-LSD was also shown to be stereospecific, D-LSD » >
L-LSD. Moreover, [ H]-LSD binding displayed regional
variations with the highest levels of binding observed in
the brain regions known to have a large 5HT innervation.
Lesions of the raphe nucei, where 5HT neurons originate,
had minimal effects on [ H]-LSD binding, suggesting that
the receptor is associated with post-synaptic membranes.
Bennett and Snyder (1975, 1976) carried out 5HT receptor
binding in mammalian brain tissue using both [ H]-LSD and
[ H]-5HT and detected high affinity saturable binding sites
with both ligands. These early studies revealed notable
differences between the [ H]-LSD and [ H]-5HT binding sites
with regard to the density of binding sites, their
regional distribution and affinity for a number of
compounds. Two interconvertible ^states' of the 5HT
receptor were proposed with [ H]-5HT labelling the
agonist 'state' and [ H]-LSD, a mixed agonist/antagonist
labelling both the agonist and antagonist 'states'.
3
[ H]-Spiperone (a neuroleptic used to label dopamine 
receptors) was found to label a population of 5HT binding 
sites in rat frontal cortex with the same pharmacological 
profile as those labelled by ( HJ-LSD in the cortex 
(Leysen and Laduron, 1977, Leysen et al, 1978), but
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3
different to those labelled with [ H]-LSD in other brain
areas. In theory if all three ligands labelled the same
population of receptors the cold ligands would in
displacement studies give similar affinities and
displacement slopes. In fact, antagonist affinity values
derived for [ H]-LSD were found to be intermediate
3 3
between ^those for [ H]-5HT and [ H]-spiperone, suggesting
that [ H]-LSD binds to sites labelled by both [ H]-5HT
and [ H]-spiperone. However, [ H]-LSD binding sites,
determined in the presence of^300nM 5HT, appear identical
to the sites labelled by [ H]-spiperone. As a result of
these findings Peroutka and Snyder (1979) proposed
subdivisions of the 5HT binding sites as an alternative to
3
the two 'state' receptor model. Binding sites for [ H]-5HT
in membranes from rat cerebral cortex were designated as
5HT , whereas binding sites for [ H]-spiperone were 
1
designated 5HT (Peroutka and Snyder, 1979; Hamon et al, 
1981; Leysen et al, 1981). This subdivision was therefore 
initially based on the distinct binding properties of the 
two sites.
Defining the 5HT binding site was originally based upon
1
the order of potency of the 5HT indole related agonists
(the usual order obtained being 5HT > 5-methoxytryptamine >
5,6-dihydroxytryptamine > tryptamine), or the weak
inhibition by classical 5HT antagonists. Some antagonists,
such as spiperone, show shallow Hill slopes which was
interpreted by Pedigo, Yamamura and Nelson (1981) as
evidence for multiple 5HT binding sites. This gave
rise to the subdivision of 5HT binding sites into 5HT
1 1A
sites and 5HT sites.
IB
5HT sites have high affinity for spiperone (2-3nM),
1A
predominate in the frontal cortex.
5HT sites have low affinity for spiperone (35000nM),
IB
predominate m  the corpus striatum.
The existence of multiple 5HT^ binding sites was 
confirmed by other groups (Nelson et al, 1980; Cortes et 
al, 1984; Pazos et al, 1984a,b) and verified by the
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discovery and introduction of the specific 5HT ligand
8-OH-DPAT (8-hydroxy-t2- (Di-n-propylamino) tetralin)
(Middlemiss and Fozard, 1983) .
3
The introduction of [ H]-8-OH-DPAT as a specific
radioligand (Gozlan et al, 1983) . has greatly aided the
3
study of 5HT1A sites. Other ligands used include? [ H]-LSD, 
[ H]-metergoline [unsuitable because of its h i ^ 1 level of 
non-specific binding (Hamon et al, 1981)] and [ H]-WB 4101 
(Norman et al, 1985).
Characterisation of 5HT sites was aided by reports
IB
that some /9-blocking agents have high affinity for 5HT
recognition sites (Middlemiss et al, 1977; Nahorski and
Willcocks, 1983). In 1985, Hoyer and colleagues introduced
125
radiolabelled iodocyanopindolol ([ I]-CYP) as a specific
ligand for the 5HT recognition site (Hoyer et al, 1985a).
IB
RU24969 (S-methoxy-3-[1,2,3,6-tetrahydropyridon-4-yl]1H- 
indole) (Euvrard and Boissier, 1980) and 5CT
(5-carboxamidotryptamine) (Saxena and Verdouw, 1985) show 
high affinity for this site, although they are 
non-selective. The piperazine, TFMPP (1-(3-trifluoromethyl- 
phenyl) piperazine) exhibits some* selectivity for the 5HT
IB
binding site (Stills et al, 1984).
A third subtype, the 5HT binding site, was first
1C
characterised in membranes from pig choroidal plexus and
cortex (Pazos et al 198 4a; Hoyer et al 1985b) and was 
3 3
labelled by [ H]-mesulergine and [ H]-5HT. Later the
5HT binding site was identified in the rat choroidal 
1C 125
plexus using [ I]-LSD (Yagaloff and Harlig, 1985) and rat
3
frontal cortex using [ H]-5HT in the presence of 100 nM 
8-OH-DPAT and lOOnM RU24969 (Peroutka, 1986). This site 
displayed nanomolar affinity for mesulergine and mianserin, 
moderate affinity for ketanserin but was devoid of affinity 
for 8-OH-DPAT, RU24969, beta blockers and specific 5HT2 
antagonists.
Recently a fourth subtype, the 5HT1D binding site has 
been characterised in membranes from bovine brain (Heuring
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and Peroutka, 1987) and pig and human brain (Hoyer et al, 
1987a) using [ H]-5HT in the presence of lOOnM 8-OH-DPAT 
and lOOnM mesulergine.
5HT2 binding sites were first identified using
[ H]-spiperone * in the frontal cortex tissue (Leysen and
Laduron, 1977? Leysen et al, 1978). The sites are
characterised by high affinity for the classical 5HT
antagonists and low affinity for 5HT (2700juM) and 5HT-like
agonists. Although 5HT only shows micromolar affinity for
these sites it is 10Q fold more potent than at other known
neurotransmitter receptors.
New 5HT antagonist ligands have been developed which
clearly label the same binding site as [ H]-spiperone.
These include [ H]-mianserin (Peroutka and Snyder, 1981), 
3 3
[ H]-mesulergine (Closse, 1983), [ H]-methiothepine
which, although it is a potent 5HT antagonist, has
unacceptably high non specific binding and is therefore of
little use as a radioligand (Nelson et al, 1979) and the
most important [ H]-ketanserin (Leysen et al, 1982a). 
125
[ I]-LSD is a highly selective 5HT^ ligand (Hartig et 
al, 1983). It has been used successfully to label 5HT
2
sites in peripheral tissues.
A more detailed examination of the characteristics of
5HT and 5HT binding sites is discussed in chapters 3 and 
1 2
4.
The term ”5HT site” has been used to describe a number 
3
of novel 5HT binding sites (Todd and Ciarenello, 1985;
Robaut et al, 1985). Including the pre-s^naptic 5HT binding
site in the rat striatum labelled by [ H]-8-OH-DPAT which
differs from the 5HT binding site in the hippocampus
(Hamon et al, 1984b and c). However, to maintain order the
'true* 5HT binding site must be reserved for the binding 
3 3
of 5HT ligands. [ H]-ICS 205-930 (3a-tropanyl)-lH-indole 
-3-carboxylic acid ester) has recently been shown to bind 
to neuroblastoma cells (Hoyer et al, 1987b) and 
[ H]-GR65630 (3-(5-methyl-lH-imidazol-4-yl)-1-(1-methyl-lH- 
indol-3-yl)-1-propanone) has been reported to bind to rat 
brain membranes (Kilpatrick et al, 1987).
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A summary of the major advances in binding to 5HT 
receptors is shown in table 1.2.
Table 1.2 Major developments in 5HT binding studies
1975/76 Bennett and Snyder first identified 5HT binding
sites using [ H]-LSD and [ H]-5HT The differences 
in binding were explained as a two-state model of 
the receptor.
3
1977 Leysen and Laduron showed [ H]-spiperone labelled a 
5HT site
3
1979 Peroutka and Snider suggested [ H]-5HT labels a
5HT site and [ H]-spiperone a 5HT site.
1. 3 2
1981 Leysen*s group introduced [ H]-ketanserin, a
potent/selective 5HT ligand
2
1981 Pedigo et a l •subdivided 5HT sites into 5HT
1 1A
and 5HT on the basis of biphasic 
IB 3
displacement curves of [ H]-5HT by spiperone
1983 Gozlan et al introduced [ H]-8-OH-DPAT as a
specific 5HT ligand 
1A
1984 Pazos, Hoyer and Palacios identified a 5HT
3 1C
subtype labelled by [ H]-mesulergine
1985 Engel's group introduced [ I]-cyanopindolol as a
5HT ligand 
IB
1987 A fourth 5HT subtype is identified in bovine
ID
(Heuring and.Peroutka)? pig and human brain (Hoyer
et al, 1987a).
1987 A 5HT binding site is identified in rat brain
3 3
using [ H]-GR65630 (Kilpatrick et al, 1988) and on
3
neuroblastoma cells using [ H]-ICS 205-930 (Hoyer 
et al, 1987b)
1.3.3 New tools in 5HT research
The major advances in 5HT receptor classification have
arisen directly from the development of drugs with high
affinities and, in some cases, selectivity for individual
receptor sites. These include ketanserin for the 5HT site
2
(Leysen et al, 1981), 8-OH-DPAT for the 5HT subtype
1A
(Middlemiss and Fozard, 1983). 8-OH-DPAT enantiomers show
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stereoselectivity at the 5HT site, in binding and
1A
functional tests (Fozard et al, 1987). Selective ligands
for the 5HT subtype include CGS 12066B (7-trifluoromethyl 
IB
-4(4-methyl-1-piperazinyl)-pyrolo(l,2-a)guinoxaline) (Neale
et al, 1987). Up to now no selective compounds have been
developed for the 5HT and 5HT subtypes. In contrast
1C ID
selective agonists and antagonists are available for the
5HT receptor. Table 1.3 lists the most selective drug 
3
tools for 5HT receptor pharmacology, at the present time.
5HT^ ligands listed in table 1.3, which have not so far 
been referred to in the text, include DOB (4-bromo-2,5- 
dimethoxyphenyl-isopropylamine); MDL 72222 (laH, 3a, 5aH- 
tropan-3-yl)3,5-dichlorobenzoate) and BRL 43694 (endo)-N- 
[9-methyl-9-azabicyclo(3,3,1)non-3-yl]-l-methyl-indazole-3- 
carboxamide).
1.3.4 Functional receptors for 5HT
Several subtypes of 5HT receptors have been discussed 
above and as stated, the first subdivision of 5HT 
receptors stems from Gaddum and Picarelli, (1957). In the 
guinea-pig ileum 5HT causes excitatory responses due to two 
mechanisms: 1. Stimulation of neuronal M (morphine)
receptors which result in acetylcholine release from 
post-ganglionic cholinergic neurons of the intramural 
plexus. 2. Stimulation of D (dibenzyline) receptors on 
smooth muscle of the guinea-pig ileum. Gaddum and Picarelli 
did substantiate their results using LSD and 
dihydroergotamine (LSD was a particularly potent antagonist 
of the D receptor) and cocaine which selectively 
antagonised the M receptor. This latter finding has since 
been confirmed (Fozard et al, 1979). The conclusion reached 
that two receptors for 5HT exist in the guinea-pig ileum 
has not been invalidated (see Feniuk, 1984; Fozard, 1984a; 
Humphrey, 1984), and this original proposal is used as the 
basis for the present functional classification.
Guinea-pig ileum M receptors have properties in common 
with rabbit heart pre-junctional excitatory receptors 
(Fozard and Mobarok Ali, 1978a), and are similar to the 5HT 
receptor subtype that initiates the Bezold-Jarisch reflex
32
Table 1.3 New tools in 5HT research
Drug site(s)-action receptor affinity
5HT agonist 
1A
5HT agonist 
1A
5HT1A partial agonist
5HT partial agonist 
1A
5HT antagonist 
1A
5HT agonist 
IB
5HT antagonist 
IB
8-OH-DPAT
DP-5CT
buspirone
ipsapirone
spiperone
TFMPP
iodocyano-
pindolol
very selective 
D
2
D
2
D , 5HT , a 
2 2 1
P P 
1 2
mesulergine
mianserin
5HT antagonist 
1C
5HT antagonist 
1C
5HT , D 
2 2 
5HT , H , a 
2 1 2
yohimbine 
rauwolseine
pindolol &
cyanopindolol
RU24969
5CT
5HT ligand 
ID
5HT 1igand 
ID
a
a
P P 1 25HT antagonist 1A
5HT partial agonist 
IB
5HT , 5HT agonist, 5HT antagonist?
IB 1A ID
5HT , 5HT & 5HT agonist
1A IB ID
DOB 5HT9 agonist
methysergide 5HT9 antagonist
cyproheptadine 5HT9 antagonist
ketanserin 5HT9 antagonist
ritanserin 5HT
2
antagonist
2-methyl-5HT 5HT9 agonist
MDL 72222 5HT9 antagonist
ICS 205-930 5HT9 antagonist
BRL 43694 5HT9 antagonist
Ondanetron 5HT
3
antagonist
5HT -like agonist 
muscarinic
5HT
1C
This table is based on that shown used by Fozard, (1987) 
and has been modified to include the majority of the 
compounds used in this thesis.
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(Fozard and Host, 1982), now termed 5HT . However, close
3
analysis of the neuronal excitatory responses induced by
5HT in guinea-pig .enteric neurons (Buchheit et al, 1985)
reveals that Gaddum and Picarelli1s M receptor is not a
5HT^ receptor. The guinea-pig D receptor is very similar to
the 5HT^ receptor found on vascular smooth muscle (Humphrey
et al, 1982; Maayani et al, 1984) although this was
disputed by Leysen et al, (1982a). The 5HT receptor
antagonist ketanserin is ineffective at the D receptor in
guinea-pig ileum (Van Neuten et al, 1981 and 1983).
A third type of 5HT functional response which mediates
the actions of 5HT via receptors distinct from 5HT and
2
5HT receptors, is more difficult to define. It may in
3
some cases be similar to the heterogeneous group of 5HT 
binding, sites. Criteria was proposed for classification of 
these receptors as M5HT -like" by Bradley et al,(1986) 
(table 1.4).
Table 1.4. Summary of proposals for classification and 
nomenclature of functional 5HT receptors
proposed
receptor Typical response agonist 
nomenclature
antagonist binding 
site
5HT -like 1 Autoreceptor, 5CT Methysergide 5HT ?1X
smooth muscle (sm) 
relaxation, 
contraction of 
some vascular sm 
tachycardia in cats
Methiothepin
5HT GI tract and vascular Ketanserin 5HT
2
sm contraction,
2
Methysergide
platelet aggregation, 
neuronal depolarisation
Cyproheptadine
5HT Depolarisation 2-methyl-5HT Cocaine ?
of peripheral MDL 72222
neurons ICS 205-930
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The classification of Bradley et al, (1986) emphasized 
the co-identity of Gaddum and Picarelli's D receptor and 
the 5HT^ binding site, conceded the likely heterogeneity of 
"5HT^-like" receptors and introduced a new category, 5HT , 
which superceded the M receptor of the functional 
classification. Although a useful reference the Bradley et 
al classification is rapidly becoming out of date. It is 
now abundantly clear that subtypes of "5HT -like" receptors 
are very much a reality (Glennon, 1987).
Functional correlates of 5HT binding sites
Until recently the lack of specific and selective
antagonists for the 5HT^ binding sites has hindered the
search for functional correlates (see Bradley et al, 1986).
However, a classification based on functional data for
"5HT -like" receptors was proposed for the following 
1
reasons
1. The carboxamide analogue of 5HT, 5CT was found to have
a greater affinity for the 5HT^ binding site than for
the 5HT binding site (Engel et al, 1983).
2
2. In functional studies 5CT was found to mimic with equal 
or greater potency, the response of 5HT in tissues 
where the receptor did not fit the D or M 
classification (Feniuk et al, 1983, 1985).
3. 5CT was less potent at 5HT2 receptors (Feniuk et al,
1985), and at M receptors (Humphrey, 1984).
"5HT -like" receptors are associated with pre-junctional 
1
inhibition of neuronal transmitter release, smooth muscle
relaxation and contraction of some cardiac and vascular
smooth muscle. Some peripheral "5HT^-like" receptors have
been identified with 5HT binding subtypes; inhibition of
1 . 
transmitter release from guinea-pig cholinergic neurons is
via a 5HT receptor (Fozard and Kilbinger, 1985) whereas 
1A
inhibition of noradrenaline (NA) release in the rat vena
cava is via a 5HT receptor (Molderings et al, 1987). The
IB
response to 5HT in the mouse bladder is via a 5HT 
* IB
receptor (Holt et al, 1986), whereas in the rat fundus
(Cohen and Fludzinski, 1987) and rat perfused kidney
(Charlton et al, 1986) the response is mediated via a
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5HT receptor which is not 5HT , 5HT or 5HT . This
1 1A IB 1C
receptor type shows moderate affinity for yohimbine so it
could belong to the 5HT^ subtype, although has yet to be
shown.
Peroutka has suggested the existence of a 5HT receptor
mediated contraction on canine and human basilar arteries
(Peroutka et al, 1983; Peroutka, 1984).
5HT^ receptors are also involved in the 5HT behavioural
syndrome (Lucki et al, 1984) providing evidence for
functional central . 5HT receptors. The effect is most
characteristically seen in rodents, but also observed in
other animals and consists of; hindlimb abduction, forepaw
treading and Straub tail. Tricklebank, (1984a,b) has shown
that agonists selective for 5HT and 5HT subtypes,
1A IB
induce different behavioural patterns.
Functional correlates for 5HT binding sites
2
A 5HT mechanism may also be involved in certain central 
2
behavioural effects produced by 5HT agonists (Glennon,
1986; Tricklebank, 1985). 5HT agonists induce head
2
twitches (Green and Heal, 1985).
Various groups have pointed out the similarity of the
5HT binding site and the vascular D receptor in the rabbit
2
aorta (Humphrey et al, 1982; Maayani et al, 1984),
guinea-pig ileum (Engel et al, 1984a and b) and in other
vascular tissues from the rat (Bradley et al, 1983; Cohen
et al, 1981). The affinity of a number of 5HT antagonists
was similar when determined by ligand binding or in vitro
isolated tissue experiments. Since ketanserin
differentiated the 5HT and 5HT binding sites it has been
1 2
used widely as a probe in 5HT receptor characterisation.
The vascular 5HT (D) receptor has been identified in many
2
tissues (see table 1.4, Humphrey, 1984). However, 
ketanserin is ineffective at the D receptor on guinea-pig 
ileum (Van Neuten et al, 1981 and 1983) which has been 
clearly identified as a 5HT receptor; a highly significant 
correlation was found for the potency of a series of 
antagonists (except ketanserin) to inhibit the contraction 
of the guinea-pig ileum and for their affinity at the 5HT^
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binding site (Engel et al, 1984a and b). In addition the 
rank order of potency of a series of agonists for causing 
contraction of guinea-pig ileum and of the rabbit aorta, 
which is undoubtedly 5HT2r was the same (Humphrey et al, 
1982; Maayani et al, 1984; Feniuk et al, 1985).
Thus the D receptor classification was becoming confused 
and has now been broadly replaced by the 5HT receptor 
terminology. Dibenzyline has been shown to have only weak 
affinity for the 5HT binding site on rat cortex membranes 
(Leysen et al, 1981).
Another difficulty in classifying 5HT receptors in this 
group occurs through the fact that 5HT at higher 
concentrations can act through other receptor types 
particularly a-adrenoceptors. Many a-adrenoceptor and 5HT 
antagonists have some affinity for both receptor types. 5HT 
has been shown to act both directly (Apperley et al, 1976; 
Fozard, 1976) and indirectly (Fozard and Mwaluko, 1976) on 
a-adrenoceptors. In the rabbit ear artery no difference is 
seen in the response to NA and 5HT when blocked by either 
phentolamine or cyproheptadine. Therefore, NA and 5HT are 
both acting through a common a-adrenoceptor (Apperley et 
al, 1976). In the rabbit aorta phentolamine and 
cyproheptadine have been shown to act through different 
receptors so that both 5HT receptors and a-adrenoceptors 
are distinguishable (Apperley et al, 1976).
Methysergide (developed by Doepfner and Cerletti, 1958) 
may be an important drug for classifying 5HT receptors on 
smooth muscle. It has a 300-400 fold higher affinity for 
5HT receptors than for a-adrenoceptors. The nature of 
action of methysergide differs between smooth muscle 
preparations. It acts as a highly specific antagonist of 
the contractile action of 5HT in smooth muscle when this 
response is seen (5HT ) and it acts as a partial agonist in 
other smooth muscle preparations where 5HT is inhibitory
("5HT -like”).
1
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Functional 5HT receptors
The term 'M receptor1 has been synonymous with 
'peripheral neuronal receptor' no matter the anatomical 
location or the functional response which it mediates (see 
Wallis, 1981). This is despite criticisms of the basis of 
the classification and no doubt reflects in part the 
initial lack of selective antagonists of these neuronal 
receptors.
Neuronal receptors have been reviewed from two main 
approaches; from functional pharmacological studies 
(Fozard, 1984a) and from electrophysiological studies 
(Wallis, 1981). Each has suggested a tentative 
classification.
Two "functional” preparations have been the focus of 
attention in the study of peripheral neuronal receptors for 
5HT. In the guinea-pig ileum the 5HT-induced contraction is 
mainly indirect and due to the release of acetylcholine 
from pre-junctional neurons. Stimulation of acetylcholine 
release was shown to be mediated by specific receptors 
since 5HT (D) receptor antagonists and antagonists of 
other receptor types could not selectively block the 
response to 5HT (Day and Vane, 1963). However, the 
receptors could be rapidly and selectively desensitised by 
5HT (Gaddum, 1953; Brownlee and Johnson, 1963). These 
receptors were designated as M receptors (Gaddum and 
Picarelli, 1957). The receptor in the guinea-pig ileum was 
insensitive to blockade by phenylbiguanide, an effective 
antagonist at neuronal receptors for 5HT in the mouse 
duodenum (Drakontides and Gershon, 1968) and which first 
indicated a difference between these M receptors.
The indirect positive inotropic effect of 5HT on the 
isolated rabbit atrium was antagonised by morphine and 
cocaine, and abolished by prior reserpinisation of the 
animal. The receptor mediating this response via release of 
neurotransmitter (NA) from sympathetic neurons was also 
described as the M receptor (Trendelenburg, 1960).
However, it has been demonstrated that differences exist 
between the M receptors in the guinea-pig ileum and rabbit 
heart. In the Langendorff perfused rabbit heart the
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positive chronotropic effect of 5HT was not selectively 
antagonised by morphine (Fozard and Mobarok Ali, 1978a). 
Furthermore the concentration of morphine which gave a 
non-selective inhibition (10/xg/ml) of the 5HT response was 
100 times greater than the concentration of morphine which 
blocked 5HT-induced transmitter release from cholinergic 
neurons in the guinea-pig ileum (Day and Vane, 1963).
Characterisation of the 5HT receptor(s), was 
facilitated by the identification of a selective 
antagonist, MDL 72222 (Fozard, 1984b). At nanomolar 
concentrations MDL 72222 blocked the 5HT-induced release of 
transmitter from sympathetic neurons of the rabbit heart 
(Fozard, 1984b). Several other M receptors were 
identified on post-ganglionic sympathetic neurons, 
parasympathetic neurons and on afferent neurons. All of 
these receptors were susceptible to blockade by MDL 72222, 
and in each case were excitatory in nature (see Fozard, 
1984a). MDL 72222 also confirmed earlier findings that the 
M receptor in the guinea-pig ileum was different from the 
other excitatory M receptors. MDL 72222 has negligible 
affinity for the M receptor in the guinea-pig ileum 
(Fozard, 1984b). Metoclopramide a competitive antagonist 
at excitatory 5HT receptors on post-ganglionic sympathetic 
nerves and on afferent neurons (Fozard and Mobarok Ali, 
1978b; Fozard and Host, 1982) is a partial agonist at M 
receptors in the ileum (Kilbinger et al, 1982). The 
selective agonist 5-methoxytryptamine similarly shows a 
difference between the M receptor in the guinea-pig ileum 
and the other excitatory neuronal receptors; in the rabbit 
heart 5-methoxytryptamine is inactive while in the ileum it 
is a partial agonist (Fozard and Mobarok Ali, 1978a).
In a separate but almost parallel study selective 
agonists and antagonists were identified which pointed to 
subtypes of M receptors in different M receptor systems 
(Richardson et al, 1985). The agonist 2-methyl-5HT was 
equipotent at M receptors in the rabbit heart, guinea-pig 
ileum and rabbit vagus nerve (although approximately 2 fold 
less potent than 5HT) while a-methyl-5HT was less potent 
than 2-methyl-5HT, but to a different degree, in each
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preparation.
A series of highly potent and selective Sandoz compounds
confirmed that the M receptors in the three systems were
different. ICS 205-930 differentiated between the
receptors in the rabbit vagus nerve (pA 10.2), rabbit
2
heart (PA2 10.8) and m  the guinea-pig ileum (pA 7.8). In 
receptor binding studies ICS 205-930 was shown to be highly 
selective as it lacked affinity for the receptor types 
tested: 5HT^, 5HT2' a r Pr dopamine, histamine, muscarinic.
These excitatory receptors which are blocked by either
MDL 72222 or ICS 205-930 now make up the category of
receptors known as 5HT receptors. (Bradley et al, 1986). A 
number of new 5HT antagonists, which are also very
selective, have been introduced; Ondanetron (GR38032F)
(Brittain, et al, 1987) and BRL 43694 (Fake et al, 1987).
1.3.5 Second messenger systems linked to 5HT receptors
The biochemical mechanisms involved in receptor effector
coupling have been characterised for the 5HT , 5HT ,
1A IB
5HT , 5HT and 5HT receptor subtypes.
1C ID 2
1. Adenylate cyclase
Barbaccia et al, (1983) first suggested that a 5HT
receptor as defined by Peroutka and Snyder, (1981) might
activate adenylate cyclase in the rat hippocampus.
Adenylate cyclase coupled to a number of receptors,
catalyses the formation of cyclic AMP from ATP. 5HT was
later shown to activate adenylate cyclase in the guinea-pig
hippocampus through a receptor which, based on the potency
of 5CT, was suggested to be the 5HT1A site (Shenker et al,
1985). This was questioned by De Vivo and Maayani, (1986)
who suggested that 8-OH-DPAT was less potent than would be
expected and acted as only a partial agonist. Markstein et
al, (1986) confirmed that the action was through a 5HT
1A
site by examining the rank order of potency of 13 agonists
for stimulation of adenylate cyclase activity and showed
there was good agreement with the rank order of affinity
for the 5HT binding site but not for the 5HT , 5HT or 
1A IB 1C
5HT sites.
2
Under appropriate assay conditions 5HT^ receptors might
40
inhibit adenylate cyclase. De Vivo and Maayani, (1985)
demonstrated that 5H T ^  agonists selectively inhibited
adenylate cyclase stimulated by forskolin in the guinea-pig
and rat hippocampus. Weiss et al, (1986) indicated that in
intact murine cortical and striatal neurons, 5HT receptor
1A
agonists inhibit cAMP accumulation induced by vasoactive
intestinal polypeptide. Therefore, present results, suggest
that 5HT1A receptors are linked to adenylate cyclase
although activation (via Gs) or inhibition (via Gi) of the
enzyme depends on the pre-exsisting state of activation.
It has been suggested that the 5HT binding
IB
sites in rats are presynaptic autoreceptors (Hibert and
Middlemiss, 1986; Engel et al, 1986). However, selective
lesioning (Verge et al, 1985, 1986) as well as controversy
over the species location of the binding site has failed to
support this. The 5HT sites have been shown to be linked
IB
in an exclusively negative way to adenylate cyclase.
5HT receptors have recently been shown to be linked to 
ID
adenylate cyclase in the calf substantia nigra (Hoyer and 
Schoeffter, 1988).
2. Alteration in K conductance
Berridge (1981) suggested that the hyperpolarizing
response to 5HT is probably via a 5HT receptor and
1
mediated by cyclic AMP. Vandermaelen and Aghajanian,
(1983) proposed that 5HT may alter the activity of
calcium-activated K channels in the dorsal raphe nucleus.
However, Andrade et al, (1986) recently demonstrated that
5HT, possibly via 5HT receptors, increases K ion
conductance in hippocampal CA1 neurons and that this
response was unaffected by application of cyclic AMP or by
chelation of intracellular Ca . The 5HT response was
abolished by prior treatment with pertussis toxin which
suggests that hippocampal 5HT receptors may be directly
+ 1A
coupled to neuronal K channels via pertussis toxin- 
sensitive G proteins (Andrade et al, 1987).
3. PI metabolism
Jafferji and Michell, first demonstrated 5HT activated 
PI metabolism in mammalian tissues in 1976. However, it was 
nearly ten years before preliminary evidence for the
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coupling of 5HT2 receptors to PI metabolism was shown in 
brain (Conn and Sanders-Bush, 1984), vascular smooth muscle 
(Roth et al, 1984) and platelets (Leysen et al, 1984). The 
ability of 5HT to mobilise intracellular calcium in 
platelets is related to an interaction of 5HT with 5HT
2
receptors (Affolter et al, 1984). Conn and Sanders-Bush
(1985 and 1986) later showed that a good correlation
existed between the Kd value determined for ketanserin
inhibition of 5HT-stimulated turnover of phosphoinositides,
and its affinity for the 5HT binding site in the rat
frontal cortex. However, the affinities of other
antagonists were not correlated in the two measurements
(Kendall and Nahorski, 1985).
5HT^ receptors in the hippocampus may also be coupled to
PI metabolism. Janowsky et al, (1984) showed that
the 5HT-stimulated PI hydrolysis was attenuated by
metergoline but not significantly by the 5HT antagonist
mianserin. Additionally the response was less sensitive to
the 5HT antagonist ketanserin in the hippocampus than in 
2
the cortex (Conn and Sanders-Bush, 1985).
Activation of the 5HT receptor in the rat choroidal
1C
plexus has also been shown to increase phosphatidylinositol 
turnover providing a possible functional correlate for this 
binding site (Conn and Sanders-Bush, 1986).
Activation of the 5HT receptor results from a fast
3
depolarisation which may be very tightly coupled to ion 
channels (Fozard 1984a).
1.3.6 Classification of 5HT receptors using 
electrophysiological techniques
Aghajanian, (1981) described three types of 5HT 
receptors using electrophysiological techniques:
51 A receptor facilitating excitation which is blocked 
by cinanserin.
52 A receptor decreasing neuronal excitability which is 
not blocked by classical 5HT antagonists. However, 
5HT is ten times more potent than LSD and 5HT 
selective agonists are effective.
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S3 An autoreceptor which is not blocked by classical 5HT 
antagonists and where LSD is more potent than 5HT.
The S2 receptor, characterised in the dorsal raphe
nucleus of the rat has been shown to be homologous with
the 5HT1A high affinity binding site (De Montigny et al,
1984) and does not resemble the S2 (5HT ) binding site.
2
A number of anomalies in the classification of 5HT 
receptors have been highlighted in this introduction, 
clearly some degree of uniformity is needed between 
binding, functional and electrophysiological studies. A 
summary of the current classification of 5HT receptors, 
adopted for this thesis is shown in table 1.5.
1.4 Clinical significance of advances in 5HT research
As knowledge of 5HT subtypes and their functions
increase then the scope for selective modulation of 5HT
mechanisms for therapeutic benefit to man also increases.
5HT partial agonists, such as buspirone, have been shown
to reduce the elevated neuronal activity associated with
anxiolysis. This could, theoretically, be achieved by
depressing 5HT neuronal firing (Andrade et al, 1987),
decreasing 5HT turnover (Hjorth and Carlsson, 1982) or
blocking 5HT post-synaptic receptors (Andrade and Nicoll, 
1A
1987). A central antihypertensive activity is also
associated with 5HT partial agonists. 5HT antagonists
1A 2
are being investigated for psychiatric conditions such as
schizophrenia, depression and anxiety. The recently
introduced 5HT compounds are also being investigated for
3
anxiolytic and antipsychotic properties, as well as for the 
treatment of migraine.
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Chapter 2: METHODS
2. METHODS
2.1. Binding Methodology
2.1.1a Membrane preparation 
Preparation of rodent membranes
A washed, total membrane fraction of the rat or gerbil
brain regions was used in the majority of binding studies.
Male Sprague Dawley rats (CD[SD] Charles River UK LTD)
(150-250g) were killed by cervical dislocation. Mongolian
gerbils (Shamrock farm, England) (60-80g) were killed by
decapitation following 6mg pentobarbital sodium (i.p.)
anaesthesia. The brains were rapidly removed and the
appropriate areas, cerebral cortex, frontal cortex
(anterior to the optic chiasma), neostriatum, hippocampus
or cerebellum carefully dissected on ice. These and all
o
subsequent operations were performed at 4 C. Heart and lung
tissue was removed when required.
Tissue was homogenised in 25 vol ice cold Tris HC1
buffer (50mM Tris HC1; pH 7.4), using a polytron PT10
tissue disrupter (setting 5, 2 x 10s bursts). The
homogenate was centrifuged at 30000xg in a refrigerated
o
centrifuge (Sorvall RC-5B) (4 C) for lOmin. The supernatant
was discarded and the crude membrane pellet washed by
centrifugation at 30000xg and resuspended in 25 vol ice
cold Tris HC1 buffer. After the third wash the resuspended
pellet was incubated in 25 vol Tris HCl buffer (pH 7.4 at 
o o
37 C) at 37 C for lOmin to remove endogenous 5HT (Nelson et
al, 1978), before being recentrifuged at 30000xg for lOmin 
o
at 4 C. The final crude membrane pellet was resuspended in 
the 3ml buffer and stored under liquid nitrogen. Membranes 
could be stored for up to 6 weeks without significant 
changes in receptor number or other binding
characteristics.
Preparation of human platelet membranes
The membranes were prepared essentially as described by 
Cheung et al, (1982). Blood was collected from male or 
female volunteers, with 3.9% (w/v) sodium tricitrate as
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anticoagulant. Platelet rich plasma (PRP) was obtained by
centrifugation at 200xg for lOmin. The PRP was then
o
centrifuged at 25000xg for lOmin at 4 C and the resultant
pellet resuspended in ice cold lysing buffer (5mM Tris HC1,
5mM EDTA, pH 7.4), homogenised using a polytron PT10 tissue
disrupter (10s) and again centrifuged at 25000xg for lOmin.
The pellet was washed once more with lysing buffer by
gentle resuspension and then centrifugation before a final
wash in Tris buffer (50mM Tris HC1? pH 7.4) followed by
o
centrifugation at 25000xg for lOmin at 4 C. The final
pellet was resuspended in assay buffer for immediate use in
the binding assay or stored under liquid nitrogen.
Preparation of vascular smooth muscle membranes
Pig hearts were collected from the abattoir and the
left descending coronary artery removed and cleaned of any
fatty adventitious tissue. The arteries (10-12/preparation)
were then finely chopped and homogenised in 25ml of ice
cold 0.25M sucrose. A ground glass-teflon homogeniser was
found to be the most efficient method. Membranes were
prepared from an initial centrifugation at lOOOxg for lOmin 
o
at 4 C followed by a second centrifugation of the
o
supernatant at 39000xg for 15min at 4 C. The membranes were
then washed twice by resuspension in assay buffer (50mM
Tris HC1, 5.7mM ascorbate, 4mM CaCl , 10/xm pargyline; pH
2
7.4) followed by centrifugation at 39000xg for 15min at 
o
4 C. The final pellet was resuspended in assay buffer for
direct use in the binding assay.
Human umbilical arteries (HUA) were collected in liquid
nitrogen, then thawed and cleaned of small amounts of fatty
adventitious tissue. The arteries (6/preparation) were
finely chopped and homogenised in 25ml of ice cold 0.25M
sucrose. Membranes were prepared from an initial
o
centrifugation at 15000xg for lOmin at 4 C and then
o
respining the supernatant at 60000xg for 30min at 4 C, in a 
Beckman L8-M ultracentrifuge. The final pellet was then 
resuspended in assay buffer for direct use in the binding 
assay.
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2.1.1b Equilibrium binding studies
Assays were carried out in a total volume of 1 or 2ml in
polypropylene disposable assay tubes (Sterlin 4.9ml). The
membrane suspension was allowed to thaw at room temperature
and diluted with the assay buffer (50mM Tris HC1; pH 7.4 at 
o
37 C containing 5.7mM ascorbate, 4mM CaCl and 10/xm
2
pargylme) unless otherwise stated, before being added to
o
the assay. Reagents were stored at 4 C before use and
o
preincubated at 37 C for lOmin before binding was initiated
by adding the membrane preparation (routinely 150-500jLtg
protein) with the radioligand and other assay additions.
Tubes were rapidly vortexed and incubated to equilibrium in
a thermostatically controlled water bath maintained at 
o
37 C. Non-specific binding (nsb) was defined as the 
amount of radioactivity bound in the presence of a very 
large excess of the neurotransmitter itself or a highly 
specific drug. Separation of bound from free ligand was 
achieved by diluting samples with 2ml of ice cold assay 
buffer to slow down the reaction and allow easy transfer 
from the assay tube, followed by vacuum filtration (22mm 
Hg) through wet Whatman GF/B glass fibre filters mounted 
either on a millipore 12 port filtration manifold 
(Millipore 1225) or on a Brandel (M-24R) cell harvester. 
Filters were washed with 15mls of room temperature assay 
buffer to remove trapped free ligand, dried under reduced 
vacuum and then transferred to scintillation vials and the 
radioactivity determined by liquid scintillation 
spectrometry. In all experiments total ligand concentration 
was determined by counting aliquots of the radioactive 
stock or aliquots taken from two additional "unfiltered" 
total tubes. Free ligand was estimated by subtracting the 
concentration of total bound ligand from the total ligand 
concentration and specific binding was determined by 
subtracting nsb from total binding.
2.1.1c Separation of bound from free ligand
Separation of bound from free ligand was carried out 
under constant vacuum (22mm Hg). The optimal number of 
washes was determined 1-5 x 5ml washes with room 
temperature buffer or ice cold buffer. Later studies were
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carried out using a Brandel M24 cell harvester. Again a 
constant vacuum pressure of 22 mm Hg was used and the 
optimum washing conditions determined, 10,20 or 30s at a 
constant flow rate of 1.5L/min.
2.1.Id Filter binding of ligands
Aliquots (1ml) of assay buffer containing either a 
saturable concentration of the radioligand or a 
concentration close to its Kd were diluted with 2ml of ice 
cold buffer and filtered under vacuum over Whatman GF/B 
glass fibre filters, which had been pretreated with 
inactivated (boiled) membranes to simulate the retardation 
of the filtration process produced by the presence of 
membrane suspension in binding assays. The filters were 
then washed with 3 x 5ml aliquots of room temperature 
buffer, and the radioactivity retained on the filters 
determined by liquid scintillation spectrometry. To assess 
the effect of non labelled compounds on radioligand filter 
binding, some of the routinely used competitors were 
included in parallel assays at the highest concentration 
used in binding studies.
2.1.1e Measurement of radioactivity
The glass fibre filters or samples containing 
radioactivity were added to 8ml of LKB optiphase 'MP' 
liquid scintillation fluid and shaken for l-2h. This was 
necessary to ensure elution of filter-bound radioactivity. 
The radioactivity present in the samples was subsequently 
determined by counting for 3min in a Packard Tricarb 460C 
liquid scintillation counter. The counts per minute (cpm) 
were converted to disintegrations per minute (dpm) using 
the Packard quench indicating parameter (QIP). A typical 
quench curve, produced in the presence of glass fibre 
filters is shown in fig. 2.1. The QIP values for samples 
ranged from 550-650, an efficiency range of 35-45%.
Iodinated samples were counted in an LKB 1282 gamma 
counter. Filters were counted directly for lmin.
2.1.If Protein assay
Membrane protein was determined using a protein assay 
kit, Pierce BCA protein assay (Smith ^et al, 1985). This 
method utilises the interaction of Cu with proteins in
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TRITIUM QUENCH CURVE FOR THE PACKARD 460C  SCINTILLATION COUNTER
Q1
02
Q3
Q4
Q5
20 Q6
JPQ7
j*Q8
JW9
+Q10____________________
260 400 53o
quench Indicating parameter (QIP)
10
860
Fig. 2.1 The quench curve was constructed using a tritium
standard, absolute activity 1.44x10 DPM/cm , and a series
of 10 quenched samples. Each vial contained 8ml scintillant
and 1ml of the standard H solution. After counting and
discarding any vials not falling within a 95% confidence
limit, the quenching agents were added: QO unquenched, Q1
absolute alcohol, Q2 2% acetone, Q3 8% acetone, Q4 20%
acetone, Q5 2% CC1 , Q5 3% CC1 , Q6 4% CC1 , Q7 4% CC1 , Q8
4 4 4 4
6% CC1 , Q9 8% CC1 and Q10 12% CC1 , and the samples
4 4 4
recounted. A plot of efficiency (eff= CPM/AA) against the
quench indicating parameter is shown. The QIP values for
samples in these studies ranged from 550-650, an efficiency
range of 35-45%.
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+
an alkaline medium to give free Cu which then binds to a 
, 4*
highly sensitive and selective detecting agent for Cu ,
bicinchoninic acid (BCA). The protein samples were mixed
with the BCA reagent and incubated for two hours at room
temperature, before the absorbance of the solution was read
at 562nm wavelength in a Pye Unicam SP 1800 UV
spectrophotometer. Membrane protein was determined against
standard solutions of bovine serum albumin (BSA) containing
25-250/ig protein.
Early protein determinations were made using a
modification of the method of Lowry et al, (1951).
2.l.lg Tissue linearity of binding
Equilibrium binding was determined as described in
section 2.1.1b except that the assay protein content was
varied between 25-2000/xg. In these experiments total and
nsb was determined in triplicate
2.1.1h Kinetic experiments
1. Association
The membrane suspension (final assay concentration
200-500/xg) and radioligand (final assay concentration <Kd)
o
preincubated at 37 C were combined in a total volume of
o
lml. The tubes were rapidly mixed and incubated at 37 C for 
varying time intervals (l-60min), before separating bound 
from free ligand by vacuum filtration using manifolds as 
described previously. Nsb was determined in parallel 
incubations. For each time point both total and nsb were 
determined in triplicate.
2. Dissociation induced by excess of cold competing ligand
The membrane preparation (final assay concentration
200-500jitg) and radioligand (final assay concentration <Kd)
o
were preincubated separately at 37 C for 20min before being 
combined in a total volume of 50mls and incubated to 
equilibrium. Dissociation was initiated by adding and 
rapidly mixing 100/Lil of the non-specific ligand. 
Aliquots (lml) were then removed at varying time periods 
and bound radioactivity separated from free as described 
previously. Nsb was determined in parallel incubations.
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2.1.11 Saturation binding assays
Equilibrium binding was determined as described in 
section 2.1.1b except that the free ligand concentration 
was varied over a saturable range. Total binding, in 
triplicate, and nsb, in duplicate, were determined for each 
ligand concentration. Free ligand concentration was 
determined at each ligand concentration as described in 
section 2.1.1b.
2•1•1j Competition studies
Equilibrium binding of a fixed concentration of 
radioligand (<Kd) was determined in duplicate as described 
in section 2.1.1b in the presence of a range (7-20) of 
concentrations of the competing ligand. Total and nsb were 
determined in duplicate before and after each competing 
ligand and the free ligand concentration was determined as 
in section 2.1.1b.
2.1.1k Data analysis
The theoretical basis of direct radioligand binding 
techniques is discussed in appendix 1.
1. Raw data manipulation
Raw data obtained from the liquid scintillation counter 
were transferred directly to a floppy disc data file on a 
Cromemco 64K or a BBC model B microcomputer. Transformation 
of the raw data into a format suitable for subsequent 
analysis was performed using a series of analysis 
programmes written for the Cromemco 64K or the BBC model B 
microcomputer.
2. Prefitting raw data
Experimental data were analysed using a combined 
graphical and analytical approach. A prefitting programme 
enabled a graphical output of the data, in an appropriate 
coordinate system. Isotherms describing the kinetic, 
saturation binding (Scatchard, 1949) or competition 
isotherms for single or multiple species of interacting or 
non-interacting sites could be superimposed upon the data 
points for visual inspection, and a series of graphical 
aids utilised to modify parameter estimates describing 
individual models. In this way it was possible to inspect 
visually the suitability of different models for describing
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the experimental results. When appropriate, the parameter 
estimates obtained graphically were utilised as initial 
estimates for further determinations in programmes which 
allowed statistical analysis.
3. Analysis of saturation binding data
Fitting of data to the appropriate models was achieved 
using the Scafit non-linear regression analysis programme 
for LIGAND (Munson and Rodbard, 1980). Comparisons between 
different binding models were made using the extra sum of 
the squares principle as outlined by Munson and Rodbard, 
(1980), and shown in equation 1.
(SS -SS ) / (df -df )
1 2  1 2  
F  ------------------------------------  Equation 1
(SS / df )
2 2
SS and df refer to the residual sum of the squares and
degrees of freedom associated with the two fits being
compared. The subscript 1 is designated to the fit with
highest number of degrees of freedom (i.e. the most
complicated model of analysis). Statistical significance of
the F value was determined from a table of the percentage
of the F distribution using df - df and df degrees of
1 2  1 
freedom as the numerator and denominator respectively.
4. Analysis of competition experiments
The inhibition of the radioligands by competing ligands 
was analysed graphically to estimate the Ic50 
(concentration of competitor displacing 50% of specifically 
bound radioligand), using a non-linear least squares 
programme specially designed for the interpretation of 
sigmoidal concentration curves in terms of total and 
non-specific binding as well as inhibition constants and 
curve steepness.
When Hill coefficients were not significantly different
from unity the concentration of competitor displacing 50%
of specific binding (IC ) was converted to an affinity
50
constant (Ki) using the expression derived by Cheng and 
Prusoff (1973) and shown in equation 2. In this expression
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[L] and Kd represent the radioligand concentration and 
dissociation constant respectively.
IC
50
Ki  ----------------  Equation 2
1'+ ([L]/Kd)
All data were initially analysed assuming a one site model 
of radioligand binding. The data, with Hill coefficients 
less than unity, were then analysed assuming a two site 
model, and the results of the curves fitting were 
statistically compared with those of the one site fit by an 
F test. The two site model was accepted if the observed fit 
was significantly better (p<0.05) than the one site fit. 
Some inhibitors of [ H]-5HT binding to rat cerebrocortical 
membranes were analysed assuming a three site model.
5. Association experiments
The theoretical aspects underlying the methods of
analysis of association kinetic binding data are discussed
in appendix 1. The observed rate constant for association
(K ) was obtained by fitting specific binding data, using 
obs
non-linear regression analysis techniques, to models of
binding which assume association with one or two species of
non-interconverting sites. The association rate constant
(K ) was determined from K as described in appendix 1.
1 obs
6. Dissociation experiments
Theoretical aspects of the analysis are discussed in 
appendix 1. The dissociation rate constant K was 
determined directly by fitting the specific binding data, 
using non linear regression analysis techniques, to models 
assuming dissociation of the radioligand from single or 
multiple species of interacting or non-interacting sites.
Statistical comparisons of the means of groups of data 
was made using the Students t-test for paired or unpaired 
data, where appropriate. A level of probability of p<0.05 
was taken to indicate satistical significance.
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2 .1.2 Modifications to the basic technique 
2.1.2a Effect of GTP
Saturation assays as described in section 2.1.1i and 
competition assays as described in section 2 .1 .1j were 
repeated in the presence of 0.1 or ImM guanos ine 
5-triphosphate (GTP) (Tris salt) to assess nucleotide 
interactions with 5HT or a -adrenoceptor binding sites.
2.1.2b Effect of ascorbate
3
[ H]-5HT is chemically unstable, and has been reported 
by numerous groups to be very sensitive to the incubation 
medium, resulting in a wide variation in the reported 
binding parameters; Kd values of 3-12nM have been reported. 
Initial experiments in this study were performed using the 
standard assay conditions, 5.7mM ascorbate and 4mM CaCl
2
described by Bennett and Snyder, (1976). Therefore the
3
effects of these buffer constituents on specific [ H]-5HT 
binding and the binding of other radioligands was 
investigated.
Washed rat cerebrocortical membranes were prepared as
described in section 2.1.1a, and [ H]-5HT binding assays
were performed as described in section 2 .1 .1b, except for
variations in the assay medium. Assays were performed in
the presence or absence of ascorbate (5.7mM), CaCl (4mM)
2
and/or EDTA (0.5mM).
2.1.2c Effect of ions
The ionic composition of the assay buffer was varied and
the effects of the monovalent ions Na and K (l-50mM) and
2+ 2+
divalent ions Ca and Mg (0.01-50mM) were examined.
2.1.2d Equilibrium temperature
The time to reach equilibrium and the amount of specific
o
binding was determined at 22 C and compared with the
o
previous results for 37 C.
2.1.2e Effect of pH
The effect of changing pH on the binding of the 
radioligands was also studied, to ensure the assays were 
performed at the. optimum pH. All assay additions, 
membranes, radioligand and drugs, were prepared in the 
appropriate pH assay buffer. Experiments were subsequently 
carried out as described previously with the only
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modification being the difference in the pH of the buffer 
used.
2.1.3 Specific 5HT binding assays
The above methodology describes in general terms the
principle techniques used in a receptor binding assay.
However, modifications are required to optimise the
requirements for different receptors and radioligands.
Specific assays for 5HT subtypes are described below:-
3
2.1.3a 5HT1A binding sites labelled by [ H]-5HT
5HT assays were performed by incubating washed rat
cerebral membranes (2.1.1a) with [ H]-5HT (2nM) for lOmin 
o
at 37 C, in the presence or absence of 12-20 concentrations
of the competing drug in a final volume of lml Tris assay
buffer (50mM Tris HC1, 5.7mM ascorbate, 4mM CaCl , 10/xm
o 2
pargyline; pH 7.4 at 37 C). Nsb was defined as the
concentration bound in the presence of ljuM spiperone
(Middlemiss, 1984). Saturation experiments were performed
under similar conditions using a range of concentrations of
[ H]—5HT (0.2-12nM).
3
2.1.3b 5HT binding sites labelled by [ H1-WB4101 
1A
Assays were performed using a modification of the method
described by Norman et al, (1985). Briefly, washed rat
3
membranes (0.5mg protein) were incubated with [ H]-WB4101
o
(2nM) for 40min at 37 C, in the presence or absence of 12
concentrations of the competing drug in a final volume of
2ml Tris assay buffer (50mM Tris HC1, 5mM MgSO , 0.5mM
o 4
EDTA; pH 7.4 at 37 C) . Nsb was defined using lOjum 5HT or
3
3/xm buspirone. [ H]-WB4101 assays were all performed in the 
presence of 30nM prazosin to mask a^-adrenoceptors. 
Saturation experiments were performed under ^identical 
conditions using a range of concentrations of [ H]-WB4101 
(0.5-8nM).
2.1.3c 5HT binding.sites labelled by [ H1-8-OH-DPAT
1A 3
The 5HT1A assays using [ H]-8-0H-DPAT were performed
using a modification of the method described by Gozlan et
al, (1983). Briefly, aliquots of the final membrane
o
suspension (0.5mg protein) were incubated for lOmin at 37 C 
with [ H]-8-OH-DPAT (InM) in the presence or absence of 12
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concentrations of the competing drug in a final volume of
2ml Tris assay buffer (50mM Tris HC1, 5mM MgSO , 0.5mM
. . 4
EDTA; pH 7.4). Specific binding was determined using 10/xm
5HT or 3/xm buspirone. Saturation experiments were performed
in a similar manner using a range of concentrations of
[ H]—8-OH-DPAT (0.2-12 nM^.
Filter binding of [ H]-8-OH-DPAT was assessed as
described in section 2 .1 .Id.
3
2.1.3d 5HT binding sites labelled by [ H1-5HT 
IB 3
The binding of [ H]-5HT to the 5HT subtype was
measured under the same conditions as described above for
the binding to the 5HT subtype (2.1.3a) except that 1/iM
1A
spiperone was included in the assay mixture (Middlemiss,
1984) . Specific binding was determined using 10/zm 5HT.
2.1.3e 5HT binding sites labelled by [ I1-CYP
IB
Assays were performed using a modification of the method
described by Hoyer et al, (1985a) . In the presence of 30/xM
isoprenaline (in order to supress binding to
/3-adrenoceptors) [ I]-CYP (150pM) was incubated to
o
equilibrium, 90min at 37 C, in the presence or absence of 
12 concentrations of the competing drug in a final volume 
of 250/il buffer (50mM Tris HC1? pH 7.4). Specific binding 
was determined in the presence of lO/nm 5HT.
Saturation assays were performed under identical 
conditions using a range of concentrations of [ I]-CYP 
(5-500pM^.
2.1.3f [ H]-ketanserin binding to rat cerebral membranes
Washed rat cerebral membranes were incubated with 
3 o
[ H]-ketanserin (InM) for 15min at 37 C in a final volume
of lml Tris assay buffer (50mM Tris HCl containing 4mM
o
CaCl^, 5.7mM ascorbate, 10/m pargyline; pH 7.4 at 37 C), in 
the presence or absence of a range of concentrations (7-22) 
of the competing drug. Nsb was determined in parallel 
experiments in the presence of 2/xm methysergide. 
Saturation assays were performed under identical conditions 
using a range of concentrations of [ H]-ketanserin 
(0.05-5nM).
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3
2.l.3g [ H]-Mianserin binding to rat frontal cortex 
membranes
Assays were performed using the method of Peroutka and
Snyder, (1981) with some modifications. In brief, washed
rat frontal cortex membranes, as described in section
3
2 .1 .1a, were incubated with [ H]-mianserin for 45min at 
o
25 C in a final volume of lml. Saturation assays were
performed using a concentration range of 0.5-10nM
[ H]-mianserin whereas competition experiments employed a
fixed concentration of InM [ H]-mianserin. Specific binding
was determined using 2/im methysergide and represented
3
approximately 50% of total binding at InM [ H]-mianserin.
Assays were performed in the presence of the H antagonist
triprolidine (0.3/im).
3
2 .1 .3h [ H]-LSD binding to human platelet membranes
Experiments were carried out using a modification of the
assay described by Geaney et al, (1984). Assay tubes
containing 0.5ml of the platelet membrane suspension
(approximately lml whole blood) were incubated with lOOjul
of [ H]-LSD in the absence or presence of a displacing
o
agent in a final volume of lml for 4h at 37 C. Saturation
curves were performed using a concentration range of
0.25-2.5nM [ H]-LSD whereas competition curves employed a
fixed concentration, of 0.5nM. Specific binding was
determined using 2/xm methysergide or 0.5/xM spiperone and
represented approximately 65% of total binding at 0.5nM
[ H]-LSD.
125
2•1•3i [ I]-LSD binding to vascular smooth muscle
Aliquots of the membrane preparation were incubated 
125
with [ I]-LSD (0.01-4nM) in a final volume of 250/xl 
o
for 60min at 37 C. Specific binding was determined in the
presence of 2/xm methysergide. Competition experiments were
125
performed using a fixed concentration of [ I]-LSD 
(0.2nM). The reaction was terminated by immediate 
filtration over Whatman GF/B filters that had been 
prewashed with buffer. The filters were washed twice with 
5ml ice-cold buffer and counted in a LKB 1282 gamma 
counter.
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2.l.3^5 [ I]-LSD binding to rat frontal cortex membranes
[ I]-LSD binding to rat frontal cortex membranes was 
performed esentially as described above. A protein 
concentration of 100/ig was found to be adequate.
2.1.4 5HT binding sites in the aerbil brain
An investigation of the characterisation and
distribution of 5HT binding sites in the gerbil brain was
undertaken. Gerbil brain membranes were prepared as
described in section 2 .1 .1a and the assays performed as
described in section 2.1.1b. Initial studies established
the normal binding characteristics of the gerbil 5HT
binding sites before assessing the effects of ischaemia.
1. Non-recovery model
The effect of 3h unilateral carotid ligation on the
affinity and number of 5HT binding sites in the gerbil
2
frontal cortex was determined. The surgery was carried out
as described in section 2.3.1a. After 3h the animals were
killed, the brains rapidly removed and the frontal cortex
separated into left and right hemispheres and stored under
liquid nitrogen until required. Tissues were pooled, 2
right or left frontal cortices, for each membrane
preparation and 5HT2 binding assays were performed using
[ H]-ketanserin as described in sections 2.1.1 and 2.1.3f.
Striatal tissue from the above study was retained so
that the effect on 5HT binding sites could also be
IB 125
assessed. The sites were labelled by [ I]-CYP and the
assay conditions were as described in section 2 .1.1 and
2 .1 .3e.
The effect of 3h death on 5HT binding sites
2
3h unilateral ischaemia is a very severe model, it was
therefore necessary to investigate if the changes seen were
in any way similar to 3h postmortem changes in 5HT binding
sites. Death was induced by cervical dislocation, air
o
embolism or decapitation. Animals were maintained at 37 C 
for 3h before dissecting out the frontal cortex and 
assaying the tissue as described in sections 2 .1.1 and 
2 .1. 3f.
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2. Recovery model
The recovery 5min bilateral ischaemia model was carried
out as described in section 2.3.1b. After 72h the animals
were again anaesthetised with 5% halothane in a 70% nitrous
oxide / 30% oxygen mix, decapitated and the brains rapidly
removed and the frontal cortex and hippocampus dissected
out. Frontal cortices from sham-operated or ligated animals
were used to determine the effect on 5HT binding sites.
2
Hippocampal tissue (3/membrane preparation) was used to
determine the effect on the affinity and density of 5HT
3 1A
binding sites. Assays were carried out using [ H]-8-OH-DPAT
as described in section 2.1.1 and 2.1.3c. Additional
3 3
studies were performed using [ H]-WB4101 and [ H]-5HT, the
later ligand was also used to look at the effect of lOmin
bilateral ligation followed by 1 or 2h reperfusion.
2.1,5 5HT binding sites in peripheral tissues 
2.1.5a [ H]-5HT binding to rat lung membranes
Membranes from rat parenchymal lung tissue were prepared
essentially as described in section 2 .1 .1a with the
exception that it proved necessary to filter the membranes
through cheesecloth after every wash to remove connective
tissue. Saturation binding assays were performed as
described in sections 2.1.1 and 2.1.3a using a range of
concentrations of [ H]-5HT (0.2-12nM).
2.1.5b 5HT receptor on guinea-pig and rabbit atria 
1
Saxena et al (1985), demonstrated the existence of 5HT 
receptors in cat heart tissue. A study was undertaken to 
assess 5HT binding in guinea-pig and rabbit heart tissue.
Guinea-pig and rabbit atrial membranes were prepared as 
described in section 2 .1 .1a for the rat cerebral membranes, 
except that as for the rat lung membranes, the homogenate 
was filtered through cheesecloth before each 
centrifugation. Saturation assays were performed using a 
concentration range of 0.5-20nM [ H]-5HT.
2.1.5c 5H T 2 receptors on human platelets
Human platelet membranes were prepared as described in 
section 2.1.1a, and assays performed using [ H]-LSD as 
described in section 2.1.3h.
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2.l.5d Pig Coronary Artery
Membranes were prepared as described in section 2.1.la.
A modification of the assay described by Engel et al,
(1984a), for the binding of [ I]-LSD to guinea-pig ileum
was used in these experiments to study the 5HT receptor
subtypes on PCA membranes. Assays were performed as
described in section 2.1.3i.
2.l.5e Human Umbilical Artery
The human umbilical artery smooth muscle preparation has
proved a useful method for studing 5HT receptors (McGrath
et al, 1985) with the advantage of using a human tissue.
These experiments describe direct binding studies to HUA.
Assays were performed essentially as described previously 
12 5
using [ I]-LSD as radioligand and 2/xm methysergide to 
define non-specific binding.
2.1.5f [ H]-Ketanserin binding to rat lung membranes
Membranes from rat parenchymal lung tissue were prepared 
as described in section 2.1.5a. Saturation assays were 
performed as described in sections 2 .1.1 and 2.1.3f using a 
range of concentrations of [ H]-ketanserin (0.05-5nM).
2.1.6 Aloha-adrenoceptor binding studies 
2.1.6a Membrane preparation
Male Sprague-Dawley rats (150-2OOg) were killed by
cervical dislocation, the brains rapidly removed and
dissected on ice. Cerebral cortices or hippocampi
(5/membrane) were homogenised in 25 volumes of Tris buffer
o
(50mM Tris HC1, 5mM EDTA: pH 7.4 at 25 C) using a polytron
PT 10 tissue disrupter (setting 10; 2 x 10s bursts). The
homogenate was then centrifuged at 38000xg for 15min. After
a second wash, the pellet obtained was resuspension Tris
o
assay buffer (50mM Tris HC1, 0.5mM EDTA; pH 7.4 at 25 C) 
before undergoing two further washes. The final pellet was 
resuspended in assay buffer for direct use in binding 
assays or stored under liquid nitrogen.
2 .1 .6b a-adrenoceptor binding assays
1. [ H]-Prazosin binding to rat cerebrocortical membranes
a -adrenoceptor competition binding assays were 
1
performed by incubating washed rat cortex membranes (300iig
60
protein) with [ H]-prazosin (0.5nM) in the presence or
absence of the competing ligand in a total volume of lml
Tris assay buffer (50mM Tris HC1, 0.5mM EDTA; pH 7.4).
Non-specific binding was defined as the concentration of
bound ligand in the presence of 10/xm phentolamine.
o
Following equilibrium (30min at 25 C) bound ligand was 
separated from free by vacuum filtration over Whatman GF/B 
glass fibre filters, which were then washed with 4 x 5ml 
ice cold buffer. Radioactivity was determined as described 
in section 2 .1 .le and data analysed as described in section 
2 .1 .1k.
Saturation assays were performed under identical
conditions using a range of concentrations of [ H]-prazosin
(0.01-8nM).
3
2. [ H]-Yohimbine binding to rat cerebral membranes
a^-adrenoceptor competition binding assays were
performed by incubating washed rat cerebral membranes
(500/xg protein) with [ H]-yohimbine (1.5nM) in the presence
or absence of a range of 12 concentrations of the competing
ligand in a total volume of 500/nl Tris assay buffer (50mM
o
Tris HC1, 0.5mM EDTA? pH 7.4 at 25 C). Non-specific binding
was defined as the concentration of bound ligand in the
presence of 10/Ltm phentolamine. Specific binding represented
60-70% of total binding at 1.5nM [ H]-yohimbine. Following
o
equilibrium (30min at 25 C), bound radioactivity was
separated and determined as described above, or using the
Brandel cell harvester as described in section 2.1.1c.
Saturation assays were performed under similar conditions
using a range of concentrations of [ H]-yohimbine
(0.l-15nM).
3
3. [ H]-Idazoxan binding to rat cerebral membranes
Initial experiments were performed under identical
conditions to [ H]-yohimbine binding assays, using a Tris
HC1 buffer system (50mM Tris HC1, 0.5mM EDTA; pH 7.4 at 
o 3
25 C). Membrane were incubated with [ H]-idazoxan (InM) to
o
equilibrium (15min) at 25 C in a final volume of lml. 
Specific binding was determined using 3/im phentolamine and 
represented 55-65% of total binding at InM [ H]-idazoxan. 
Saturation experiments were carried out under identical
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. . .  3
conditions using a range of concentrations of [ H]-idazoxan
(0.1-12nM). Membranes were collected through Whatman GF/B
filters, which were washed with 2 x 5ml Tris buffer (50mM
o
Tris HC1, pH 7.4 at 25 C), and the radioactivity determined
as described above.
33. [ H]-Yohimbine binding to human platelet membranes
Membranes were prepared as described in section 2.1.1a.
The binding assay used was a modification of the assay
described by Cheung et al, (1982) and very similar to the
3
assay described above for [ H]-yohimbine binding to rat
cerebral membranes. Briefly platelet membranes (lml whole
blood/ assay tube) were incubated with [ H]-yohimbine
(1.5nM) in the presence or absence of the competing drug 
o
for 30min at 25 C in a Tris HC1 assay buffer (50mM Tris 
HC1, 0.5mM EDTA, pH 7.4) in a final volume of 500/xl.
Specific binding was determined using 10/nn phentolamine and 
represented 75-85% of total binding at 1.5nM 
[ H]-yohimbine. Bound radioactivity was separated and 
determined as described above. Saturation assays were 
performed under identical conditions using a range of 
concentrations of [ H]-yohimbine (0.1-15nM).
4. [ H]-Idazoxan binding to human platelets
Platelet membranes were prepared as described in section 
2.1.1a and incubated with [ H]-idazoxan in a Tris HC1 or 
physiological buffer using the conditions for the assay 
described above for [ H]-idazoxan binding to rat cerebral 
cortex.
2.1.6c The effect of assay buffer constituents on
3 3
[ H]-yohimbine and [ H]-idazoxan binding
Preliminary studies were undertaken to assess the 
binding characteristics of the two radioligands using the 
following incubation mediums:-
o
1. Tris HC1 buffer pH 7.4 at 25 C.
o
2. Physiological salt solution pH 7.4 at 25 C containing
(mM): NaCL, 118; KCL, 4.8; CaCL , 1.3; KH PO , 1.2;
2 2o 4
MgSO , 1.2; NaHCO , 25; equilibrated at 25 C with 95%
4 3
O / 5% CO before use; pH 7.4.
2 2 o 2+
3. Tris HC1 buffer pH 7.4 at 25 C containing 2.6mM Ca
o 2 +
4. Tris HC1 buffer pH 7.4 at 25 C containing 5mM Mg
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2.1.6d The effect of chemical modifying agents on 
-adrenoceptor binding sites
Membrane pretreatments: Membranes (l-4mg/ml protein)
were preincubated with 1 or lOmM N-ethylmaleimide (NEM) or
phenylglyoxal (PGL) in 50mM Tris buffer (pH 7.4) in a final
o
volume of 0.5ml. Preincubations were performed at 37 C for 
20min and terminated by addition of 0.5ml ice cold buffer 
containing 8% (w/v) polyethyleneglycol and centrifuged for 
lmin at 30000xg. The membranes were washed twice more and 
finally resuspended in buffer only for use in the binding 
assays. This method was adapted from Mattens et al, (1984).
Saturation binding assays and competition assays were 
performed with control and ^retreated rat cortex and 
hippocampus membranes using [ H]-yohimbine to label the 
-adrenoceptors as described in section 2 .1 .6b.
2.2 5HT functional assays
2.2.1a 5HT autoreceptor
Presynaptic receptors regulating 5HT, can be studied 
+ 3
using K - evoked release of [ H]-5HT from preloaded rat
frontal cortex slices.
1. Preparation of slices
Rat frontal cortices were rapidly dissected and chopped
at 300/m intervals in two directions using a Mcllwain
tissue chopper. The slices were transferred to 5ml of
gassed Krebs buffer (mM): 118 NaCl, 4.8 KC1, 25 NaHCO^, 1.2
MgSO .7H 0, 1.2 KH PO , 1.3 CaCl , 10 glucose, 0.06
4 2 2 4 2
ascorbic acid, 0.03 disodium EDTA; gassed with 95%/5%
O /CO at pH 7.4) containing 1/m pargyline. After a 15min
2 2 o
preincubation period at 37 C, the slices were washed three
times resuspended in 5ml Krebs buffer containing 0.1/m
3
[ H]-5HT and incubated for 30min. The slices were then
washed three times with cold Krebs buffer and incubated for
3
a further 30min to allow efflux of [ H]-5HT to reach 
equilibrium.
2. Assay
Drugs were added to the slices at 2min (agonists) or
63
12min (antagonists) before exposure to elevated levels of
K (60K). All experiments using agonists were performed in
the presence of 5/xM of the uptake blocker imipramine. After
o
5min incubation at 37 C, the slices were pelleted by a 2min
centrifugation at lOOOxg (or by rapid filtration over
Whatman GF/B filters supported on a 12 port manifold
system). The samples were then stored on ice where
appropriate to prevent further release. Aliquots (250/liI)
were prepared for scintillation counting. The remaining
medium was aspirated and the tissue pellet dissolved in
500jul Soluene before counting.
2.2.lb Platelet aggregration
Human blood from male and female volunteers was collected
in 3.9% sodium tricitrate (ratio 9:1). Platelet rich plasma
(PRP) was obtained by spinning the blood at 2 00xg for
5 4
lOmin. The PRP was adjusted to 2.5x10 - 5x10 platelets
mm , with platelet poor plasma (PPP) on a platelet coulter 
counter. A sample of PPP was obtained by a second spin of 
PRP at 1440xg for lOmin.
The measurement of platelet aggregation was performed 
using a PAP4 aggregometer. The rate and extent of
aggregation were assessed by measuring the slopes of
percentage transmission, 100% transmission set using PPP.
Platelet aggregations were carried out in response to 5HT 
(10/zM) as the amplification effects of 5HT were found to be 
greatest on responses induced by threshold concentration of 
collagen. The ability of various antagonists to inhibit the 
5HT amplification of platelet aggregation induced by 
collagen was examined.
o
Aliquots of PRP were pre-incubated at 37 C with the test 
compound or distilled water for 3min before the addition of 
collagen which again was allowed to equilibrate for 3min 
before 5HT was added. The reaction was followed for a 
further 3min.
2.2.1c 5HT mediated contraction of PCA
Pig hearts were obtained from the abattoir. The lateral 
descending coronary arteries were removed and cut into 
helical strips (2x15mm). Four preparations were obtained 
from each coronary artery. The strips were suspended in
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30ml organ baths containing Krebs salt solution (NaCL
118.93mM, KCL 4.69mM, MgSO l.OlmM, KHPO 1.18mM, NaHCO
4 4 3
25mM, CaCL 2.5mM, ll.lmM glucose; pH 7.4, gassed with 5% 
2 o
C02 m  95% oxygen) at 37 C. The tension of the strips was
recorded isometrically, with the strips stretched to an
initial tension of 500mg. The strips were allowed to
equilibrate for 2h, during which time the bathing medium
was changed every 15min. During this time the resting
tension of the strips declined to about 100 to 200mg which
then remained constant throughout the experiment. Pargyline
(10/iM) was added to the baths 30min before the agonist to
prevent inactivation by monoamine oxidase. In each
experiment two cumulative concentration response curves
(CRC's) for 5HT were established. Graded concentrations of
antagonist were added to 3 of the strips, whilst the 4th
strip acted as control, and were allowed to act for 30min
before a third 5HT CRC was determined. The increase in
tension was plotted against agonist concentration on a log
scale. The degree of antagonism was qualified in terms of
the dose-ratio, which was determined by the ratio of the
EC values before and after the additions of antagonist. 
50
Correction was made for any spontaneous change in 
sensitivity by dividing the dose-ratio obtained following 
the antagonist by the dose-ratio obtained in the control 
strip.
The results were plotted graphically in the form of a
Schild plot (Arunlakshana and Schild, 1959) for the
estimation of pA values. The slope and intercept were also
2
assessed using linear regression.
2.3 Gerbil stroke models
2.3.1a Non-recovery unilateral model
The availability of a suitable animal model facilitates 
greatly experimental study of the disease and ultimately 
the pharmacological intervention necessary to arrest or 
cure the disease in man. The finding that the blood supply 
to the brain of the Mongolian gerbil is unique in lacking
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communicating arteries which make up the circulus 
arteriosus has made it a suitable model for the study of 
stroke (Kahn, 1972). Ligation of the one common carotid 
artery has been reported to cause a unilateral hemispheric 
infarction (Levine & Payan, 1966) with an alteration in the 
level of neurotransmitters. Unfortunately only 30-50% of 
gerbils are susceptible to developing ipsilateral 
hemispheric ischaemia following unilateral carotid 
ligation. Therefore separation of stroke-prone from 
stroke-resistant animals must be achieved before any 
assessment of biochemical changes can be made.
Adult gerbils, weight range 60-8Og, were anaesthetised 
with 6mg pentobarbital (i.p.) and the right common carotid 
artery exposed in the paratracheal region, dissected free 
of the accompanying vagosympathetic nerve trunk and 
ligated. In the sham-operated animals, the carotid artery 
was exposed, the ligature put in place but not tied. 
The animals were maintained under anaesthetic and given a 
top up dose of lmg pentobarbital (i.p.) if required. After 
3h the animals were decapitated, the brain rapidly 
removed and a microscopic (x40) examination of the anterior 
blood supply made on ice before separating the brain into
left and right hemispheres and dissecting out the
appropriate regions.
2.3.1b Recovery bilateral model
A second model, 5min global ischaemia and 72h recovery, 
involves the bilateral occlusion of both common carotid 
arteries. Global models of ischaemia such as the rat 4 
vessel occlusion (4V0) model (Pulsinelli and Brierley,
1979) are difficult to produce because in addition to 
ligating the carotid arteries, the vertebral arteries have 
to be cauterised which is both surgically demanding and
time consuming. However, ligation of both common carotid
arteries in the gerbil produces a global cerebral ischaemia 
in all animals with an inadequate anastomosis between the 
anterior and posterior circulatory systems; this is 
suggested to be 60% by Levy and Brierley, (1974) and 
estimated to be closer to 80% in these studies.
Adult gerbils weight range 60-80g, were anaesthetised
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with 5% halothane in a 70% nitrous oxide / 30% oxygen gas 
mixture. Halothane was then reduced to 1.5%, to minimise 
the effect of the anaesthetic, and maintained at this level 
for the remainder of the surgical procedure. The left and 
right common carotid arteries were exposed through a 
paratracheal incision and simultaneously occluded with 
microvascular clamps. The clamps were removed after 5min, 
the wound dusted with antibiotic powder and surgically 
closed. Animals regained consciousness within 2min. Seventy 
two hours following induction of the 5min period of 
ischaemia, the animals were killed, the brains rapidly 
removed and dissected on ice. Identical surgical procedures 
were carried out on the sham— operated animals with the 
exception of the occlusion of the carotid arteries.
2.3.2 The effect of unilateral occlusion on the 
electroencephalogram of the Mongolian gerbil
This study was to determine if a correlation exists 
between inhibition of the electroencephalogram (EEG) 
activity and cerebrovascular deficit. Gerbils weighing 
60-80g, were anaesthetised with 5% halothane in a 70% 
nitrous oxide / 30% oxygen mixture. After induction the
halothane concentration was reduced to 1.5% and maintained 
at this level throughout the remainder of the experiment. 
The EEG was recorded by subcutaneous needle electrodes 
between the left and right temporal region. Following 
recording of a control trace the right or both common 
carotid arterys were ligated as described above and 
recording resumed. At termination of the experiment, the 
brain was perfuse fixed with 10% formal saline with added 
Indian ink by left ventricular injection. The circulus 
arteriosus was examined microscopically for anatomical 
classification.
2.3.3 The effect of cerebral ischaemia on 5HT levels
These studies describe a simple subjective system for 
assessing the possibility of stroke in an animal by 
analysis of 5HT changes and where necessary by an 
anatomical investigation of the connections that make up
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the circulus arteriosus.
Surgical procedures were carried out as described for 
the non-recovery gerbil stroke model. After a 30min, lh or 
3h unilateral ligation, the anterior vascular anatomy of 
the animals was carefully graded before dissecting out the 
the left and right frontal cortex or corpus striatum, which 
were then weighed before being homogenised in 2ml 0.1M 
perchloric acid and stored under liquid nitrogen until 
required. The effect of a 5min bilateral occlusion of both 
common carotid arteries on the 5HT and 5HIAA levels in 
the frontal cortex was also determined for direct 
comparison with binding data.
Determination of 5HT levels
To lml of sample, 3ng dihydroxybenzylamine (DHB) was 
added as internal standard. To measure 5HT, samples were 
centrifuged at 9000xg for 5min and 100/zl of the supernatant 
was injected onto a high performance liquid chromatography 
system (HPLC) coupled to a coulometric electrochemical 
detector (ECD) maintained at a carbon electrode voltage of 
+0.4 V. Indalamine separation was achieved by reverse-phase 
chromatography using an octadecyl polymer coated silica 
column (Ultrasphere i.p., 250 x 4.6mm) and a short pre­
column (60 x 5mm i.d.) packed with an octadecyl coated 
pellicular support (CO: Pell ODS, Whatman). The mobile
phase was composed of a water:methanol mixture (90:10 v/v)
containing 0.ImM KH PO , 0.3mM sodium octyl sulphonate and
2 . 4
O.lmM EDTA, and the flow rate was maintained at lml/min. 
All chemicals used were HPLC grade. The mobile phase 
was gassed with helium and filtered before use.
5HT and 5-hydroxyindole acetic acid (5HIAA) standards 
were assayed under the same conditions at concentrations of 
5, 2, 1, and 0. 5ng/100/il. New standards were made up every
day and remained stable for up to 8h if kept on ice and in 
the dark.
3
Breakdown products of [ H]-5HT, after passing through 
the column, were collected at 3 0s intervals and the 
radioactivity determined by liquid scintillation 
spectrometry.
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2.3.4 Functional correlates for changes in 5HT binding
2.3.4a The effect of the 5min bilateral ligation followed 
by 72h recovery on the number of quipazine 
induced head shakes
Gerbils were assessed for head twitch behaviour pre- and 
post-ischaemia. The animals were divided into two groups, 
sham-operated and ligated, and control numbers of head 
shakes were determined. The head twitch behaviour was 
provoked by subcutaneous administration of quipazine 
(25mg/kg) in the back of the neck. 30min later the number 
of head twitches were counted over a 15min period. The 
animals were then rendered ischaemic, by 5min bilateral 
ligation, and recovered for 72h. They were retested 24 and 
72h post -ischaemia. Identical surgical procedures were 
carried out on the sham-operated animals with the exception 
of the occlusion of the carotid arteries. Head twitches 
were counted without prior knowledge of the treatment 
given.
2.3.4b The effect of 3h unilateral ligation on the 5HT
binding sites in the gerbil as assessed by
autoradiography
Animals were subjected to a 3h unilateral ligation as
described in section 2.3.1b. The animals were then killed,
the brains rapidly removed and an assessment of the
cerebral vasculature made. The brains were then prepared
for autoradiographic visualisation of 5 HT2 binding sites.
10 micron sections of frozen gerbil brain were prepared on
a microtome cryostat and thaw-mounted onto gelatin-coated
coverslips. Sections of frontal cortex were dried and
125
incubated in Tris HC1 buffer containing InM [ I]-LSD for 
60min at room temperature to label 5 HT2 binding sites. 
Parallel sections were prepared containing 2jiM methysergide 
to determine non-specific binding. Following the 
incubation the sections were washed for 2xl0min in fresh
ice cold buffer and dried under a cold air stream. The
3
sections were then exposed to Hyperfilm H for 4.5 days, in 
a Harvard cassette with rare earth intensifying screens. 
The resultant autoradiograms were developed and printed
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onto photographic paper.
2.3.4c Behavioural observations
Animals were subjected to a 5min bilateral or unilateral 
ligation as described in section 2.3.1b and allowed to 
recover. The animals were then carefully observed for 
circling behaviour towards the lesioned hemisphere, which 
is associated with the development of cerebral infarction 
(Kahn, 1972) and for any evidence of "5HT behavioural 
syndrome" (Lucki et al, 1984; Tricklebank, 1985).
2.4 Drugs
Reagents used were of the highest analytical grade. 
Drugs were kindly donated by their manufacturers, 
synthesised at Syntex (Palo Alto) or purchased. The 
following drugs were used:-
(-)Adrenaline bitartrate (Sigma), BDF-6143
*
hydrochloride , Bufotenine oxylate (Sigma), Buspirone
@
hydrochloride (Bristol-Meyers), 5CT (Glaxo), Compound X , 
*
Cyanopindolol , Cyproheptadine hydrochloride (Merck, Sharp
and Dohme), Desipramine hydrochloride (Geigy),
*
5,6-dihydroxytryptamine (Sigma), DP-5CT , Domperidone 
(Janssen), Dopamine hydrochloride (Sigma), Histamine 
dihydrochloride (Sigma), 8-OH-DPAT bromide (Research 
Biochamicals), 5HT creatinine sulphate (Sigma),
Idazoxan , Imiloxan hydrochloride (Syntex), Imipramine 
hydrochloride (Sigma), Indoramin hydrochloride (Wyeth), 
Isoprenaline bitartrate (Sigma), Ketanserin tartrate 
(Janssen), d-Lysergic acid diethylamine (Sandoz), MDL72222 
(Merrell Dow), Mianserin (Organon), Mesulergine (Sandoz^, 
Methysergide bimaleate (Sandoz), MJ 13 653 ,
N-ethylmaleimide (Sigma), (-)Noradrenaline bitartrate 
(Sigma), Oxymetazoline hydrochloride , Panuramine (Wyeth), 
Phentolamine mesylate (Ciba), Pindolol (Sandoz), 
Phenylglyoxal (Sigma), Prazosin hydrochloride (Pzifer), 
Propranolol hydrochloride (ICI), Quipazine maleate (Miles), 
Rauwolscine hydrochloride (Carl Roth), Ritanserin
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(Janssen), RU24969 (Roussel), Spiperone (Janssen), TFMPP 
hydrochloride (Research Biochemicals), Triprolidine
hydrochloride (Wellcome), UK 14304 tartrate (Pzifer),
WB4101 (Ward Blenkinsop), WY 26703 hydrochloride (Wyeth), 
Yohimbine hydrochloride, (Sigma), Zimeldine hydrochloride 
(Astra).
Radioligands:-
Amersham
3
[ H]-5HT (20Ci/mmol),
[ H]-WB4101 (2ICi/mmol),
[ H]-1SD (11.8Ci/mmol) 
“ ~5
[ H]-8-OH-DPAT (206Ci/mmol), 
125
12!
[ I]-LSD (2000Ci/mmol)
Dupont
3
[ H]-Ketanserin (61.8Ci/mmol),
3
[ H]-Mianserin (10.2Ci/mmol), 
3
[ H]-Yohimbine (87Ci/mmol),
3
[ H]-Prazosin (82Ci/mmol).
[ Il-CYP 
3
[ H]-Idazoxan
(1890Ci/mmol), 
(60Ci/mmol),
* Compounds synthesised by Syntex (Palo Alto).
@ This compound is a novel drug still undergoing research 
within the company. At such time when the drug comes under 
a patent this thesis shall be updated to include the 
available data. It is the same compound referred to by S.J. 
MacLennan (1986).
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AIMS OF THESIS
During the course of this thesis an enormous amount of 
work on 5HT receptors has been published. When appropriate, 
experiments have been designed to take advantage of as well 
as add to current knowledge.
The initial objective of this thesis was the 
characterisation of 5HT subtypes using ligand binding 
techniques. Methods were devised for the study of
1. 5HT binding sites
2. 5HT binding sites
2
Once specific and selective assays had been established, 
the aims of the study were then to evaluate
3. functional correlates for 5HT binding sites
4. the effect of cerebral ischaemia on 5HT 
neuropharmacology
5. possible 5HT/NA interactions, including the 
possibility of a -adrenoceptor subtypes
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Chapter 3: STUDIES ON 5HT RECEPTOR SUBTYPES
3. STUDIES ON 5HT RECEPTOR SUBTYPES
1
3.1 Introduction
Ligand binding studies have shown that there are at
least four 5HT binding sites, which have been designated
5HT , 5HT , 5HT and 5HT . Although Bradley et al, 
1A IB 1C ID
(1986) hesitated to include the 5HT subtypes in their
1
functional classification, referring to all such receptors 
as "5HT -like", it is now clear that functionally distinct 
5HT^ subtypes occur and that these show a similar 
pharmacological profile to the 5HT^ binding sites.
5HT Binding sites 
1
5HT binding sites all show nanomolar affinity for 5HT 
1 3
and can be labelled using [ H]-5HT, unlike 5HT and 5HT
2 3
binding sites which show approximately 400 and 25 fold
lower affinity respectively.
5HT binding sites are found in peripheral and central
tissues in many species. They are widely distributed in the
brain, particularly in the hippocampus, and are located
both pre- and post-synaptically (Hall et al, 1985). Several
compounds show selectivity for this site including N,N
Dipropyl 5-carboxamidotryptamine (DP-5CT) (Hagenbach et al,
1986), 8-OH-DPAT (Hjorth et al, 1982), buspirone (Hjorth
and Carlsson, 1982) and ipsapirone (Glaser et al, 1985).
Activation of central 5HT receptors results in neuronal
1A
inhibition, hypotension and bradycardia, aspects of the 5HT
behavioural syndrome, hyperalgesia, hyperphagia and
induction of a discriminative stimulus. 5HT peripheral
1A
receptors mediate enteric neuronal inhibition and
contraction of certain blood vessels, such as the basilar
artery in the dog (Peroutka et al, 1983).
The 5HT site is usually studied in the rat cortex or 
1A 3
hippocampus using [ H]-8-OH-DPAT. It is controversial as to
whether 5HT compounds such as 8-OH-DPAT, buspirone and 
1A
ipsapirone act as agonists, partial agonists or
3
antagonists. On [ H]-acetylcholine release from
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electrically stimulated guinea-pig ileum, buspirone and
ipsapirone act as antagonists whereas 8-OH-DPAT acts as a
partial agonist (Fozard and Kilbinger, 1985). All three
compounds act as agonists at the 5HT presynaptic receptor
1A
located on serotonergic cell bodies in midbrain raphe
nuclei (Hutson et al, 1986). However, an antagonist/
partial agonist action has been described for buspirone
for the reversal of 8-OH-DPAT-induced behavioural syndrome
(Clague and Spedding, 1987). Hypothermia following
8-OH-DPAT is suggested as a possible index of pre-synaptic
5HT function (Goodwin et al, 1987) although disputed by 
1A
Hutson et al, (1986). The '5HT behavioural syndrome'
following 8-OH-DPAT is suggested as an index of
post-synaptic 5HT receptor sensitivity (Goodwin et al,
1A
1987).
5HT binding sites are found in rodents (Pedigo et 
IB
al, 1981), although controversy exists as to whether they
are also found in man (Middlemiss et al, 1986). Several
compounds show high, affinity for this site such as 5CT
(Saxena and Verdouw, 1985), RU24969 (Euvrard and Boissier,
1980) and some 0 -blockers e.g. propranolol, pindolol
(Middlemiss et al, 1977; Nahorski and Willcocks, 1983),
although none of these compounds are selective.
Recently a selective 5HT ligand: CGS 12066B, has been
introduced (Neale et al, 1987). Some evidence suggests that
the 5HT subtype may be the inhibitory autoreceptor (Engel 
IB . . .
et al, 1986). However, a postsynaptic binding site has
been identified in the rodent brain which is inhibited by
5HT compounds RU24969 and 5CT but not by the 
IB
B-adrenoceptor antagonists. The 5HT site is generally
IB
studied in rat cortex or striatum using
125 125
[ I]-iodocyanopindolol ([ I]-CYP) m  the presence of
30/xM isoprenaline (Hoyer et al, 1985a) . The 5HT binding
IB
site is widespread in rodent brain.
5HT binding sites are found in the brain of a number 
1C
of species particularly higher mammals such as man and pig 
(Pazos et al, 1984a and b). Large numbers are found in the
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choroidal plexus suggesting a possible link with CSF 
production although this has still to be established. A few 
compounds show high affinity for this site although, as 
yet, no selective compound has been identified. The 5HT
1C
site is generally studied in the rat or pig choroidal
plexus using [ H]-mesulergine as the radioligand
(Pazos et al, 1984b). A recent interesting report describes
the successful cloning of the 5HT receptor cDNA and the
1C
expression of functional 5HT receptors in Xenopus oocytes 
injected with rat brain mRNA (Lubbert et al, 1987).
A 5HT subtype has been suggested to exist because 
50-70% of specific, high affinity 5HT^ binding of [ H]-5HT 
in the bovine brain cannot be described as 1A, IB or 1C 
(Heuring and Peroutka, 1987). The site is characterised by 
high affinity for 5CT, intermediate affinity for RU24969 
whereas 8-OH-DPAT is weak and the p -blockers are inactive. 
The site is widespread in bovine and human brain 
particularly in the globus pallidum and the substantia 
nigra. At present there is no known functional correlate
but there are many "5HT -like" responses which show
i. .some pharmacological similarities (Cohen and Fludzmski, 
1987; Charlton et al, 1986).
As described in the introduction, 5HT binding studies
were first carried out by Bennett and Snyder, (1976) using 
3 3 .
[ H]-5HT and [ H]-LSD. These were the only radioligands
available for the study of 5HT binding sites at the start
3 1
of this thesis. [ H]-5HT was used m  early studies to
investigate further 5HT binding sites.
An extensive study of the binding of [ H]-5HT to rat
cerebral membranes was undertaken and included:-
1 . a careful assessment of ligand binding assays.
2 . a detailed assay development; equilibrium binding 
assays, binding kinetics, the influence of assay 
conditions including pH, temperature, buffer ions and 
other modulators.
3. a large number of competition curves were generated 
to determine if multiple "states" or multiple binding
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sites were present.
Binding assays were established for the 5HT and 5HT
1A IB
binding sites in the rat cortex, hippocampus and striatum. 
3
[ H]-5HT proved to be unstable, therefore more stable and
selective radioligands were used as they became available.
A comparison of the binding ^characteristics of 5HT
subtypes was made using:- [ H]-5HT, [ H]-WB4101 and
3 3
[ H]-8-OH-DPAT to study the 5HT binding site and [ H1-5HT 
125 1A
and [ Il-CYP to study the 5HT binding site.
IB
The characterisation and distribution of 5HT
1
binding sites in the gerbil brain was undertaken. The 
gerbil was chosen as it is a useful model for examining the 
effects of cerebral ischaemia on receptors and receptor 
mediated processes, (see chapter 5).
A number of attempts were made to establish 5HT^ binding 
assays using peripheral tissues in the rat, namely heart 
and lung.
Finally, where possible, functional correlates for the
5HT binding sites were undertaken.
1
The figures and tables are included at the end of the 
results section.
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3.2 Results
3.2.1a Equilibrium binding studies
Preliminary results
. . 3
Preliminary studies indicated that [ H)-5HT bound to a
saturable population of binding sites on rat
cerebrocortical membranes with nanomolar affinity. However,
the binding was complex and required careful resolution.
The first^problem encountered was the chemical instability
of the [ H]-5HT ligand available. Fig. 3.1 shows the
composition of [ H]-5HT stored for two months in a
o 3
sealed vial at 4 C. Separation of [ H]-5HT by HPLC
indicated that some of the breakdown products were
electrically active i.e. gave a signal on the
electro-chemical detector. Comparison of the HPLC trace and
the radioactivity determined from the collected eluates
indicated that almost all (90%) of the accumulated
electroactive peaks were radioactive, although only 3 3% of
the radioactivity was 5HT. Therefore care had to be taken
at all times to store the [ H]-5HT as recommended, to use
only at > 96% purity and to prevent breakdown of the ligand
during the assay. Inclusion of ascorbic acid in the assay
was found to prevent the decomposition of [ HJ-5HT,
however, ascorbate itself has effects on the 5HT binding
assay (see below).
3.2.1b Separation of bound from free ligand
Preliminary kinetic experiments indicated a relatively
slow rate of dissociation (t > lmin) of [ H1-5HT from
1/2
washed cerebral membranes indicating the suitability of 
using vacuum filtration procedures for separating bound 
from free ligand. Specific binding of [ H]-5HT was not 
markedly different when filtration was performed using 2-5 
x 5ml washes with buffer at room temperature (fig. 3.2). 
Washing with room temperature or ice cold buffer made no 
difference to the recoverable amount of specific binding. 
However, the optimum conditions was the use of 3 x 5 ml 
washes with buffer at room temperature.
Care was taken to close the vacuum after filtering each
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manifold and to remove the lid and dry the filters. This 
was carried out in order to prevent any further 
dissociation of the ligand-receptor complex due to residual 
moisture left on the filter. The vacuum was applied at a 
constant 22mm Hg. Higher vacuum pressure resulted in a 
significant decrease in recoverable specific binding 
probably due to protein loss through the glass fibre 
filter. The vacuum was applied for lmin before filtering 
and a 5ml wash used to wet the filter. Any port filtering 
too quickly or too slowly was discarded from the assay.
Later assays were developed using a 24 place Brandel 
cell harvester (M-24R) to separate bound from free. In this 
method 2 x 10s washes (flow rate 1.5L/min) with room 
temperature buffer was found to be the optimum conditions 
for filtration. The vacuum was applied at a constant 22mm 
Hg and was opened 30s before filtering and a 10s wash used 
to wet the filter. After filtering the filters were dried 
for 5s under vacuum. The Brandel proved to be advantageous 
allowing 24 samples to be filtered and dried under 
identical conditions with a higher recovery of counts. In 
addition the Brandel gave rise to greater reproducibility 
than that obtained through millipore manifolds.
3.2.1c Filter binding of ligands ^
Filter binding to Whatman GF/B filters of [ H]-5HT was 
negligible through the saturation range of 0 .2-12nM. 
Antiabsorbants applied to the filter such as bovin serum 
albumin (2%) had no significant effect on the amount of 
recoverable specific binding and therefore were not used in 
these studies. Competing ligands at the maximal 
concentrations used in displacement studies had no 
significant effect on filter binding.
3.2.Id Tissue linearity of binding
Specific binding of [ H]-5HT (2nM) was linear over a 
protein level of 50-1200/xg. In all studies a protein level 
well within this range was used.
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3.2.1e Kinetic experiments
Association
3
[ H]-5HT (2nM) bound rapidly to rat cerebrocortical
o
membranes (500/ig) at 37 C reaching half maximal binding in 
1.2min and attaining equilibrium in 3min (fig. 3.3). All 
subsequent experiments were performed using a lOmin 
incubation period.
Dissociation
The binding was found to be completely reversible since,
when excess unlabelled 5HT (10/iM) was added, the bound 
3 o
[ H]-5HT was completely dissociated in 3min at 37 C (fig.
3.3). The half life for dissociation of bound [ H]-5HT was
o o
difficult to determine at 37 C. However, at 22 C a
dissociation rate constant (K ) of 0.0025/s was
-1 o
calculated. The association rate constant at 22 C was 
5
3x10 /M/s. Therefore the dissociation constant (Kd)
determined from the ratio of K /K was found to be 8.3nM.
-1 1
3.2.If Definition of non-specific binding
5HT itself was found to displace [ H]-5HT from rat
cerebral membranes in a monophasic manner with a Hill
slope not significantly different from unity (see table
3.5). Displacememt of specific binding reached a plateau at
2/xM, (fig. 3.4), and remained constant up to 200/liM. For
this reason 5HT at 10/iM (>1000 fold excess) was used to
define non-specific binding in all subsequent studies.
Under these conditions 75% specific binding was available 
3
at 2nM [ H]-5HT.
3.2.1^ Saturation binding assays
[ H]-5HT was found to bind with high affinity to rat
cerebral cortex (Kd 4.8±0.4nM; Bmax 290±6fmol/mg protein)
(fig. 3.5) and rat striatum (Kd 4.55±0.5nM; Bmax
o
395±12fmol/mg protein) when assayed at 37 C using a
concentration range of 0.2-12nM. The nsb, defined by 10/iM
5HT, was approximately linear over this concentration
range. Scatchard transformations of the specific binding
isotherm showed a very slight upward curvature. This could
not be statistically resolved and therefore no multiple 
3
[ H]-5HT binding sites could be assumed from saturation 
binding data, although the possibility of two or more
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binding sites with approximately the same affinity for 
[ H]-5HT could not be ruled out.
Fillion et al, (1978) suggested a second low affinity 
binding site for [ H]-5HT (Kd 10-30nM). Under the 
conditions described in this study no binding of [ H]-5HT 
to a low affinity site was observed.
3
3.2.2 In vitro modulation of specific r H1-5HT binding
3.2.2a Effect of GTP
Fig. 3.6 shows the Scatchard transformation of the
3
saturation data for the binding of [ H]-5HT to rat cerebral
membranes in the presence or absence of ImM GTP. GTP
reduces significantly the affinity of [ H]-5HT for the 5HT
binding sites (Kd 4.8 to 8.2nM). In competition experiments
in the presence of ImM GTP all agonists/partial agonists
tested (5HT, 5CT and 8-OH-DPAT) and 5HT antagonists showed
a significant decrease in affinity (table 3.1). The results
are presented as apparent IC values (i.e. IC values
50 50
corrected for the free ligand concentration) because even
in the presence of GTP all the compounds except 5HT itself
showed Hill slopes of less than unity.
3.2.2b Effect of ascprbate
3
Specific [ H]-5HT binding to rat cerebral cortex is
decreased in the presence of 5.7mM ascorbate (table 3.2).
However, if 4mM CaCl is included in the incubation medium
2
specific binding is maintained. The inclusion of EDTA
(0.5mM) also protects against the deleterious effects of
ascorbate (table 3.2).
3.2.2c Effect of ions
Monovalent cations, l-50mM NaCl and l-50mM KC1, were
3
found to inhibit specific [ H1-5HT binding and therefore
2+ 2+
were not used. However, divalent cations, Ca and Mg ,
over a concentation range of l-10mM enhanced specific 
3 . . . .
[ H]-5HT binding, above this concentration the binding is
inhibited (fig. 3.7). A concentration of 4mM divalent ions
was used in all subsequent assays.
3.2.2d Equilibrium temperature
Specific binding of [ H]-5HT to rat cerebrocortical
o . . .
membranes at 37 C reached equilibrium within 10mm, even
80
at the lowest ligand concentration. At 22 C equilibrium was 
reached within 30min with no significant difference in the 
Kd or Bmax (table 3.3).
3.2.2e Effect of pH
3
The effect of pH on specific [ H]-5HT binding is shown 
in fig. 3.8. The binding was stable over the pH range 
7.2-7.8 and then declined at higher pH values. A pH of
7.4 was chosen for all subsequent assays unless otherwise 
stated.
3.2,3 Specific 5HT binding assays
3.2.3a 5HT binding sites labelled by [ H]-5HT
The earliest studies in this thesis used [ H]-5HT to 
label 5HT binding sites in the rat cerebral cortex and 
corpus striatum. Spiperone was found to inhibit the binding 
of [ H]-5HT in a biphasic manner (fig. 3.9) as first shown 
by Pedigo et al, (1981). Therefore a further investigation 
of the 5HT subtypes was undertaken.
1. Rat striatal membranes
Studies of the high affinity, spiperone sensitive
3
[ HJ-5HT binding site were performed using 1/iM spiperone 
to determine nsb. The binding site could be termed 5HT 
by the definition of Middlemiss, (1984). This work was 
carried out before the availability of selective 5HT
1A
ligands. Table 3.4 shows the affinity values of a wide 
range of compounds determined for this site. 5HT itself 
showed nanomolar affinity whereas other agonists NA, DA and 
histamine were inactive. a -Adrenoceptor antagonists, 
yohimbine and phentolamine showed low affinity.
However, the /?-adrenoceptor antagonists propranolol and 
pindolol showed moderate affinity. The 5 HT2 antagonists 
ketanserin, cyproheptadine and mianserin showed low 
affinity whereas D-LSD showed high affinity, and 
methysergide and spiperone showed moderate affinity. It was 
concluded that [ H]-5HT under these conditions labels a 
site in the rat corpus striatum which is a subtype,
i.e. having high affinity for 5HT itself, and not a 5HT2 
subtype since it has moderately low affinity for classical
5HT antagonists.
2
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The affinity values of the same series of compounds were 
3
determined using [ H]-5HT binding to rat corpus striatum in
the presence of l^M spiperone, to block the high
affinity spiperone sensitive part of the binding, Nsb was
defined using 10/zM 5HT. The remaining portion of binding
(approximately 55%) is to a 5HT subtype (Middlemiss,
IB
1984). The results are presented in table 3.4. 5HT was the
only active agonist showing nanamolar affinity. D-LSD
again showed high affinity and methysergide moderate
affinity although both were lower than that obtained at the
5HT site. Pindolol and propranolol showed higher affinity
for the 5HT binding site. From this data it was concluded 
IB 3
that in the presence of 1/xM spiperone [ H]-5HT labels a
5HT subtype.
IB
2. Rat cerebrocortical membranes
Later studies were performed in the rat cortex using
computer modelling to determine the 5HT subtypes.
5HT was found to displace [ H]-5HT from rat frontal
cortex membranes in a monophasic manner (table 3.5).
However, all other compounds tested showed biphasic or
triphasic displacement curves, as determined by
computer-assisted analysis. The affinity values are
presented in table 3.5. The greatest selectivity between
the two sites was obtained with 8-OH-DPAT (>1,000 fold).
Triphasic competition curves were obtained for 5CT (fig
3.10) and RU24969 against [ H]-5HT binding to rat cortex
membranes providing evidence that [ H]-5HT labels 3
distinct 5HT sites in these membranes.
1 3
Therefore [ H]-5HT was found to label clearly two
distinct binding sites, 5HT and 5HT . The subtypes could
1A IB .
be distinguished by pharmacolgical manipulation of the 
assay or using computer assisted analysis. The 5HT
XA
binding site was characterised by high affinity for 
8-OH-DPAT, spiperone and methysergide whereas RU24969 and 
pindolol showed higher affinity for the 5HT1B subtype (see 
also Table 3.12).
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3
Other [ H]-5HT high affinity binding sites?
The triphasic displacement observed for 5CT and RU24969
inhibition of [ H]-5HT binding in the rat cerebral cortex
provided evidence for a third high affinity binding site.
However, because of the small percentage of binding it was
difficult to fully characterise this site. An attempt to
study this site was made using [ H]-5HT in the presence of
lOOnM 8-OH-DPAT to block 5HT and lOOnM cyanopindolol to
1A
block 5HT1B binding. Specific binding was defined using
lOjuM 5HT. Under these limited conditions, only 20% specific
binding, 5HT still showed high affinity (IC 55nM) and the
50
5HT antagonists methysergide, mianserin and ketanserin 
2
showed moderate affinity, whereas the /8-blockers pindolol 
and propranolol were inactive. The a-adrenoceptor 
antagonist yohimbine was also inactive.
Experiments to be discussed in chapter 6 showed
3
[ H]-yohimbine to label two distinct binding sites with
nanomolar affinity. Yohimbine has also been reported to
have moderately high affinity for the 5HT response in the
rat fundus. Therefore can a high affinity 5HT binding
site, which has nanomolar affinity for yohimbine, be
detected in the rat brain. Yohimbine showed only low
3
affinity for the three [ H]-5HT binding site-* described
above, 5HT (IC 1250nM), 5HT (IC >10,000nM) and
1A 50 IB 50
5HT (IC >10,OOOnM). However, no other high affinity 
3 1C 50
[ H]-5HT binding site could be detected in the rat
cerebrum in the presence of known 5HT , 5HT and 5HT
1A IB 1C
selective compounds (fig. 3.11).
Therefore the investigation for a yohimbine sensitive 
3 . . .
[ H]-5HT binding was continued in a higher species. A
fourth [ H]-5HT binding site was reported to exist in pig
and human brain (Hoyer et al, 1987a) and bovine brain
(Heuring and Peroutka, 1987). Unlike the rat, in the
presence of lOOnM 8-OH-DPAT (to block 5HT^ binding) and
lOOnM mesulergine (to block 5HT binding) 30% specific
3 1C
[ H]-5HT binding remains in the bovine frontal cortex. This
binding was not blocked by lOOnM cyanopidolol but was
displaced by 5HT (7nM) and yohimbine (52nM).
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Are any of the high affinity 5HT binding sites related to 
the high affinity 5HT uptake site?
Table 3.6 shows the affinity values of 5HT uptake
blockers for the 5HT and 5HT binding sites labelled by 
3 1A IB
2nM [ H]-5HT. The 5HT uptake blockers, although potent at
inhibiting 5HT uptake are devoid of affinity at the 5HT
1A
and 5HT binding sites.
IB
Further studies on subtypes of 5HT binding sites on rat 
cerebral membranes were performed using more selective 
radioligands.
3
3.2.3b 5HT binding sites labelled by [ H1-WB4101 
1A 3
In the presence of 30nM prazosin, [ H]-WB4101 was
found to label a single population of sites in the rat
cortex (Kd 1.9±0.6nM; Bmax 121±20fmol/mg protein) and the
rat hippocampus (Kd 1.25±0.3nM; 420±30fmol/mg protein).
The site is characteristic of the 5HT binding site as
1A
shown by its high affinity for 5HT and 5HT1A selective
compounds 8-OH-DPAT and buspirone (table 3.7). All
inhibition curves were described adequately by a model
assuming one binding site. The Hill coefficents determined
were not significantly different from unity. It was found
that a number of compounds showed higher affinity for the
hippocampal 5HT binding site, including 5HT and the 5HT
1A . 1A
selective ligands 8-OH-DPAT, buspirone and WB4101 and the
a -adrenoceptor antagonists yohimbine and rauwolscine. 5HT 
2 . . . .  
and yohimbine showed statistically significantly higher
affinity for the hippocampus 5HT^ binding site, p<0.02 and
p<0.01 respectively.
3
3.2.3c 5HT binding sites labelled by [ H]-8-OH-DPAT 
3 1A
[ H]-8-OH-DPAT was shown to label a saturable population
of high affinity sites in the rat cortex (Kd 1.3±0.8nM;
Bmax 102±10fmol/mg protein) and hippocampus (Kd l.l±0.7nM;
Bmax 534±18fmol/mg protein). 5HT was found to have high
affinity (nM) for the [ H]-8-OH-DPAT binding site as did
5HT selective compounds 8-OH-DPAT, buspirone and WB4101 
1A
whereas the 5HT selective compounds ketansenn and the 
2
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5HT^/5HT selective compound mesulergine were inactive
(table 3.8). Compounds with high 5HT /5HT selectivity
IB 1A
ratios were not available for this study. The Ki value
determined for RU24969 is a log order less than its
reported affinity for 5HT sites. 8-OH-DPAT has low
IB 125
affinity for the 5HT site labelled by [ Il-CYP in the
IB 3
presence of 30/xM isoprenaline (pKi 4.20) or [ H]-5HT in the
3
presence of 1/iM spiperone (pKi<5) . Therefore [ H]-8-OH-DPAT
is unlikely to label a 5HT binding site.
IB 3
In contrast to the inhibition curves for [ H]-5HT
binding to rat cerebral cortex, all the compounds tested
displaced [ H]-8-OH-DPAT with Hill slopes not significantly
different from unity.
3
The effect of GTP on [ H]-8-OH-DPAT binding
The effect of GTP on the affinity of compounds for the
5HT site labelled by [ H]-8-OH-DPAT was examined. The 
1A
inclusion of ImM GTP in saturation assays resulted in a
3
significant increase in the Kd of [ HI-8-OH-DPAT for 5HT
1A
binding sites (1.3±0.8nM to 4.1±0.6nM; n=3; p<0.05) with no
change in the Bmax (102±10 to 105±15fmol/mg protein).
Similarly a two to three fold increase in the Ki values for
inhibition of [ H]-8-OH-DPAT binding was found for 5HT and
buspirone. Fig. 3.12 shows the inhibition of
[ H]-8-OH-DPAT binding to rat cerebrocortical membranes by
the putative 5HT agonist/antagonist buspirone in the
presence or absence of ImM GTP. The results would suggest
that buspirone is at least a partial agonist at this site.
3
[ H]-8-OH-DPAT filter binding
Peroutka and Demopulos, (1986) suggested that
3 . .
[ H]-8-OH-DPAT binds specifically to glass fibre filters
when the assay is performed in a 50mM Tris HC1 buffer.
However, they reported that if 0.1% ascorbate is added to
the buffer there is no apparent specific labelling of
Whatman GF/B filters. Since the present studies were
carried out using Whatman GF/B filters specific filter 
3
binding of [ H]-8-OH-DPAT was investigated. The assay
conditions for [ H]-8-OH-DPAT binding are described in
section 2.1.3d. The incubation medium consisted of 50mM
o
Tris HC1, 5mM MgSO , 0.5mM EDTA; pH 7.4 at 37 C, and under
4
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these conditions no specific filter binding was found (fig. 
3.13) .
125
3.2.3d 5HT binding sites labelled by [ I]-CYP
X 2 5 16
[ I]-CYP was found to bind to a single class of high
affinity binding sites (Kd 0.1±0.05; Bmax 190±12fmol/mg
protein) on rat corpus striatum. The binding site showed
the characteristics of a 5HT site, ie high affinity for
IB
5HT, 5CT and RU24969 but only low affinity for the 5HT
1A
selective compound 8-OH-DPAT and the 5HT /5HT selective
1C 2
compound mesulergine. It also showed moderate affinity for 
the /3-blockers propranolol and pindolol (table 3.9).
3.2.4 A comparison of the binding of different^radioliqands
The density of binding sites labelled by [ H]-8-OH-DPAT
(102fmol/mg protein) and [ H]-WB4101 (112fmol/mg protein)
in the rat cerebral cortex are similar. The
characterisation of the two sites by the 5HT ligands is
shown in table 3.10 and the correlation drawn in fig. 3.14
(r=0.971;p<0.001). A good correlation was found indicating
that both ligands label a similar population of binding
sites. Both radioligands unlike [ H]-5HT appeared to label
a single population of binding sites. However, as with 
3
[ H]-5HT, the binding of both ligands is regulated
differentially by divalent cations and guanine nucleotides.
This is consistent with the view that both ligands act as
3
agonists at the 5HT subtype. As [ H]-8-OH-DPAT was the
most selective ligand identified, and since [ H]-WB4101
assays have to be performed in the presence of an
a -adrenoceptor antagonist, [ H]-8-OH-DPAT was used in 
1
further studies of 5HT binding sites.
1A 3
A similar comparison was made of the binding of [ H]-5HT
in the presence of luM spiperone in the rat cortex with 
125
[ I]-CYP to rat striatal membranes. The affinity values
3 125
for inhibition of [ H]-5HT and [ I]-CYP binding are
presented in tables 3.12 and 3.9 respectively. A similar
affinity was determined for 5CT, RU24969, pindolol and
propranalol, suggesting that both radioligands probably
bind to the same population of sites, the 5HT subtype.
IB
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3.2.5 A comparison of the binding in different rat brain 
regions
The distribution of 5HT^ subtypes in the rat brain is 
shown in table 3.11. The pharmacological characterisation 
of each subtype in the rat cerebral cortex is shown in 
table 3.12.
3.2.6 5HT  ^binding sites in the gerbil brain
In the“gerbil, as in the rat, regional differences in 
3
the binding of [ H]-5HT were found. The highest density was
found in the hippocampus, followed by striatum and cortex.
The use of selective ligands showed that both 5HT and
1A
5HT binding sites were present in the gerbil. The largest 
IB
number of 5HT sites occured in the hippocampus whereas 
1A
5HT binding sites were prominent in the cortex and 
IB
striatum. The data from saturation experiments is
presented in table 3.13. A typical saturation curve of 
3
[ H]-8-OH-DPAT binding to gerbil hippocampus is shown m  
fig. 3.15.
3
Inhibition of [ H]-5HT binding in the gerbil cortex was 
carried out using a wide range of 5HT ligands. 5HT itself 
showed monophasic displacement curves and, as for the rat, 
lOjiM 5HT was used to define nsb. However, all the other 
compounds tested showed biphasic displacement curves. 
Affinity values are presented in table 3.14. 5CT and 
RU24969 both produced biphasic displacement curves unlike 
in the rat cortex. No evidence of a third site could be 
found.
The affinity value for 8-OH-DPAT (7.95) at the 5HT
1A
site was three log orders higher than its affinity for the
5HT subtype (<5). RU24969 shows higher affinity for the
IB
5HT site (8.74) compared with its affinity for the 
IB . . .
5HT site (7.31). 8-OH-DPAT and RU24969 inhibit total
3 1A
[ H]-5HT binding, using 10/iM 5HT to define nsb, in a
biphasic manner as shown in fig. 3.16, 4 0% of the binding
is to the 5HT subtype whereas 60% is to the 5HT
1A 3 .IB
subtype. D-LSD showed high affinity for [ H]-5HT binding
(8.9) and a monophasic inhibition curve (fig. 3.16).
These results suggest that [ H]-5HT labels only two high
87
affinity sites in the gerbil frontal cortex. A good
correlation can be made between the affinity values for
inhibition of [ H]-5HT binding to putative 5HT binding
sites in the rat and gerbil (r<0.952; p<0.001) (fig.
3.17). Interestingly yohimbine shows 10 fold higher
affinity for the rat 5HT binding site. A similar
1A
correlation can be drawn between the 5HT binding site in
IB
the rat and gerbil cortex (r<0.988; p<0.001)
3.2.7 5HT binding sites in peripheral tissues
3.2.7a [3H]-5HT binding to rat3lung membranes
Saturation experiments of [ H]-5HT binding to rat lung
parenchyma membranes showed only a small percentage of
specific binding: approximately 20% at 2nM [ H]-5HT
compared with 75% in the rat cortex. Scatchard
transformations of the specific binding data showed 
3
[ H]-5HT binding to a low number (Bmax 30fmol/mg protein)
of high affinity sites (Kd 4nM) (fig. 3.18). The binding
was specifically inhibited by cold 5HT (IC5Q 22nM). The
only other compound found to displace the binding was 5CT
(IC 200nM), 5HT uptake blockers imipramine and
50
desimipramine (DMI) were inactive.
3.2.7b 5HT receptor on guinea-pig and rabbit atria
No detectable specific binding was found for [ H]-5HT 
binding to guinea-pig or rabbit atrial membranes at
ligand concentrations up to 20nM. More selective ligands 
with higher specific activity are needed if specific
binding to guinea-pig and rabbit atria is to be
demonstrated.
3.2.8 Functional 5HT binding sites
1
3.2.8a 5HT autoreceptor
Release of [ H1-5HT from rat frontal cortex slices was
t 2+ 3
found to be [K ]- and [Ca ]-dependent. Release of [ H]-5HT
was modulated by a presynaptic 5HT receptor as indicated
by the concentration-dependent inhibition of the 5HT^
agonists 5HT and 5CT. The effect of [K ] on the release of
[ H]-5HT is shown in fig. 3.19. From a [K ] concentration
88
+
curve a concentration of 60 mM K was chosen for all
subsequent studies. Fig. 3.20 shows the dose-dependent
inhibition of [ H]-5HT release by 5HT (IC 6x10 M).
—7 50
5CT (IC 3x10 M) was also shown to inhibit the release 
50
whereas the 5HT /5HT antagonist mianserin and the 5HT
2 1C 3
antagonist MDL 72222 did not affect the 5HT-induced
inhibition.
3.2.8b Effect of chronic dosing of an antidepressant on 
5HT1A binding sites in the rat hippocampus
Using binding techniques, a receptor function can be
examined indirectly. A drug of known action can be given
to an experimental animal and then the receptors assessed
by ligand binding assays.
Considerable evidence exists to show chronic
antidepressant treatment causes a decrease in the density
of /3-adrenoceptors in rat brain. However, less is known
about the effect that antidepressant treatment has on other
receptor systems. A decrease in the density of 5HT2 binding
sites has been reported to occur following antidepressant
treatment and this has lead to the suggestion the
sites play a role in depression. This study was carried out
to determine if chronic administration of DMI, a clinically
effective antidepressant, affected the 5HT binding site
characterised in the hippocampus.
Forty male sprague dawley rats (150-200g) were allocated
into two groups and dosed with either distilled water or
desmethylimipramine (7.5mg/kg i.p. o.d.) for 14 days.
Twenty four hours after the last dose the animals were
sacrificed. The brains were dissected on ice and the
hippocampal tissue removed and stored under liquid
nitrogen. Membranes were prepared from pooled tissue
(3-4/preparation) as described in section 2.1.1a and 
3
[ H]-8-OH-DPAT saturation assays performed as described m  
section 2.1.3c. A significant decrease in the number of 
5HT,*. binding sites was seen in the DMI treated animals
I n
compared with control (table 3.15). A slight but not 
significant increase in affinity was also seen.
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BREAKDOWN PRODUCTS OF [ 3H ] -5 H T
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Fig. 3.1 shows the composition of [ H]-5HT stored for two
o 3
months in a sealed vial at 4 C. Separation of [ H]-5HT by
HPLC and collection of the fractions for scintillation
counting, indicated that some of the breakdown products
were both electrically active and radioactive. Almost all
(90%) of the accumulated electroactive peaks were
radioactive, although only 33% of the radioactivity was
5HT.
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EFFECT OF WASHING ON RECOVERABLE 
SPECIFIC [ 3H ] -5 H T  BINDING
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Fig. 3.2 shows the effect of washing the filters, to 
seperate bound from free radioactivity, on the recoverable 
percentage of specific binding. Specific binding was 
determined by subtracting nsb from total binding.
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ASSOCIATION & DISSOCIATION OF [3H]-5HT BINDING 
TO RAT CEREBRAL CORTEX
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3
Pig. 3.3 Association and dissociation of [ H]-5HT binding.
Association; membranes were incubated with [ H]-5HT (2nM) 
o o .
at 37 C or 22 C for varying time intervals, before
separating bound from free ligand as described^in methods.
Dissociation; membranes were incubated with [ H]-5HT (2nM) 
o o . . .
at 37 C or 22 C to equilibrium before dissociation was
initiated by adding 10/zm cold 5HT. Aliquots were then
removed at varying time intervals and the bound
radioactivity separated from free.
Specific binding was determined by subtracting nsb from
total and is expressed in fmol/mg protein.
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5HT INHIBITION OF [3 H ] -5 H T  BINDING
5 0
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3
Fig. 3.4 Inhibition studies of [ H]-5HT to rat
cerebrocortical membranes were conducted over a
-11 -3
concentration range of 1x10 -1.34x10 M 5HT.
o
Incubations were performed for lOmin at 37 C in a Tris 
HC1 buffer (50mM Tris HC1, 5.7mM ascorbate, 4mM CaCl^, 
10/xm pargyline; pH 7.4). The data describes a single 
experiment performed in duplicate.
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C3H ]-5 H T  BINDING TO RAT CEREBRAL CORTEX
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Fig, 3.5 Specific binding of [ H]-5HT (l-14nM) to rat 
cerebrocortical membranes. Specific binding is defined as 
that binding displaced by 10/xm 5HT, and the data describes 
a single experiment performed in duplicate.
94
EFFECT OF GTP ON [ 3H ]-5 H T  BINDING
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Fig. 3.6 Scatchard tranformations of the specific binding 
3
of [ H]-5HT (l-12nM) to rat cerebrocortical membranes m  
the absence or presence of ImM GTP.
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EFFECT OF CATIONS ON THE SPECIFIC BINDING
OF [ 3H ] - 5 H T  TO RAT CEREBROCORTICAL MEMBRANES
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Fig. 3.7 Membranes were incubated with [ H]-5HT (2nM) for 
o
lOmin at 37 C in 50mM Tris HC1 buffer (pH 7.4) containing
CaCl (0.01-50mM), MgSO (0.01-50mM), NaCl (l-50mM) or KC1 
2 4 3
(l-50mM). The specific binding of [ H]-5HT is expressed as
a percentage of that found in the absence of cations. Each
point represents the mean of three experiments performed in
duplicate.
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EFFECT OF INCUBATION pH ON SPECIFIC BINDING
OF [ 3H ] -5 H T  TO RAT CEREBROCORTICAL MEMBRANES
3
Fig. 3.8 Membranes were incubated with [ H]-5HT (2nM) for 
o
lOmin at 37 C in 50mM Tris HCl assay buffer, pH 7.0-8.0.
3
The specific binding of [ H]-5HT is expressed as a 
percentage of that determined at pH 7.4. Data represents 
the mean of two experiments performed in duplicate.
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SPIPERONE INHIBITION OF [ 3H]-5HT BINDING TO 
RAT STRIATAL MEMBRANES
log spiperone concentration (M)
3
Fig. 3.9 Inhibition studies of [ H]-5HT binding to rat
striatal membranes were conducted over a concentration
-10 -4
range of 3x10 -1x10 M spiperone. Incubations were
o
performed for lOmin at 37 C in a Tris HC1 buffer (50mM Tris 
HC1, 5.7mM ascorbate, 4mM CaCl^, 10/Ltm pargyline, pH 7.4). 
Non-specific binding was determined in the presence of 
10£tm 5HT. The data describes a single experiment
performed in duplicate. Computer-assisted curve fitting 
procedures showed a two site fit was significantly 
better than a one site fit, p<0.01.
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5C T INHIBITION OF [ 3H ] -5 H T  BINDING
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Fig. 3.10 Inhibition studies of [ H]-5HT to rat
cerebrocortical membranes were conducted over a
“11 -3
concentration range of 1x10 -1.34x10 M 5CT.
o
Incubations were performed for lOmin at 37 C in a Tris HC1 
buffer (50mM Tris HC1, 5.7mM ascorbate, 4mM CaCl^, 10/im 
pargyline; pH 7.4). Non-specific binding was determined in 
the presence of lOfim 5HT. The data describes a single 
experiment performed in duplicate. Computer-assisted curve 
fitting procedures showed a three site fit was 
significantly better than a one or two site fit,
p<0.001.
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REMAINING SPECIFIC [ 3H ] -5 H T  BINDING IN THE RAT CEREBROCORTICAL MEMBRANES
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Pig. 3.11 Remaining specifc [ H]-5HT binding to rat 
cerebral membranes in the presence of:- 1. 10/m 5HT = 0%
used to determine nsb in [ H]-5HT binding assay; 2. 1/un 
spiperone = 40% used to define specific binding to 5HT
1A
binding sites; 3. 3/xm buspirone = 40% also used to define
specific 5HT binding; 4. 1/m cyanopindolol = 10% blocks
5HT and 5HT sites; 5. 1/im mesulergine = 80% blocks 
1A IB
5HT binding sites; 6. 1/m methysergide = 0% blocks all
1C 3
specific jj H]-5HT binding; 7. 1/m LSD = 0% blocks all
specific [ H]-5HT binding; 8. 1/m yohimbine = 75% equal to
its IC concentration at 5HT binding sites.
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EFFECT OF GTP ON BUSPIRONE INHIBITION OF [ 3H ]-8-O H -D P A T BINDING
TO RAT CEREBROCORTICAL MEMBRANES
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Fig. 3.12 Membranes were incubated with [ H]-8-OH-DPAT
-10 -5 o
(InM) and buspirone (1x10 -1x10 ), at 37 C for 10mm in
a final volume of 2ml Tris assay buffer (50mM Tris HC1, 5mM
MgSO , 0.5mM EDTA; pH 7.4), in the absence or presence of
ImM GTP. Non-specific binding was determined in the
presence of 10/xm 5HT.
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FILTER BINDING OF [ 3H]-8-OH-DPAT
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[ 3H]-8-OH-DPAT (nM)
Fig. 3.13 Relationship between total, nsb and specific
3
binding and ligand concentration. [ H]-8-OH-DPAT
concentrations of 0.05-9nM were incubated with control or
o
inactivated rat hippocampal membranes at 37 C for lOmin in
Tris HC1 buffer (50mM Tris HC1, 5mM MgSO , 0.5mM EDTA; pH
4
7.4). Non-specific binding was determined in the presence 
of 10/xm 5HT.
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CORRELATION BETWEEN pKI VALUES FOR [ 3H ]-8 -O H -D P A T  &
[ 3H ] -W B 4 1 0 1  BINDING IN RAT CEREBRAL CORTEX
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Fig. 3.14 Correlation between binding affinities of
3 3 .
compounds for [ H]-8-OH-DPAT and [ HJ-WB4101 binding to
rat cerebrocortical membranes.
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[3H]-8-0H-DPAT BINDING TO GERBIL HIPPOCAMPUS
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Fig 3.15 Specific binding of [ H]-8-OH-DPAT to gerbil
hippocampus Specific binding is defined as that binding
displaced by 10/im 5HT, and the data describes a single
experiment performed in duplicate.
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INHIBITION OF SPECIFIC [ 3H ] -5 H T  BINDING TO GERBIL CORTEX
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Fig. 3.16 Inhibition studies of [ H]-5HT to gerbil
cerebrocortical membranes were conducted over a
-9 -6
concentration range of 1x10 -3x10 M 8-OH-DPAT,
RU24969 and d-LSD. Incubations were performed for lOmin at 
o
37 C in a Tris RC1 buffer (50mM Tris HC1, 5.7mM ascorbate,
4mM CaCl , 10/xm pargyline; pH7.4). Non-specific binding was 
2
determined in the presence of 10/xm 5HT. The data represents 
a single experiment performed in duplicate.
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pKI VALUES FOR [ 3H ]-5 H T  BINDING
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Fig. 3.17 Correlation between binding affinities of 
3
compounds for [ H]-5HT binding to 5HT1A sltes in rat and 
gerbil cortical membranes.
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Fig. 3.18 Specific binding of [ H]-5HT to rat lung 
membranes. Specific binding is defined as that binding 
displaced by lOjLtm 5HT. The data describes a single 
experiment performed in duplicate.
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EF F E CT  OF  [K*]  ON THE  RELEASE OF [ * H ] - 5 H T  FROM RAT FRONTAL CORTEX SL ICES
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Fig. 3.19 Effect of [K ] on the % release of [ HJ-5HT from
rat frontal cortex slices over a 5min time period.
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EFFECT OF 5HT & 5HT ANTAGONISTS ON [K  + ]  EVOKED RELEASE OF 
[ 3H ] - 5 H T  FROM RAT FRONTAL CORTEX SLICES
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Fig. 3.20 Effect of 5HT, MDL 72222 and mianserin on 
+ 3
K -evoked release of [ H]-5HT from frontal cortex slices.
Data is the mean ± s.e.m. of 3 determinations. Statistical
significance with respect to control was assessed using a
paired Student*s t test. *p<0.01, **p<0.001.
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3
Table 3.1 Effect of GTP on affinity values for [ H]-5HT 
binding to rat cerebrocortical membranes
IC (nM)
50
control ImM GTP
5HT 2.5 +
5CT 0.5 +
8-OH-DPAT 8 ±
methysergide 120 +
spiperone 220 +
0.5 5.1 ± 0.9
0.09 1.3 ± 0.1
0.8 12 ± 1.2
5.6 135 ± 12
23 280 ± 20
3
Membranes were incubated with [ H]-5HT (2nM) and a range of
concentrations of the competing ligand in Tris buffer
(50mM Tris HC1 containing 5.7mM ascorbate, 4mM CaCl , 10fim
o 2
pargyline; pH 7.4) for lOmin at 37 C, in the presence or
absence of ImM GTP. Nsb was defined using 10/m 5HT. Data
represents the mean ± s.e.m. of 2-5 experiments performed
in duplicate.
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Table 3.2 The effect of incubation medium on the specific 
binding of [ H]-5HT
Specific binding of 
Additions [ H]-5HT (%control)
Control 100
(Ascorbate + CaCl )
Ascorbate 65 + 5
EDTA 95 + 4
Ascorbate + EDTA 91 + 4
CaCl 83 ± 3
2
Ascorbate + EDTA + CaCl 92 + 5
2
3
Membranes (500/xg protein) were incubated with [ H]-5HT
(2nM) in Tris buffer (50mM Tris HCl; pH 7.4) containing
ascorbate (5.7mM), EDTA (0.5mM) and CaCl (4mM) where
o 2
indicated, for lOmin at 37 C. Nsb was defined using 10/un
5HT.
Ill
Table 3.3 Effect of equilibrium temperature on [ H]-5HT 
binding to rat cerebral cortex
Incubation Kd Bmax
Temperature (nM) (fmol/mg protein)
o
22 C 4.65 ± 0.8 286 ± 15
O
37 C 4.80 ± 0.4 290 ± 6
o
Membranes were incubated to equilibrium (lOmin at 37 C; 
o 3
30min at 22 C) with [ H]-5HT (0.2-12nM) m  a tris assay 
buffer (50mM Tris HCL, 5.7mM ascorbate, 4mM CaCl^, 10/xm 
pargyline; pH 7.4). Data represents the mean ± s.e.m. of 
three experiments performed in duplicate.
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Table 3.4 Affinity values determined for the inhibition of 
[ H]-5HT binding in the rat striatal membranes
IC (nM)
3 50
[ H] -5HT [ H]-5HT±l/m
spiperone
(5HT ) (5HT )
1A   IB ~
5HT antagonists
ketanserin 900 ± 50 >10,000
methysergide 1 2 5 ± 2 0  3 5 0 ± 4 5
cyproheptadine 1,000 1,000
mianserin 1,995 990
D-LSD 4 ± 0.5 6 ± 0.8
Dopamine antagonists
spiperone 80 ± 20 18,000
a-Adrenoceptor antagonists
prazosin >10,000 >10,000
phentolamine 2,000 >10,000
yohimbine 1,250 >10,000
imiloxan >10,000 >10,000
0-Adrenoceptor antagonists
propranolol 360 ± 20 160 ± 25
pindolol 66 ± 10 30 ± 8
Agonists
5HT 6 ± 2 20 ± 3
dopamine >10,000 >10,000
noradrenaline >10,000 >10,000
histamine >10,000 >10,000
----------------------------  3----------------- ;-------
Membranes were incubated with [ H]-5HT (2nM) in the
absence, 5HT binding, or presence, 5HT binding, of 1/m 
1A IB
spiperone, in a Tris buffer system (50mM Tris HC1, 5.7mM
ascorbate, 4mM CaCl , 10/rn pargyline; pH 7.4) for lOmin at 
o 2
37 C. Specific binding was determined by parallel
incubations in the presence of 1/m spiperone for 5HT
JL **
binding or 10/m 5HT for 5HT binding. Data represents the 
mean ± s.e.m. of 2-5 experiments performed in duplicate.
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3
Table 3.5 [ H]-5HT binding to rat cerebrocortical 
membranes
Affinity (nM)
compound Site 1 Site 2 Site 3
5HT 6.3 ± 0.6 (100%)
5CT 0.5 ± 0.3 (43%) 10.6 ± 5 (39%) 40000 (18%)
8-OH-DPAT 8.0 ± 1 (42%) >10000 (58%)
RU24969 42 ± 10 (33%) 1.5 ± 0.5 (37%) 500 (30%)
Spiperone 220 ± 15 (40%) >10000 (60%)
3
Membranes were incubated with [ H]-5HT (2nM) and a range of
concentrations of the competing ligand (12-22) in Tris
buffer (50mM Tris HCl containing 5.7mM ascorbate, 4mM
o
CaCl , 10/xm pargyline; pH 7.4) for 10 min at 37 C. Specific 
2 . . .  
binding was determined from parallel incubations with 10/Ltm
5HT. Data was anaylsed using computer-assisted curve
fitting procedures, a two or three site fit was only
accepted if statistically significant. Results represents
the mean ± s.e.m. of 3-5 experiments performed in
duplicate.
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Table 3.6 Affinity values of imipramine, panuramine,
desipramine and zimeldine for 5HT , 5HT
3 1A IB
binding sites and [ H]-5HT uptake sites
Affinity value (PKi^ A
compound 5HT 5HT [ H1-5HT
1A IB
imipramine 4.5 ± 0.1 <5 7.55 ± 0.06
panuramine 4.2 ± 0.2 <5 7.41 ± 0.04
desipramine <4 <5 6.84 ± 0.03
zimeldine <4 <5 6.28 ± 0.03
3
Membranes were incubated with [ H]-5HT (2nM) in the
absence, 5HT binding, or presence, 5HT binding, of 1/m 
1A IB .
spiperone, in a Tris buffer system (50mM Tris HC1, 5.7mM
ascorbate, 4mM CaCl , 10/m pargyline; pH 7.4) for lOmin at
o 2
37 C. Specific binding was determined from parallel
incubations in the presence of 1/m spiperone for 5HT
1A
binding or 10/m 5HT for 5HT binding. Data represents 2
IB.
experiments performed in duplicate.
3
Inhibitory affinity constants for [ H]-5HT uptake sites
in the guinea-pig corpus striatum. Values quoted from
Kilpartick, Goodwin and Brown, (1986).
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Table 3.7 A comparison of the 5HT binding sites
1A
labelled by WB4101 in the rat cortex and rat 
hippocampus
pKi
compound rat cortex rat hippocampus
5HT 7.98 + 0.1 8.75 + o to
#
8-OH-DPAT 8.06 + 0.15 8.50 + 0.25
Quipazine 6.12 + 0.5 5.80 ± 0.3
TFMPP 6.83 ± 0.3
RU24969 8.01 + 0.2 7.95 + 0.2
Buspirone 7.92 + 0.1 8.21 ± 0.3
WB4101 8.60 ± 0.2 8.90 + 0.4
Methysergide 7.33 + 0.2 7.45 + 0.2
Ketanserin
Yohimbine
<5
6.10 + 0.1 6.90 +
**
0.1
Rauwolseine 6.77 + 0.2 7.35 + 0.2
WY26703 6.6 ± 0.3 6.95 ± 0.1
Idazoxan 5.9 + 0.2 5.7 ± 0.1
Membranes were incubated with [ H]-WB4101 (2nM) for 40min
o
at 37 C, in the presence or absence of 12 concentrations of
the competing drug in a final volume of 2ml Tris assay
buffer (50mM Tris HC1, 5mM MgSO , 0.5mM EDTA; pH 7.4 at 
o 4 3
37 C) . Nsb was defined using 10/im 5HT. [ H]-WB4101 assays
were all performed in the presence of 30nM prazosin to mask
a -adrenoceptors. The concentration of drug to inhibit
specific binding by 50% was obtained graphically and
converted to a Ki value using the relationship Ki
=IC /(1+[L]/Kd), where [L] represents the free ligand 
50 . . .  . .
concentration and Kd = the equilibrium dissociation
constant of the radioligand. The Hill slopes for all
compounds tested were not significantly different from
unity. Values shown are the mean Ki is.e.m. of at least
three experiments performed in duplicate.
*P<0.02, **P<0.01 relative to rat cortex
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Table 3.8 pKi values for 5HT binding site in the rat
1A 3
hippocampus labelled by [ H]-8-OH-DPAT
Ligand pKi
5HT ligands
5HT 8.65
8-OH-DPAT 8.52
Quipazine 5.47
RU24969 8.01
Buspirone 8.10
WB4101 8.75
Methysergide 7.15
Ketanserin 5.38
Mesulergine <5
a-adrenoceptor antagonists 
Yohimbine 6.77
Rauwolscine 7.27
WY26703 6.88
Idazoxan 5.60
 ----------------------------------- 3--
Membranes were incubated with [ H]-8-OH-DPAT (InM) for 
o
lOmin at 37 C, in the presence or absence of 12
concentrations of the competing drug in a final volume of
2ml Tris assay buffer (50mM Tris HC1, 5mM MgSO , 0.5mM
o 4
EDTA; pH 7.4 at 37 C) . Nsb was defined using 10/im 5HT. The
concentration of drug to inhibit specific binding by 50%
was obtained graphically and converted to a Ki value using
the relationship Ki =IC /(1+[L]/Kd), where [L] represents
50
the free ligand concentration and Kd = the equilibrium 
dissociation constant of the radioligand. The Hill slopes 
for all compounds tested were not significantly different 
from unity. Values shown are the mean Ki ( s.e.m fall 
within 5%) of at least three experiments performed in 
duplicate.
117
Table 3.9 Affinity values for 5HT binding sites labelled 
125 IB
by [ I]-CYP in the rat striatum
compound pKi
5HT 7.9±0.15
5CT 8.2±0.2
RU24969 8.510.2
8-OH-DPAT <5
Mesulergine <5
Propranolol 7.110.15
Pindolol 6.910.1
125
Membranes were incubated with [ I]-CYP (150pM) for 90min 
o
at 37 C, in the presence or absence of 12 concentrations of 
the competing drug in a final volume of 250ul Tris assay 
buffer. Nsb was defined using 10/xm 5HT. The concentration 
of drug to inhibit specific binding by 50% was obtained 
graphically and converted to a Ki value using the 
relationship Ki =IC /(1+[L]/Kd), where [L] represents the 
free ligand concentration and Kd = the equilibrium 
dissociation constant of the radioligand. The Hill slopes 
for all compounds tested were not significantly different 
from unity. Values shown are the mean Ki Is.e.m. of at 
least three experiments performed in duplicate.
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3
Table 3.10 A comparison of the binding of [ H]-8-OH-DPAT 
and [ H]-WB4101 to rat cerebral cortex
pKi
3 3
compound [ H]-8-OH-DPAT [ H]-WB4101
5HT 8.52 + 0.1 7.98 ± 0.1
8-OH-DPAT 8.50 + 0.2 8.06 + 0.15
Buspirone 7.85 + 0.15 7.92 + 0.10
WB4101 8.80 + 0.3 8.60 ± 0.2
Methysergide 7.20 + 0.35 7.33 ± 0.2
RU24969 7.80 + 0.2 8.01 + 0.2
Ketanserin <5 <5
Mesulergine 5.60 + 0.3 -
Quipazine - 6.12 + 0.5
TFMPP 6.83 ± 0.3
Assays were performed as described in methods and in the
legends to tables 3.7 and 3.8. A diagramatic representation
of the correlation between the binding affinities of the
3 3 .
above compounds for [ H]-WB4101 and [ H]-8-OH-DPAT binding
sites in the rat cerebral cortex can be seen in fig. 3.16.
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Table 3.11 Saturation data for 5HT binding sites in
different brain areas in the rat
F. Cortex Striatum Hippocampus
LIGAND
Bmax Kd 
* **
Bmax Kd Bmax Kd
5HT
1A
5HT 135±8 4. 8±1 158110 4.511.5 _
WB4101 121±20 1.9±0.6 - - 420130 1.2510.3
8-OH-DPAT 102±10 1.310.8 - - 543118 1.1010.7
5HT
IB
5HT 140*8 4.710.9 25018 4.612.0
CYP — — 190112 0.110.05
* Bmax fmol/mg protein
** Kd nM
Saturation binding assays were performed using membranes
for rat cortex, striatum or hippocampus, incubated to
equilibrium with a variety of radioligands; [ H]-5HT, 
3 3 125
[ H]-WB4101, [ H]-8-OH-DPAT or [ I]-CYP. Assays were
performed as described in methods section 2.1.3. Values
shown were obtained using the non-linear itterative curve
fitting programme 'Ligand1 (Munson & Rodbard, 1980), and
are the mean ± s.e.m. of 3-5 experiments performed in
duplicate.
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Table 3,12 Comparison of the affinities of several drugs
for 5HT , 5HT and 5HT binding sites in rat 
1A IB 1C
cerebral cortex
Affinity (nM)
Compound 5HT
1A
5HT
IB
5HT
1C
5HT 8.25 7.71
5,6 diOHT 6.22 6.22
5CT 9.30 7.97 5.40
8-OH-DPAT 8.09 <5
RU24969 7.38 8.82 6.30
Buspirone 7.85 <5
Ketanserin 5.65 5.65
D-LSD 8.40 8.28
Spiperone 7.10 ; <5
Methysergide 6.70 -
Mianserin <5 6.05
Pindolol 7.18 7.55
Propanolol 6.70 6.95
Phentolamine 5.30 5.40
Yohimbine 6.30 <5
Prazosin <5 <5
A profile of the binding characteristics of 5HT^ subtypes 
in the rat cerebral cortex.
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Table 3.13 Saturation data for 5HT binding sites in
different brain areas in the gerbil
Cortex Striatum Hippocampus
Bmax Kd 
* **
Bmax Kd Bmax Kd
5HT
1A
5HT 132±6 4.95±1.0 124112 3.9911.2 6001120 6.1211.5
WB4101 - - - - 347143 1.4310.2
8-OH-DPAT - 458116 4.4910.9
5HT
IB
5HT 145110 5.3010.8 267112 4.5010.9 140112 4. 7510.65
CYP - - 308120 0.7710.2 —
* Bmax fmol/mg protein 
** Kd nM
3
Membranes were incubated with [ H]-5HT (0.2-12nM) m  the
absence. 5HT binding, or presence, 5HT binding, of 1/Lun 
1A IB ,
spiperone, in a Tris buffer system (50mM T n s  HCl, 5.7mM
ascorbate, 4mM CaCl , 10/tim pargyline; pH 7.4) for lOmin at 
O 2
37 C. . Specific binding was determined by parallel
incubations in the presence of 1/xm spiperone for 5HT
1A
bindinq or lOum 5HT for 5HT binding. Values shown were
IB .
obtained using the non-linear itterative curve fitting
programme 'Ligand' (Munson & Rodbard, 1980), and are the
mean ± s.e.m. of 2-4 experiments performed in duplicate.
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Table 3*14 Comparison of the affinities of several drugs
for 5HT , 5HT and 5HT binding sites in 
1A IB 2
gerbil frontal cortex
Affinity (nM)
Compound 5HT
1A
5HT
IB
5HT 8.50 7.85
5CT 9.45 8.45
8-OH-DPAT 7.95 <5
RU24969 7.31 8.74
Buspirone 7.62 <5
Ketanserin 5.50 5.73
D-LSD 8.60 8.55
Spiperone 7.30 <5.00
Cyproheptadine 6.20 -
Methysergide 6.95 -
Mianserin 5.80 5.65
Propanolol 6.40 6.95
Phentolamine <5 -
Yohimbine 5.30 -
Prazosin <5
A profile of the binding characteristics of 5HT^ subtypes 
in the gerbil cerebral cortex.
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Table 3.15 The effect of chronic dosing of desipramine on 
5HT binding sites in the rat hippocampus
Kd Bmax
Treatment n nM fmol/mg protein
Placebo 6 0.9 ± 0.05 533 ± 40
*
DMI 6 0.8 ± 0.07 350 ± 43
(7.5mg/kg i.p.
o.d. 14 days)
w
p<0.01
Animals were dosed with distilled water or DMI (7.5mg/kg
i.p. o.d.) for 14 days. Hippocampal membranes
(3/preparation) were incubated with [ H]-8-OH-DPAT
o
(0.2-12nM) for lOmin at 37 C, in a final volume of 2ml Tris
assay buffer (50mM Tris HC1, 5mM MgSO , 0.5mM EDTA; pH 7.4 
o 4
at 37 C). Nsb was defined using 10/zm 5HT. Values shown
were obtained using the non-linear itterative curve fitting
programme 'Ligand1 (Munson & Rodbard, 1980), and are the
mean ± s.e.m. of 6 experiments performed in duplicate.
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3.4 Discussion
During the course of this thesis a vast amount of data
has been published on 5HT^ receptor subtypes and their
biological significance. A clearer, but as yet incomplete
classification of 5HT^ receptors has emerged. This has
occured through the increasing availability of potent and
selective compounds for these sites. Binding studies with
[ H]-5HT indicate that there are at least four subtypes of
"SHT^-like" receptors each with a distinct pharmacology,
which have been designated 5HT , 5HT (Pedigo et al
1A IB
(1981), 5HT (Pazos et al, 1984a), and 5HT (Heuring & 
1C ID
Peroutka, 1987). Functional correlates, implying biological
significance, have now been established for each of these
5HT^ receptor subtypes. The experiments described in this
chapter added to and have taken advantage of current
knowledge and selective compounds, when available. The
results were described in terms of the new binding
classification wherever possible and this will be
continued in the discussion.
The major finding of the present study is that three
distinct 5HT subtypes can be identified in the rat
1
cerebral cortex (5HT , 5HT and 5HT ) whereas evidence
1A IB 1C
of only two binding sites could be found in the rat
striatum (5HT and 5HT ). Rat hippocampus appears to
1A IB
predominantly contain 5HT binding sites. In contrast no
5HT binding sites were identified in the gerbil cerebral 
1C . . .
cortex, although 5HT and 5HT binding sites were found
1A IB ;
in all the regions examined in the gerbil, i.e. cortex,
striatum and hippocampus. Studies on the regional
distribution of 5HT binding sites in other species
indicate that significant interspecies differences exist.
The rat, guinea-pig and gerbil show large differences in
the regional distribution of 5HT^ binding sites whereas in
the mouse no significant difference is observed in the
3
density of [ H]-5HT binding in the hippocampal, cortex or 
striatal membranes (Hamon et al, 1984c). A quite different 
distribution is observed in the bovine brain where maximal
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binding takes place in the substantia nigra and globus 
pallidum (Peroutka & Snyder, 1981); this has recently been 
described as a 5HT^ binding site (Heuring and Peroutka, 
1987). In the rat (Pazos et al, 1985) binding to the 
substantia nigra and globus pallidum is to a 5HT
IB
binding site. In man the highest densities of binding sites
are found in the frontal cortex, hippocampus, (5HT , Hoyer
1A
et al, 1986) substantia nigra and pallidum (Pazos et al, 
1987). The latter is most likely to be the 5HT
ID
subtype (Heuring and Peroutka, 1987; Hoyer et al, 1987a).
The 5HT binding site is apparently absent from human, 
IB
bovine and pig brains (Hoyer et al, 1985b, 1986). This is
of interest since it would appear that CNS tissues lacking
5HT1B sites may instead possess central 5HT binding
sites. A report by Middlemiss et al, (1986) on the effect
of Alzheimer's disease on 5HT binding sites suggested that
there are 5HT binding sites in the human brain. However, 
IB 3
the 5HT binding was defined using [ H]-5HT in the 
IB
presence of 1/xM spiperone and therefore could be labelling
potentially any of the 5HT binding sites with the
1
exception of the 5HT binding site. Furthermore only a
limited pharmacological profile was given: the 5HT^, 5HT
and 5HT ligands tested were inactive although 8-OH-DPAT 
3
showed a log order higher affinity than would be predicted
for its inhibition of 5HT binding sites.
3 IB
The binding of [ H]-5HT to rat cerebral cortex membranes 
was complex. Analysis of radioligand binding data generally 
assumes a reversible bimolecular reaction occuring between 
the ligand and receptor and that this interaction obeys the 
law of mass action. One radioligand and one site 
interaction should produce linear Scatchard plots and 
competition curves for competitive antagonists, with Hill 
coefficients equal to unity. However, more complex results 
are often found. On the assumption that no experimental 
artefacts contribute to the complex binding curves, then 
alternative explanations of the results must be found. The 
ability of guanine nucleotides and divalent ions to 
modulate H-agonist binding may lead to complex drug 
competition curves. Alternatively non-sigmoidal curves of
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3
H-ligands may indicate that multiple and distinct binding
sites are being labelled. Both of these models for
interpreting the results will be discussed.
The addition of lmM GTP to the assay shifted the
binding of [ H]-5HT (to membranes of rat cerebral cortex)
to the right thus decreasing the affinity of the ligand as
reported by Sills et al, (1984). This suggests that, like
the a^-adrenoceptor and the 0-adrenoceptor, the agonist
binds to a high affinity state of the 5HT receptor which 
. „ 1A
is induced by GTP, through a guanine nucleotide binding
protein. In the present studies multiple affinity states
could not be determined in saturation studies up to 25nM 
3
[ H]-5HT, although slight curvilinearity of the Scatchard
plots was noted. A relatively small shift in the affinity
(1-3 fold) was observed in this study, which was
considerably less than the 10-100 fold shifts reported
for a -adrenoceptor agonists (U1Prichard, 1981).
Therefore the resolution at present may not be sufficient
to distinguish two affinity states from saturation data.
The addition of lmM GTP did not alter the Bmax of
5HT binding. This contrasts with the GTP-induced
1A
significant increases in a -adrenoceptor density reported
2
by (U*Prichard, 1981). Thus it would appear that the 5HT 
receptor unlike the a -adrenoceptor which exists 
predominantly in a low affinity state, must already exist 
to a greater extent in a high affinity state. All competing 
drugs tested in the presence of GTP showed a decrease in 
affinity but interestingly still showed Hill slopes less 
than unity.
The effects of other modulators on the binding of
3
[ H1-5HT to rat cerebral cortex were also examined.
3
[ H]-5HT was found in these studies to be very unstable 
which suggested that an antioxidant is necessary. Andresen 
and Shih, (1986)' showed that >1% oxidation of [ H]-5HT can 
lead to increased specific binding which is not 
receptor-related but can be inhibited by the inclusion of 
ascorbate in the assay. Recently Hamblin et al, (1987) 
reported that the decomposition products of [ H]-5HT appear 
to bind to two saturable sites on brain membranes which
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mimic "specific” ligand-receptor binding.
Ascorbic acid is commonly used as an antioxidant agent
for protecting biogenic amines. However, the inclusion of
ascorbic acid in binding assays has been reported to be
deleterious for several neurotransmitter binding sites,
0-adrenoceptors (Heikkila, 1983), dopamine (Chan et al,
1982), opiate (Leslie et al, 1980) and 5HT (Weiner et
al, 1982). When included in the assay ascorbate was found
to cause a significant decrease in specific binding. A
3
reduction in both the affinity and number of [ H]-5HT
binding sites was shown by Muakkassah-Kelly et al, (1982),
which has been attributed to the ability of ascorbate to
enhance iron-dependent lipid peroxidase activity in
membrane preparations. It is proposed that disturbances in
the lipid matrix environment of the receptor, as a
consequence of the enhanced peroxidase activity, leads to
the observed loss of binding capacity and a shift in the
operating and cryptic forms of the receptor available to
the radioligand. The effect of ascorbic acid is complex,
displaying a bell-shaped concentration effect curve: lipid
peroxidation accompanied by a marked decrease in [ H]-5HT
binding has been reported to occur at ascorbate
concentrations as low as 0.025mM and reaching a maximum at
0.5mM. Increasing the ascorbate concentration above 0.5mM
reverses the inhibition of [ H]-5HT binding. However, above
6mM the binding decreases probably because of an
auto-inhibitory effect of ascorbate on the peroxidising
system (Muakkassah-Kelly et al, 1982).
Ascorbate (5.7mM) was found in these studies to decrease
the amount of specific binding at 2nM [ H]-5HT. The
addition of CaCl (4mM) was found to slightly inhibit the
2
ascorbate-induced lipid peroxidation, which partly explains
2+ 3 t t
the effects of Ca ions on the [ H]-5HT binding, as did
the lipid peroxidase inhibitor EDTA (0.5mM). The results
of this study would argue that when ascorbate is used as
antioxidant, the inclusion of CaCl is necessary to
3 2
maintain the specific binding of [ H]-5HT. The antioxidant 
properties of EDTA were not investigated because this 
ligand chelates divalent ions which have been shown to be
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. . 3
beneficial to the binding of [ H]-5HT.
In the present studies lipid peroxidase activity was 
not measured directly. In order to definitively determine 
if the observed effects of ascorbate were due to its 
ability to stimulate this enzyme, it would be necessary to 
measure peroxidase activity in the membrane preparations 
used and to examine the effects of ascorbate in the 
presence of specific inhibitors of lipid peroxidase (eg 
a-naphol or propyl gallate; Heikkila et al, 1982).
It should also be mentioned that ascorbate has also been 
reported to decrease ligand binding in several systems by a 
mechanism independent of lipid peroxidase (Heikkila et al, 
1982) .
In addition rat brain is a rich source of ascorbic acid. 
Thus the endogenous ascorbate may promote a degree of 
peroxidase-induced degradation of the [ H]-5HT binding site 
or the anulus that surrounds the receptor altering the 
receptor integrity (eg lipid matrix) during membrane 
preparation.
o o
Changing incubation temperature between 22 C and 37 c
did not effect the specific binding of [ H]-5HT to rat
cerebral cortex membranes and no significant difference was
found in the affinity or Bmax. This contrasts with the
report of Hall et al, (1986) showing that in the rat
striatum and rat hippocampus a significant increase in
3 o
affinity for [ H]-5HT was found at 23 C compared 
o
with 37 C with no change m  Bmax. Therefore the
differences found in the Kd values for [ H]-5HT in
different brain regions could partly be a result of the
differential effects of temperature. All experiments in the
o
present stud^ were carried out at 37 C.
Specific [ H]-5HT binding to rat cortex showed the same 
pH dependency as has been reported for the rat striatum and 
hippocampus (Hall et al, 1986), i.e. an increase from pH 
6.5-7.8, and then a decline at a pH greater than 8.0.
In would appear that multiple affinity states ^cannot 
explain the complex competition curves seen for [ H]—5HT 
binding. Therefore the exsistence of subtypes of 5HT^
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binding sites was investigated. [ H]-5HT was shown to label
three subpopulations of 5HT^ binding sites in the rat
cortex as shown by 5CT (present study), RU24969 (Peroutka,
1986) and (-)21-009 [(-)-4(3-ter-butyl-amino-2-hydroxypro-
poxy) indol-2-carbonic acid isopropylester) (Hoyer et al,
1985a & b). These results were determined using computer
curve-fitting analysis which is limited in its ability to
differentiate sites that have a less than 6 fold
selectivity for a given compound (DeLean et al, 1982). In
the present study affinity values determined from computer 
3
analysis of [ H]-5HT binding were compared with values
obtained in selective 5HT and 5HT binding assays.
1A IB
Compounds such as 5HT showed competitive inhibition of
[ H]-5HT binding but when tested in selective assays was
found to have different affinities for the two sites.
Interestingly compounds such as methysergide still showed
biphasic displacement curves in the 5HT assay, providing
IB
evidence for more than two binding sites. Important
information can be gained from both computer analysis
of competition curves and pharmacologically
manipulated assays. However, a better pharmacological
characterisation of the binding site usually awaits the
development of more selective radioligands.
Spiperone and 8-OH-DPAT showed high affinity for one of
the [ H]-5HT binding sites, which was shown to be a
homogeneous population by directly labelling with 
3 3
[ H]-8-OH-DPAT (Gozlan et al, 1983) and [ H]-WB4101 (Norman
et al, 1985). [ H]-5HT binding using 1/lxM spiperone to
determine the nsb, correlated well with the binding of the
new ligands. A series of selective ligands have been
identified for this subpopulation of 5HT binding sites
1A
including DP-5CT, buspirone and ipsapirone. All showed 
competitive inhibition of [ H]-8-OH-DPAT binding which 
suggests that it binds to a homologous population of sites
in the hippocampus.
Comparing the percentage inhibition of [ H]—5HT binding
is a complex way of determining the affinity of a compound
at 5HT , 5HT or 5HT unless its affinity for one or 
IB 1C
more of these sites is already known. The 5HT binding
IB
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site is difficult to study as assays have to be performed 
,, 3
in the presence of a blocking agent; [ H]-5HT in the
presence of 1/xM spiperone to block 5HT binding sites or 
± Z o  ' 2A
[ I]-CYP in the presence of a /?-blocker. The site has
been defined as RU24969 > 5CT » » >  8-OH-DPAT as well as
high affinity for the /9-adrenoceptor antagonists
cyanopindolol and (-)21-009. The 5HT site identified in
IB
this study agrees with this classification. However,
Peroutka, (1986) suggested that D-LSD has a relatively low
affinity for the SHT^ site (170nM) compared with the
5HT site (4nM) in the rat. The results of this study 
1A
could not confirm the findings of Peroutka, (1986), D-LSD
showed equal affinity for 5HT /5HT binding sites in the
IB 1A
rat and gerbil.
5HT and 5HT binding sites were characterised in the 
1A IB
gerbil. Both subtypes showed a similar profile to that
described for the rat, and a good correlation could be
drawn between the binding to rat and gerbil cortex. So as
in the mouse and rat a 5HT binding site exists in the
IB
gerbil. However, no evidence of a 5HT binding site was
1C
found in the gerbil cortex.
Preliminary investigations revealed a fourth 5HT binding
site in bovine cortex, representing 30% of specific 
3
[ H]-5HT binding, which was resistant to lOOnM 8-OH-DPAT,
and lOOnM mesulergine, and therefore was unlikely to be
5HT or 5HT . In addition the binding was not blocked 
1A 1C . . .
by lOOnM cyanopindolol, however, 5HT binding sites are
IB
reported not to exsist in this tissue. The site showed 
moderate affinity for yohimbine (52nM). Heuring and 
Peroutka, (1987) have defined this site as a 5HT1D binding 
site present in all regions of the bovine brain. It has 
also been identified in pig and human brain (Hoyer et al, 
1987a), and suggested to be linked to adenylate cyclase in 
the calf substantia.nigra (Hoyer and Schoeffter, 1988). In 
this study no evidence of this site could be found in the 
rat brain, although functional evidence of a SHT^-like 
receptor, based on its affinity of yohimbine, could be 
present in the rat fundus (Cohen and Fludzinski, 1987) and 
rat kidney (Charlton et al, 1986). Further characterisation
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of this site must await the development of selective 
ligands.
Neither the 5HT or 5HT binding sites labelled by 
3 1A IB
[ H]-5HT showed any similarities with the 5HT uptake site.
3
Indeed it is unlikely that [ H]-5HT at a concentration of
3
2nM would label the uptake site as against [ H]-paroxetine
binding to 5HT uptake site on rat cerebrocortical
membranes, 5HT has an affinity (Ki) value of 698nM (Habert
et al, 1986). [ H]-8-OH-DPAT has been shown to label the
uptake site in rat striatal membranes. Although this is a
low affinity site (Kd 34nM) compared with its affinity for
the 5 H T ^  receptor (Kd l.lnM). Again 5HT has only moderate
affinity for this site (IC 1530nM) (Schoemaker and
50
Langer, 1986).
Preliminary investigations of the peripheral 5HT
binding sites, showed that a high affinity, low capacity
binding site exists in rat lung tissue. A full
characterisation of the site was not carried out as only
low percentage of specific binding was obtained with 
3
[ H]-5HT, although 5HT was shown to inhibit the binding in
a concentration-dependent manner (IC50 22nM)• 5HT is a
potent bronchodilator in man, and has been shown to be
inactivated during circulation through the pulmonary
vascular bed by an active transport process.
Autoradiographic localisation has confirmed that pulmonary
endothelial cells are the site of 5HT uptake. Therefore
presumably a 5HT uptake site should be present on the lung
endothelial cells. However, it is unlikely that the uptake
site was labelled in this study as imipramine and DMI were
inactive. 5CT did show moderate inhibition (IC 2 00nM) and
50
therefore it would interesting to repeat the study with the 
more selective radioligands with higher specific 
activities, to determine if this binding site represents a 
5HT subtype. Das and Steinberg, (1985) identified two 
populations of [ HJ-5HT binding sites in a purified lung 
mitochondrial preparation and a high capacity site in lung 
microsomal membranes; this finding suggests that in 
addition to the lung serving as a metabolic site for 5HT it
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may also have a physiological role. In order to confirm 
this, delineation of 5HT receptor types and the 
identification of their location must occur.
In contrast to the limited data in the lung, a great 
deal is known about the interaction of 5HT on the 
myocardium. It has been suggested that 5HT acts on the 
cardiac tissue via a direct action on 5HT receptors, 
(Saxena et al, 1985), by an indirect action on 5HT
3
receptors present on sympathetic ganglia (Fozard, 1984a) or
by a direct action on /? -adrenoceptors (Trendelenburg,
1960). The failure to detect specific [ H]-5HT binding to
guinea-pig or rabbit.atria may be because either both
3
tissues possess a very high affinity [ H]-5HT binding site 
or the density of 5HT sites is so low that it is beyond 
the sensitivity of the binding assay.
Investigation in this laboratory have shown that
behavioural tests may be the best functional correlate for
central 5HT receptors. In this study a significant
decrease in 5HT receptor number in the hippocampus
1A
following chronic antidepressant treatment may indicate a
possible role for 5HT receptors in the aetiology of
1A
depression, which should be further investigated.
A study of the 5HT autoreceptor was undertaken. Rat
cerebrocortical slices were loaded with [ H]-5HT. After
washing, the slices released tritium at a low basal rate
which was enhanced by elavated K levels, and was markedly 
2+ , . .
Ca dependent. Reproducibilty was difficult to obtain,
each concentration was incubated individually in an
eppendorf test tube containing as far as possible the same
amount of slices. It was felt that concentration response
curves could have been better achieved in a perfusion
system. Nevertheless 5HT and 5CT were^shown to cause a
concentration-dependent reduction in K -evoked release of 
3
[ H]-5HT presumably by the interaction with a 5HT
presynaptic autoreceptor. Mianserin and MDL72222 were
inactive, which suggests the the response is not via a
5HT , 5HT or 5HT receptor. Engel et al, (1986) using a 
2 1C 3
wide range of 5HT ligands, showed this response to be via a
5HT receptor.
IB
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Chapter 4S STUDIES ON 5HT^ RECEPTORS
4. STUDIES ON 5HT RECEPTORS
2
4.1 Introduction
5HT^ binding sites were first detected using the
neuroleptic [ H]-spiperone in rat frontal cortex (Leysen &
Laduron, 1977). The sites were characterised by a high
affinity for known 'classical' 5HT antagonists, including
cyproheptadine, methysergide and LSD , (which are all high
affinity but non-selective 5HT2 ligands) and low
micromolar affinity for 5HT. However, [ H]-spiperone has
also been proposed as the ligand of choice for labelling
dopamine (D ) receptor binding sites (Leysen et al, 1977).
Therefore, binding to 5HT sites had to be carried out in
2
the presence of a dopamine antagonist. Other radioligands
have been used, although all of them have the disadvantage
of labelling with high affinity more than one type of
binding site. [ H]-LSD (Peroutka and Snyder, 1979; Burt et
3
al, 1976) and [ H]-metergoline (Hamon et al, 1981) were
found to label 5HT and 5HT receptor binding sites and
probably also dopamine binding sites. [ H]-mianserin
(Peroutka and Snyder, 1981) was shown to label 5HT2 anc*
histamine receptors. In contrast [ H]-methiothepin
(Nelson et al, 1979) showed predominantly nonspecific
binding to the lipid component of membranes. The first
relatively selective radioligand to be introduced was
[ H]-ketanserin (Leysen et al, 1982a), although this ligand
has been reported to label a -adrenoceptors in human and
1
pig brain membranes (Hoyer et al, 1987c). However, the
3
introduction of [ H]-ketanserin has led to numerous studies 
of 5HT binding sites. Correlates for 5HT^ binding sites 
have been shown in animal models from behavioural and 
pharmacological studies (Yap and Taylor, 1983; Lucki et 
al, 1984; Cohen et al, 1985).
This chapter principally describes the binding 
characteristics of [ H ] —ketanserin. In addition, earlier 
studies undertaken before the availability of
134
3[ H]-ketanserin will be discussed. A comparison of the
binding characteristics of three radioligands.
3 . 3 125
[ H]-ketanserin, [ H]-mianserin and [ I]-LSD, was made
in rat frontal cortex. Limited regional distribution
studies of 5HT^ binding sites in four regions of the rat
and gerbil brain? frontal cortex, striatum, hippocampus
and cerebellum were also undertaken.
Peripheral 5HT2 binding sites were also
studied and where possible compared with functional
preparations in the same tissue. A pharmacological profile
of 5HT sites on human platelets was determined using 
3 2
[ H]-LSD and compared with a functional platelet
aggregation test. Binding sites in the rat lung membranes
was also examined using [ H]-ketanserin. [ I]-LSD was
used to study 5HT sites on vascular smooth muscle, namely
2
human umbilical artery (HUA) and pig coronary artery (PCA).
The PCA was also examined in an 'in vitro' organ bath
preparation in which 5HT mediated contraction of vascular
smooth muscle via 5HT receptors.
2
During the course of this study an interesting Syntex 
compound emerged with high 5HT^ affinity but showing low 
Hill slopes in competition assays, so a more detailed 
investigation of binding of this, compound X, was 
undertaken.
The figures and tables are included at the end of the 
results section.
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4.2 Results
3
4.2.1a [ H]-Ketanserin binding studies 
. . . 3
Initial results indicated that [ H]-ketanserin bound to
a single population of saturable binding sites on rat
frontal cortex membranes with nanomolar affinity.
Preliminary kinetic experiments indicated a relatively
slow rate of dissociation of [ H]-ketanserin from washed
cerebral membranes suggesting the suitability of using
vacuum filtration procedures for separating bound from free
3
ligand. In addition filter binding of [ H]-ketanserin 
represented less than 1% of the total binding through the 
saturation range of 0.05-5nM. Specific binding of 
[ H]-ketanserin was not significantly different when 
filtration was performed using 2 or 3 x 10ml washes with 
buffer at room temperature. The most favourable conditions 
employed 2 x 10ml washes. Washing with ice cold buffer 
slightly increased the amount of recoverable specific 
binding. In all experiments the washing buffer used was the 
same as the assay buffer. The methods for applying vacuum 
filtration were performed as described in results section 
3.2.1b.
In later studies separation of bound from free was 
achieved using the Brandel cell harvester. 2 x 10s washes 
(flow rate 1.5L/min) were found to be optimal.
4.2.1b Tissue linearity
3
Specific binding of [ H]-ketanserin (0.5nM) was linear 
when the assay protein concentration was increased from 
50-1250/zg and in all studies a protein concentration well 
within this range was used.
4.2.1c Kinetic experiments 
Association
3
[ H]-Ketanserin (InM) bound rapidly to rat frontal 
cortex membranes (300/xg) at 37 C reaching half maximal 
binding in 2min (fig. 4.1) and remained constant for a 
period >20min. All subsequent experiments were performed 
using a 15min incubation period.
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Dissociation
The binding was completely reversible. Addition of 
excess methysergide (2/xM) resulted in complete dissociation 
of the bound [ H]-ketanserin within 5min (fig. 4.1). The 
dissociation was temperature dependent, occurring more 
rapidly at higher temperatures which probably explains why 
slightly more specific binding was recovered with the use 
of ice-cold washing buffer.
4.2.Id Determination of non-specific binding
After investigation of a number of different compounds,
methysergide was selected to define non-specific binding.
Ketanserin itself displaced [ H]-ketanserin binding from
1x10 -3x10 M, resulting in approximately 85% specific
binding (fig. 4.2). At concentrations in excess of O.ljuM,
it was also found to displace the binding to extensively
boiled tissue preparations, which probably represented a
'ketanserin binding site' i.e. displaceable non-specific
binding. Therefore an underestimation of the true affinity
values would result from using ketanserin to define nsb. No
displacement from boiled membranes was obtained
methysergide at concentration up to 10 M.
Methysergide concentration curves reached a plateau at
0.3/zM and remained constant up to 100/xM. A concentration of
2/xM methysergide was selected to define nsb in all
subsequent experiments. Specific binding at 0.5nM 
3
[ H]-ketanserin represented approximately 75%. 5HT (see
fig. 4.4) showed similar percentage of specific binding to
methysergide. However, a concentration of 3 00/iM would be
required to define nsb.
4.2.le Saturation experiments
3 . . .
[ H]-Ketanserin was found to bind with high
affinity (0.42±0.05nM) to a single class of saturable
binding sites (Bmax 240±25fmol/mg protein) on rat frontal
cortex membranes when assayed at 37 C using a concentration
range of 0.05-5nM (fig. 4.3). When the concentration range 
3
of [ H]-ketanserin was extented to 20nM a more complex
binding isotherm was produced, which could be resolved into
two or more sites. This could indicate that above 5nM 
3[ H]-ketanserin labels a significant percentage of other
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site(s) in the frontal cortex. Ketanserin was shown to have 
high affinity for receptors, (pKi 8.0) (Leysen et al,
1981) a^-adrenoceptor receptors (pKi 7.7) (section 
6.2.2) and 5HTic binding sites (pKi 7.2) (section 
3.2.3a). Therefore all subsequent experiments were carried 
out at concentration.^ 5nM.
4.2.If Competition curves
The site was characterised by a high nanomolar affinity 
for 'classical' 5HT antagonists belonging to different 
chemical classes. 5HT itself shows micromolar binding 
affinity but was found to bind at least 100 fold more 
potently to this site than did other neurotransmitters 
tested. A summary of the affinity values obtained for a 
wide range of compounds is shown in table 4.1.
4.2.2 Modifications to the basic technique 
4.2.2a Effect of guanine nucleotides
Agonist inhibition curves performed in the presence of
lmM GTP showed a significant decrease in affinity. The
inhibition curve for 5HT in the absence (IC 2 60nM) and
50
presence (IC 249QnM) of GTP is shown in fig. 4.4.
50 . .
Bufotenine (IC 690nM) also showed a significant decrease 
50
in affinity in the presence of GTP (IC50 1790nM) with a
slight increase in the Hill slope (table 4.2). No 
significant difference was seen in the IC50 values 
determined for the antagonists ketanserin, spiperone, and 
cyproheptadine in the absence or presence of GTP. 
4.2.2b Effect of ions
3
As shown in table 4.3 the binding of [ H]-ketanserin to
rat frontal cortex membranes was influenced by additions to
3
the Tris assay buffer. All [ H]-ketanserin assays m  this
o
study were performed in a Tris HCl buffer (pH 7.4 at 37 C)
containing 5.7mM ascorbate, 4mM CaCl^ and 10/xM pargyline
(control). In the presence of only ascorbate a significant
decrease in the affinity was found. A decrease in the Bmax
was also seen, although this did not reach significance. A
similar decrease in the binding was found when assays were
performed in a physiological salt buffer (NaCl 118mM, KC1
4.7mM, MgSO 1.2mM, KH PO 1.2mM, NaHCO 25mM, CaCl 
. 4 2 4 3 2
1. 3mM) .
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4.2.2c Equilibrium temperature
[ H]-ketanserin binding to rat frontal cortex membranes
reached equilibrium after 15min at 37°C in a final
volume of 1ml. Equilibrium was achieved even at the lowest
o
ligand concentrations. At 22 C equilibrium was reached
within 25min with no significant difference in the Kd or
o
Bmax (table 4.4). For consistency 37 C was chosen for all 
subsequent experiments.
4.2.2d Effect of pH .
3Specific [ H]-ketanserin binding to rat frontal cortical 
membranes is not significantly different over the pH range 
of 7.0-8.0 (fig. 4.5). A pH of 7.4 was used in all 
subsequent studies. Similarly no significant change was 
seen in affinity values for cold ketanserin over the pH 
range 7.2-7.8 ; pKi values determined were:- 8.72±0.07 at pH 
7.2, 8.72±0.06 at pH 7.4, 8.75±0.06 at pH 7.6 and 8.7410.07 
at pH 7.8. The Hill slopes were determined and found not to
be significantly different from unity.
4.2.3 Specific 5HT binding assays
2
The initial studies of 5HT binding sites were made 
3 2
using [ H]-ketanserin binding to rat frontal cortex, as
described above. However, a number of other ligands were
used to characterise central 5HT binding sites.
3 2 4.2.3a [ H]-mianserin binding to rat frontal cortex
3
[ H]-Mianserin saturation curves were best fitted to a
two site model; a high affinity site (4nM) and a lower
affinity 5HT site (llnM). The high affinity site was shown 
2
to be a H binding site by Peroutka and Snyder, (1981). 
Therefore all [ H]-mianserin assays were carried out in the 
presence of a histamine blocker, 0.3/xM triprolidine. Under 
these conditions [ H]-mianserin was found to label a 
saturable population of high affinity binding sites in the 
rat frontal cortex (Kd 9.2±0.9nM, Bmax 160±25fmol/mg 
protein) (see table 4.6). Only 45% specific binding was 
available at the Kd concentration. The binding site is
the 'lower' affinity site for [ H]-mianserin, which has 
only a low percentage of specific binding and labels fewer 
binding sites than [ H ] -ketanserin.
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4*2,?b C I]“LSD binding to rat frontal cortex12 5
[ I]-LSD was found to label a single population of 
high affinity sites (Kd 0.7±0.1nM, Bmax 237±3Ofmol/mg 
protein), ^*3 * a similar number of binding site to those
labelled by [ H]-ketanserin (see table 4 .6 ).
4.2.4 A comparison of 5HT radiolicrands
2 ; 3
 ^ A comparison of the binding of [ H]-ketanserin,
[ H]-mianserin and [ I]-LSD to rat frontal cortex was
carried out. The affinity values for a wide range of
compounds for the site labelled by these different ligands
can be seen in table 4.5. A good correlation was apparent
between [ H]-ketanserin and [ H]-mianserin (r=0.828;
3 125
p<0.05) and between [ H]-ketanserin and [ I]-LSD
(r=0.877; p<0.05). This significant correlation suggests
that the ligands label the same site namely the 5HT
2
binding site.
4.2.5 A comparison of 5HT binding in different rat brain
regions —
Saturation experiments were carried out to assess
[ H]-ketanserin's binding to different brain regions.
Table 4.6 shows the Kd and Bmax values obtained in four
regions of the rat brain; frontal cortex, striatum, 
hippocampus and cerebellum. The frontal cortex was rich in
5HT binding sites whereas only a low number of sites was
2 . . .  
found in the hippocampus and no binding was detected in the
cerebellum. Competition curves for ketanserin and
methysergide (see fig. 4.2) were performed in each tissue
to assess the degree of displaceable non-specific binding;
frontal cortex 10%, striatum 15%, hippocampus 5% and
cerebellum 10%. Therefore the 'ketanserin binding site' was
found to be present in all brain regions even in the
cerebellum where significant specific 5HT2 binding could
not be detected.
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4.2.6 5HT^ binding sites in gerbil brain
[ H]-ketanserin saturation curves (0.05-5nM) to gerbil
frontal cortex membranes (300/xg membrane protein) were
performed in a Tris HC1 buffer system (50mM Tris HC1; pH
7.4 containing 5.7mM ascorbate, 4mM CaCl and 10/xm
pargyline). The binding was saturable, reversible and of
high affinity. Iterative non-linear analysis of the binding
isotherms demonstrated a single class of high affinity
sites with a Kd of 0.48±0.03nM and a Bmax of 206±20fmol/mg
protein (n=5). A representative experiment is shown in fig.
4.6. Scatchard transformations of the specific binding
isotherm revealed linear plots, which suggests that in
3
the gerbil, as in the rat, [ H]-ketanserin binds to a
single population of high affinity sites over this
concentration range.
3
[ H]-ketanserin (InM) bound rapidly to gerbil frontal
o
cortex membranes (300/xg) at 37 C reaching full association
within 3min and maintained this level for >30min. The
binding was found to be completely reversible: when 2/zM
methysergide was added the bound [ H]-ketanserin was
completely dissociated within 6min. All conditions
determined for [ H]-ketanserin binding to rat frontal
cortex were applied in the study of 5HT2 binding sites on
gerbil cerebral membranes.
The displacement of [ H]-ketanserin by various 5HT
antagonists and agonists is shown in table 4.7. The
antagonists ketanserin, spiperone, cyproheptadine,
methysergide, mianserin and ritanserin were potent
inhibitors of [ H]-ketanserin binding with Ki values in the
nanomolar range. The 5HT agonist, 8-OH-DPAT and the 5HT
1A 1A
and 5HT agonists 5CT and RU24969, as well as 5HT itself, 
IB 3 . . .
showed micromolar affinity for [ H]-ketanserin binding. The
results of such displacement studies provide evidence that 
3
[ H] —ketanserin is binding to a ^ ^ 2  S1^e in frontal
cortex of the gerbil. [ H ] -ketanserin has been shown 
to bind to an a -adrenoceptor binding site. However, in 
this study the oc —adrenoceptor antagonist prazosin showed 
only low affinity (pKi 5.3). A good correlation can be made 
between the affinity of the above compounds for the 5HT2
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site on gerbil frontal cortex and the values obtained for 
rat frontal cortex (fig. 4.7). Interestingly 5HT showed a 5 
fold lower affinity for the 5HT binding site on gerbil 
frontal cortex compared with rat frontal cortex.
In the gerbil, as in the rat, regional differences in 
the density of SHT^ binding sites were found. The highest 
density found in the frontal cortex > striatum >> 
hippocampus but no significant specific binding in the 
cerebellum (table 4.8). The Kd value obtained for the 
hippocampus was similar to that determined for the frontal 
cortex. However, a slight but significant decrease in 
affinity was found in the striatum (p<0.05).
4.2.7 5HT  ^binding sites in peripheral tissues 
4.2.7a Platelets
Preliminary investigations of peripheral 5HT binding
sites in this study were undertaken using [ H]-LSD binding
to human platelet membranes. [ HJ-LSD was found to bind to
a saturable population of high affinity sites (Kd
0.83±0.07; Bmax 81±8fmol/mg protein).
The 5HT antagonists, ketanserin, methysergide and 
2 . . .  
cyproheptadine were all found to be potent inhibitors of
[ H]-LSD binding to human platelet membranes (table 4.9),
with Hill slopes not significantly different from unity.
Similar binding affinities ^were found for compounds
inhibiting the binding of [ H]-LSD to human platelet 
3
membranes and [ H]-ketanserin binding to rat frontal cortex 
(table 4.9). Yohimbine showed only low affinity for this 
binding site (10 fold less than it's affinity for 5HT2 
binding sites on rat frontal cortex), 8-OH-DPAT and 
prazosin were inactive.
4.2.7b Pig coronary artery
The protein recovery in this membrane preparation was 
very low. The tissue was very fibrous, homogenisation was 
difficult and recovery of the membranes could only be made
at a maximum centrifugation of 39000xg.
3
Initial studies with [ H]-ketanserin binding to PCA were 
ineffective. Specific binding could be detected only above 
lOnM [3H]-ketanserin (fig. 4.8) and represented <£0.1% of
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the free ligand concentration. High levels of nsb were 
found representing 90% of total binding at lOnM
[ H]-ketanserin. The binding could be inhibited only by 
high concentration of ketanserin (>io M) and therefore was 
probably to a displaceable non-specific site (ketanserin
binding site) and not to a 5HT^ receptor binding site 
[ I]-LSD, with a specific activity of >74TBq/mmol, was
found to label with high affinity a 5HT binding site on
PCA membranes (fig. 4.9). However, a large percentage nsb
was present. Only a low number of sites was labelled, which
may have been the result of a poor membrane preparation.
Nevertheless, the binding was probably to a 5HT binding
site, as it was inhibited by ketanserin (Ki 16nM)and
methysergide (Ki 25nM).
4.2.7c Human umbilical artery
The binding to HUA proved more sucessful than to PCA for
a number of reasons. The tissue was less fibrous, the
arteries (6/ preparation) were finely chopped, ground using
a glass pestal and mortar and then homogenised in ice cold
0.25M sucrose using a polytron PT10 homogeniser (5 x 10s
bursts). After filtering through a single layer of
cheesecloth the homogenate was spun at 15000xg for lOmin at 
o
4 C. The supernatant was then respun at 60000xg for 30min 
o
at 4 C. The resultant pellet was resuspended in assay
o
buffer (50mM Tris HCl, pH 7.4 at 37 C, containing 4mM
CaCl , 5.7mM ascorbate and 10/m pargyline). This membrane 
2 . 
preparation proved successful unlike those prepared using
Tris HCl buffers or slow centrifugation speeds. The higher
recovery of 5HT binding sites was sufficient for use in
[ I]-LSD binding assays. Therefore, a characterisation of
the 5HT binding site(s) on HUA was undertaken.
5HT is a potent agonist in the HUA: at the physiological
oxygen tension (pO =l5mmHg) contraction is mediated via
2 . . .  
5HT receptors. At higher pO (120mmHg) contraction is via
both "5HT -like" and 5HT receptors (MacLennan and McGrath,
12 5 2
1986). [ I]-LSD was found to bind to a saturable
population of high affinity sites (Kd 0.4nM? fig 4.10).
This binding site was characteristic of the si^e,
showing high affinity for the ^ ^ 2  antagonists and low
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affinity for the 5HT ligand buspirone and the
1A
5HT /5HT ligand pindolol (table 4.10, fig 4.11).
jm ia
The affinity values obtained from binding studies for
effective antagonists were in good agreement with the pA
• . 2 values for functional antagonism of receptors that were
previously defined as 5HT2 (Table 4.10). However, so far,
no evidence was found in these binding studies for the
existence of the "SHT^-like" receptor which mediates
contraction of the HUA under high pO conditions
2
(MacLennan and McGrath, 1986)
These investigations of HUA suggest that it is a useful 
tissue for the study of vascular 5HT receptors using 
ligand binding techniques.
4.2•7d [ H]-ketanserin binding to rat lung membranes
No specific binding of [ H]-ketanserin to rat lung 
membranes could be detected over the concentration range 
0.05-5nM.
4.2,8 Complex interactions at the 5HT binding site
2
In competition studies to determine the affinity of 
compounds for the 5HT binding site labelled by
[ H]-ketanserin on rat frontal cortex, all the antagonists 
described above, e.g. methysergide, spiperone and 
ketanserin, showed monophasic inhibition curves with Hill 
slopes not significantly different from unity. However, 
during the course of the study a Syntex compound (compound 
X) was found to produce shallow competition curves (IC^ 
28.1±6.2nM), with a low Hill slope, 0.67±0.05, n=6 . Further 
investigation of this complex binding phenomena was
undertaken. Several possible explanations were examined, 
including the influence of assay constituents and 
conditions, agonist activity of compound X or negative 
co—operativity. It is important to note that heterogeneous 
steady state binding phenomena, due to multiple, 
independent binding sites or to interconvertible affinity
states, also resemble the situation of negative
co-operativity.
Assay constituents and conditions
The competition curves for compound X were repeated in
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different buffer systems containing no or a high (8mM)
concentration of CaCl^. A decrease in the specific binding
was seen in buffer without Ca ions (see table 4.3).
However, no significant change was seen in the affinity or
nH values for compound X in either buffer; no Ca2+ ic
2+ 50
29.1nM, nH 0.69 or high Ca IC 27.6, nH 0.75.
 ^ 50
Changes in pH over the range 7.2-7.8 had no effect on
the affinity value for compound X, as previously reported 
for ketanserin, 4.2.2d.
Effect of GTP
Inclusion of GTP has been shown to decrease the affinity 
values for agonists in this assay (fig. 4.4, Table 4.2) 
but to have no effect on antagonist binding. The inclusion 
of ImM GTP in the competition assays for compound X had no 
effect on the binding parameters determined, IC5Q 28.6nM, 
nH 0.72. Therefore it is unlikely, although not impossible, 
that compound X is an agonist at 5HT2 sites* In addition, 
compound X was shown to have no agonist activity in the HUA 
(MacLennan, 1986).
Multiple binding sites
The competition curve for compound X could ^be
statistically fitted to two sites; site 1 IC5Q 5*2x10 M,
46% and site 2 IC 5.4x10 M, 54% (fig. 4.12). 
Significance of the two site fit was assessed by the error 
of the sum of the squares method (see methods) . Earlier 
work showed that under these assay conditions InM
[ H]-ketanserin labels only sites anc* n°t
Q: -adrenoceptor or histamine receptors, for which it 
has lower affinity (lOnM) . In any case compound X has
been shown to have low affinity for a^-adrenoceptor (pKi 
5.9) and histamine receptors (pKb 5.56). It is possible 
that [ H]-ketanserin labels an as yet uncharacterised site. 
However, a wide variety of compounds from very different 
classes of structure to ketanserin produce Hill 
coefficients close to unity (tables 4.1 & 4.5).
Saturation experiments
The type of inhibition [ H]-ketanserin binding by 
compound X was further investigated. Specific 
[3H]-ketanserin binding with increasing [ H]-ketanserin
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concentrations was assayed in the absence of drug or in the
presence of of 1x10 M compound X. Experiments were
performed under the usual incubation conditions. Results
analysed in Scatchard plots are presented in fig. 4.13.
Compound X caused a significant decrease in the number of
-8
binding sites:- control 240±25, 1x10 compound X 82±10
(n=4) (p<0.001)*gand an increase in the affinity:- control 
0.42±0.05, 1x10 compound X 0.2410.06 (n=4). Therefore the 
inhibition was non-competitive.
The results of these studies would suggest that compound 
X has a non-competitive interaction at the 5HT binding 
site on rat frontal cortex, labelled by [ H]-ketanserin.
4.2.9 5HT functional assays 
2
4.2.9a Platelet aggregation
5HT activates platelets of various mammalian species.
Human platelets respond to 5HT with a shape change and only
weak reversible aggregation (Baumgartner and Born, 1968).
However, 5HT amplifies the human platelet aggregation
induced by other agonists, via; adenosine-51-diphosphate
(ADP), collagen, adrenaline and noradrenaline. De Clerck et
al (1984a & b) showed that ketanserin causes potent and
selective inhibition of 5HT-induced and 5HT-amplified human
platelet aggregation, suggesting the presence of a
functional 5HT receptor on the platelet. The aim of this 
2
part of the study was to show that inhibition of 5HT-
induced platelet aggregation can be used as a simple
functional test of 5HT antagonism.
2
5HT antagonists inhibited in a concentration—dependent 
manner the 5HT amplification of platelet aggregation 
induced by collagen in human PRP. The a^-adrenoceptor 
antagonist, prazosin, was inactive and the -adrenoceptor 
antagonist, yohimbine, showed some activity at 
concentrations probably corresponding to its affinity 
for 5HT receptors (Ki l,550nM; see table 4.9) (table 
4.11 and fig. 4.14). There is a good correlation between 
the inhibition of [ H]—LSD binding to human platelet 
membranes and inhibition of 5HT induced platelet
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aggreggation which can be seen in fig. 4.15.
4.2.9b Pig Coronary Artery
Characterisation of the receptor which may mediate the
response to 5HT in the isolated PCA was made using
antagonists.
_ g  “5
Cumulative additions of 5HT (1x10 -1x10 M) caused
concentration-related contractions of the isolated PCA (see 
figs. 4.16 and 4.17). which was well maintained at each 
response. The pD^ for 5HT was 6.8±0.1, n=8.
Following washout of the drug, there was a slow
relaxation to baseline tension which was complete within
lh. The second concentration response curve (CRC) to 5HT 
was performed 2h after the first and was found to be not 
significantly different from the first. Successive CRC's to 
5HT in the PCA could therefore be reproduced with 
minimal shift.
Methysergide
Methysergide was a potent antagonist of ^5HT. CRC's to 
5HT in the presence of methysergide (1x10 -1x10 M) were
parallel (fig. 4.16). The results were plotted graphically 
in the form of a Schild plot for the estimation of pA2 
value, determined to be 8.4 (8.1-8.7). The slope was also 
assessed using linear regression and determined to be 
0.95±0.05, which was not significantly different from 
unity.
Ketanserin
-7 -5
Ketanserin (1x10 -1x10 M) displaced the 5HT CRC m  a
parallel manner at all concentrations (fig. 4.17). The 
Schild plot had a slope of 0.98±0.05 and the estimated 
for ketanserin against 5HT was 8.9 (8.7-9.1).
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A SSO C IA TIO N  & DISSOCIATION OF [ 3 H ]-K E TA N S E R IN  BINDING  
TO RAT FRONTAL CORTEX AT 3 7 ° C
to ta l1 200
9 0 0
6 0 0
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time (min)
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s p e c if ic9 0 0
6 0 0
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3
Pig, 4.1 Association and dissociation of [ H]-ketanserin 
binding.
Association; membranes were incubated with
3 o
[ H]-ketanserin (InM) at 37 C for varying time intervals,
before separating bound from free ligand as described in
methods.
Dissociation; membranes were incubated with
3 o
[ H]-ketanserin (InM) at 37 C to equilibrium before
dissociation was initiated by adding 2/xM methysergide.
Aliquots were then removed at varying time intervals and
the bound radioactivity separated from free.
Specific binding was determined by subtracting nsb from
total.
148
METHYSERGIDE & KETANSERIN INHIBITION OF [ 3H]-KETANSERIN BINDING
100o>
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log [drug3(M)
3
F i g .  4 . 2  Inhibition studies of [ H]-ketanserin (InM) to
rat frontal cortical membranes were conducted over a
-11 -6
concentration range of 1x10 -1.31x10 M methysergide
o
or ketanserin. Incubations were performed for 15min at 37 C
in a Tris HC1 buffer (50mM Tris HCl, 5.7mM ascorbate,
4mM CaCl , 10/zM pargyline; pH 7.4). The data describes a 
2
single experiment for each competitor performed in 
duplicate.
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[»H]-KETANSERIN BINDING TO RAT FRONTAL CORTEX MEMBRANES
total specific
nsb
C3 H]-ketanserln (nM) [ 3 H]-ketanserin (nM)
• i
boundboundbound
3
Fig. 4.3 Saturation binding of [ H]-ketanserin to rat 
frontal cortical membranes. Specific binding is defined 
as that binding displaced by 2/iM methysergide. The data 
describes a single experiment. A and B show total, nsb and 
specific binding as a function of the free ligand 
concentration. C,D and E show the Scatchard tranformations 
of the total, specific and nsb, respectively. Graphs like 
this were produced for all saturation assays performed in 
this study, and allowed the identification of rogue points 
before analysing the data via 'Ligand'.
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EFFECT OF GTP ON 5HT INHIBITION OF [ 3H]-KETANSERIN BINDING
0
O control
•  GTP
-57 -6 -34-8
log [5 H T ]  (M)
3
Fig. 4.4 Membranes were incubated with [ H]-ketanserin
-9 -3 o
(InM) and 5HT (3x10 -1x10 ) , at 37 C for 15min in a final
volume of 1ml Tris assay buffer (50mM Tris HCl, 4mM
CaCl , 5.7mM ascorbate, 10/zM pargyline; pH 7.4), in the 
2
absence or presence of ImM GTP. Non-specific binding was 
determined in the presence of 2/xM methysergide.
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EFFECT OF INCUBATION pH ON SPECIFIC BINDING
OF [ 3H]-KETANSERIN TO RAT FRONTAL CORTEX
100o>c
■5c
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o
©
a*»
7.27.0 7.4 7.6 8.07.8
pH
3
Fig. 4.5 Membranes were incubated with [ H]-ketanserin
o
(InM) for 15min at 37 C in 50mM Tris HCl assay buffer, pH 
7.0-8.0. The specific binding is expressed as a percentage 
of that determined at pH 7.4. Data represents the mean of 
two experiments performed in duplicate.
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[ 3H]  —K E T A N S E R I N  B I ND I N G  TO GERBIL F R O N T A L  C O R T E X
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Pig. 4.6 Specific binding of [ H]-ketanserin to gerbil 
frontal cortex. Specific binding is defined as that 
binding displaced by 2/xm methysergide, and the data 
describes a single experiment performed in duplicate.
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pKi  V A L UE S  FOR [ 3H]  —K E T A N S E R I N  BI NDING
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Pig. 4.7 Correlation between binding affinities of
3
compounds for [ H]-ketanserin binding to rat and gerbil 
frontal cortical membranes.
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[ 3 h ] - k e t a n s e r i n  b i n d i n g  t o  p i g  c o r o n a r y  a r t e r y
tota l
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specific
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[ * H ] - k e ta n s e r ln  (nM)
Pig. 4.8 Relationship between total, nsb 3anc* specific
binding and ligand concentration. [ H]-ketanserin
concentrations of 0.05-25nM were incubated with pig
o . . .
coronary artery membranes at 37 C for 15min m  Tris HCl
buffer (50mM Tris HCl, 4mM CaC12, 5.7mM ascorbate, 10/m
pargyline; pH 7.4). Non-specific binding was determined in
the presence of 2/m methysergide.
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[ 125I]-LSD BINDING TO PIG CORONARY ARTERY
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Fig. 4.9 Relationship between total, nsb and specific
binding and ligand concentration. [ I]-LSD concentrations
of 0.01-4nM were incubated with pig coronary artery
o
membranes at 37 C for 60min in Tris HCl buffer (50mM Tris
HCl, 4mM CaCl , 5.7mM ascorbate, 10/m pargyline; pH 7.4). 
2
Non-specific binding was determined in the presence of 2/m 
methysergide.
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C 125I ] —LSD B I ND IN G TO HUMAN UMBI LI CAL A R T E R Y
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Fig. 4.10 Specific binding of [ I]-LSD to human umbilical
125
artery membranes. Membranes were incubated with [ I]-LSD
o
(0.01-4nM) at 37 C for 60min in Tris HCl buffer (50mM Tris
HCl, 4mM CaCl , 5.7mM ascorbate, 10/Ltm pargyline; pH 7.4). 
2
Non-specific binding was determined in the presence of 2/im 
methysergide. The data describes a single experiment 
performed in duplicate.
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INHIB IT ION OF [ ’ “ ID-LSD BINDING
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Fig. 4.11 Inhibition studies of [ I]-LSD binding to HUA
membranes were conducted over a concentration range of 
-11 -4
1x10 -1x10 M ketanserin, methysergide and phentolamine.
o
Incubations were performed for 15min at 37 C in a Tris HCl
buffer (50mM Tris HCl, 5.7mM ascorbate, 4mM CaCl , 10/xm
2
pargyline, pH 7.4). Non-specific binding was determined in 
the presence of 2/xm methysergide. The data describes a 
single experiment for each competitor performed in 
duplicate.
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COMPOUND X INHIBITION OF [ 3H]-KETANSERIN BINDING
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Fig. 4.12 Inhibition studies of [ H]-ketanserin to rat
frontal cortical membranes were conducted over a
-10 -5
concentration range of 1x10 -1x10 M compound X.
°
Incubations were performed for 15min at 37 C in a Tris HCl 
buffer (50mM Tris HCl, 5.7mM ascorbate, 4mM CaCl^, 10/un 
pargyline; pH 7.4). Non-specific binding was determined in 
the presence of 2/tm methysergide. The data describes a 
single experiment performed in duplicate. Computer-assisted 
curve fitting procedures showed a two site fit was 
significantly better than a one site fit, p<0.001.
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3
Scatchard plots of specific [ H] -ketanserin binding to rat 
cerebrocortical membranes in the presence or absence of 
compound X
•  control
i
o
x
T3
C3
O
XI
80 160
bound (fm ol/m g protein)
2 40
Kd Bmax
nM fmol/mg protein
0.41 2 4 0
0 .2 2  79
Fig. 4 . 1 3  Scatchard plots of specific [ H]-ketanserin 
binding to rat frontal cortical membranes in the absence 
and presence of compound X. Incubations were performed for 
15min at 37°C in a Tris HCl buffer (50mM Tris HCl, 5.7mM 
ascorbate, 4mM CaCl , 10/xm pargyline; pH 7.4). Non-specific 
binding was determined in the presence of 2/im 
methysergide. The data represents a single experiment.
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INHIBITION OF PLATELET AGGREGATION
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Pig, 4.14 Platelet aggregation was carried out in response 
to 5HT (lOjtim) and collagen (160nM) in the absence or 
presence of increasing concentrations of compound X,
ketanserin or prazosin.
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F i g .  4 . 1 5  Correlation of affinity of compounds for [ H]-LSD 
binding to human platelet membranes and inhibition of 
5HT-induced platelet aggregation.
162
THE EFFEC T OF METHYSERGIDE ON THE 5H T RESPONSE IN PCA
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Pig. 4.16 Log concenration-response curves (CRC's) to 5HT 
in the presence of methysergide in longitudinal strips of 
pig coronary artery (n=4). CRC's to 5HT were constructed 
twice in each of four preparations from the same artery. 
Response (ordinate) was calculated as a % of the maximal 
response to 5HT of the first curve. In three of the four 
preparations the second CRC was repeated in the presence of 
one concentration of methysergide. In the fourth (control) 
preparation the first and second CRC's were constructed 
without antagonist in order to assess the change in 
sensitivity to 5HT with time. Vertical bars are the mean + 
s.e.m.
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THE E F F E C T  O F K E T A N S E R IN  o n  THE 5 H T  R ESPON SE IN PCA
1 0 0
■ control raiponit
10
E
1.0
10'
20
log agon is t concantratlon (M)
Fig. 4.17 Log concenration-response curves (CRC’s) to 5HT 
in the presence of ketanserin in longitudinal strips of pig 
coronary artery (n=4). CRC's to 5HT were constructed twice
in each of four preparations from the same artery. Response 
(ordinate) was calculated as a % of the maximal response to 
5HT of the first curve. In three of the four preparations
the second CRC was repeated in the presence of one
concentration of ketanserin. In the fourth (control)
preparation the first and second CRC's were constructed 
without antagonist in order to assess the change in 
sensitivity to 5HT with time.
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Table 4.1. The affinity of selective antagonists and
agonists for the 5HT binding site
2
pKi (nM)
8.72 ± 0.06 
8.00 ± 0.15 
8.20 ± 0.10 
7.95 ± 0.08 
<5
6.7 ± 0.15 
<5 
<5 
<5 
<5
6.32 ± 0.11 
<4 
<4 
<4
"3
Membranes were incubated with [ H]-ketanserin (0.5nM) for 
o
15min at 37 C, in the presence or absence of 12
concentrations of the competing drug in a final volume of
2ml Tris assay buffer (50mM Tris HCl, 5.7mM ascorbate, 4mM
o
CaCl , 10/xm pargyline; pH 7.4 at 37 C) . Nsb was defined
using 2/xm methysergide. The concentration of drug to
inhibit specific binding by 50% was obtained graphically
and converted to a Ki value using the relationship Ki
=IC / (1+ [L]/Kd) , where [L] represents the free ligand 
50 . . .  ,. .
concentration and Kd = the equilibrium dissociation
constant of the radioligand. The Hill slopes for all
compounds tested were not significantly different from
unity. Values shown are the mean Ki of at least three
experiments performed in duplicate.
ketanserin
methysergide
cyproheptadine
mianserin
imiloxan
yohimbine
prazosin
domperidone
propranolol
triprolidine
5HT
noradrenaline
dopamine
isoprenaline
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Table 4.2 Effect of GTP on affinity values for 
[ H]-ketanserin binding to rat frontal cortical membranes
Ic (nM)
50
control nH ImM GTP nH
5HT 260 ± 35 0.85±0.05 2490 ± 70 0.88±0.06
*
bufotenine 690 ± 20 0.75±0.03 1790 ± 85 0.92±0.08
ketanserin 2 ± 0.08 0.90±0.03 1.8 ± 0.1 0.92±0.04
spiperone 1.6 ± 0.05 0.95±0.04 1.6 ± 0.09 0.94±0.05
cyproheptadine 6 ± 0.15 0.99±0.04 6 ± 0.15 1.02±0.03
methysergide 10 ± 0.2 0.93±0.03 13 ± 0.2 0.96±0.04
Membranes were incubated with [ H]-ketanserin (0.5nM) for 
o
15min at 37 C, in the presence or absence of 12
concentrations of the competing drug in a final volume of
2ml Tris assay buffer (50mM Tris HCl, 5.7mM ascorbate, 4mM
CaCl , lO/urn pargyline; pH 7.4 at 37 C) in the presence or 
2
absence of ImM GTP. Specific binding was determined by 
parallel incubations in the presence of 2/xm methysergide. 
Data represents the mean ± s.e.m. of 2-5 experiments 
performed in duplicate.
*P<0.001 relative to control
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Table 4.3 Effect of ascorbate and buffer ions on 
[ H]-ketanserin binding to rat frontal cortical membranes
Kd Bmax
nM fmol/mg protein
Control 0.42±0.05 240±25
*
5.7mM ascorbate 0.68±0.08 173±20
* *
physiological 0.86±0.07 183±30
Membranes were incubated to equilibrium with 
3
[ H]-ketanserin (0.5nM) in a 50mM Tris HCl buffer (pH 7.4 
o
at 37 C) containing 5.7mM ascorbate, 4mM CaC12 and 10MM 
pargyline (control), or containing only 5.7mM ascorbate or 
a physiological buffer as described in section 4.2.2b. Data 
represents the mean ± s.e.m. of three experiments performed 
in duplicate.
Statistical significance, relative to control.
*p<0.05; **p<0.01.
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Table 4.4 Effect of equilibrium temperature on 
[ H]-ketanserin binding to rat frontal cortical membranes
Kd Bmax
(nM) (fmol/mg protein)
48±0.08 222±18
42±0.05 240±25
Membranes were incubated to equilibrium (15min at 
o o 3
37 C; 25min at 22 C) with [ H]-ketanserin (0.05-5nM) in a
Tris assay buffer (50mM Tris HCL, 5.7mM ascorbate, 4mM
CaCl , 10/zm pargyline; pH 7.4). Data represents the mean ±
s.e.m. of three experiments performed in duplicate. No
significant difference was found in any group.
Incubation
Temperature
o
22 C 0
o
37 C 0
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Table 4.5 Characterisation of the 5HT binding site in the 
rat frontal cortical membranes
Ki (nM)
LSD ketanserin mianserin
5HT antagonists
ketanserin 1.9 2 2.5
methysergide 7 10 12
cyproheptadine 4 6 3
mianserin 15 11 5
Dopamine antagonist
spiperone 1.7 1.6 1.4
a-Adrenoceptor antagonists
prazosin 1,259
phentolamine - 1,000 -
yohimbine - 200 -
imiloxan - >10,000 -
0-Adrenoceptor antagonist
propranolol 8,000
Agonists
5HT 694 501 562
dopamine >10,000 >10,000 >10,000
noradrenaline >10,000 >10,000 >10,000
histamine >10,000 >10,000 >10,000
 -------------------------------------- .--------------------3--------------------- ;
Membranes were incubated with [ H]-ketanserm (0.5nM) for 
o
15min at 37 C, in the presence or absence of 12
concentrations of the competing drug in a final volume of 
2ml Tris assay buffer (50mM Tris HC1, 5.7mM ascorbate, 4mM 
CaCl , 10/m pargyline; pH 7.4 at 37 C) . Nsb was defined 
using 2/m methysergide. The concentration of drug to 
inhibit specific binding by 50% was obtained graphically 
and converted to a Ki value using the relationship Ki
=IC /l+[L]/Kd) , where [L] represents the free ligand
concentration and Kd = the equilibrium dissociation
constant of the radioligand. The Hill slopes for all 
compounds tested were not significantly different from 
unity. Values shown are the mean Ki ( s.e.m. fall within 
5%) of at least three experiments performed in duplicate.
Table 4.6 Regional distribution of 5HT binding sites in
the rat brain
Bmax Kd
(fmol/mg protein) (nM)
Radioligand
Frontal
cortex
ketanserin
mianserin
LSD
Striatum
Hippocampus
Cerebellum
ketanserin
ketanserin
ketanserin
240±25
160±25
237±30
0.42±0.05 
9.2 ±0.9 
0.7 ±0.1
175±15
86±7
ND
0.61±0.7 
0.52±0.8 
ND
ND No detectable specific binding 
Saturation assays were performed as described in methods 
section 2.1.3, using rat membranes; frontal cortex, 
striatum, hippocampus or cerebellum, a variety of 
radioligands; [ H]-ketanserin, [ H]-mianserin or
[ H]-LSD. Values shown were obtained using the non-linear 
itterative curve fitting programme 'Ligand* (Munson & 
Rodbard, 1980), and are the mean ± s.e.m. of 3-5 
experiments performed in duplicate.
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Table 4.7 Affinity values for the 5HT binding site on 
gerbil frontal cortical membranes
pKi (nM)
ketanserin 8.65 ± 0.09
spiperone 8.90 + 0.05
ritanserin 9.20 + 0.08
methysergide 8.25 + 0.09
cyproheptadine 8.35 + 0.05
mianserin 8.20 + 0.04
5HT 5.62 + 0.04
8-OH-DPAT <5
RU24969 5.98 + 0.05
5CT 5.70 + 0.05
Prazosin 5.30 + 0.05
Membranes were incubated with [ H]-ketanserin (0.5nM) for 
15min at 37 C, in the presence or absence of 12 
concentrations of the competing drug in a final volume of 
2ml Tris assay buffer (50mM Tris HC1, 5.7mM ascorbate, 4mM 
CaCl , 10/xm pargyline; pH 7.4 at 37 C) . Nsb was defined 
using 2/nm methysergide. The concentration of drug to 
inhibit specific binding by 50% was obtained graphically 
and converted to a Ki value using the relationship Ki 
=IC / (1+ [L]/Kd) , where [L] represents the free ligand 
concentration and Kd = the equilibrium dissociation 
constant of the radioligand. The Hill slopes for all 
compounds tested were not significantly different from 
unity. Values shown are the mean Ki ± s.e.m. of at least 
three experiments performed in duplicate.
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Table 4.8 Regional distribution of 5HT binding sites in
the gerbil brain
Bmax Kd
(fmol/mg protein) (nM)
Frontal cortex 
Striatum 
Hippocampus 
Cerebellum
206 ± 25 
190 ± 10 
50 ± 14 
ND
0.48 ± 0.03 
*
1.90 ± 0.6 
0.76 ± 1.8 
ND
ND No detectable specific binding
Membranes were incubated with [ H]-ketanserin (0.05-5nM) in
a Tris buffer system (50mM Tris HC1, 5.7mM ascorbate, 4mM
CaCl , 10/xm pargyline; pH 7.4) for 15min at 37 C. Specific 
2 . . .  
binding was determined by parallel incubations m  the
presence of 2/zm methysergide. Values shown were obtained
using the non-linear itterative curve fitting programme
'Ligand' (Munson & Rodbard, 1980), and are the mean ±
s.e.m. of 2-5 experiments performed in duplicate.
Statistical significance, relative to frontal cortex.
*p<0.05.
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Table 4.9 Affinity values for 5HT binding sites on human
2
platelet membranes
Ki (nM) nH
Ketanserin 10 0.88
cyproheptadine 20 0.90
methysergide 25 0.97
5HT 205 0.80
8-OH-DPAT >10,000
yohimbine 1,550 0.79
prazosin >10,000
3
Membranes were incubated with [ H]-LSD (0.5nM) for 4h at 
o
37 C, in the presence or absence of 12 concentrations of
the competing drug in a final volume of 2ml Tris assay
buffer (50mM Tris HC1, 5.7mM ascorbate, 4mM CaCl , 10/un
o 2 1
pargyline; pH 7.4 at 37 C) . Nsb was defined using 2/un
methysergide. The concentration of drug to inhibit specific 
binding by 50% was obtained graphically and corrected for 
free ligand concentration. Values shown are the mean Ki ( 
s.e.m fall within 5%) of at least three experiments 
performed in duplicate.
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Table 4.10 Inhibition of [ I]-LSD binding to human 
umbilical artery membranes
Antagonist pKi (nM) n
*
PA2
n
Ketanserin 8.88 ± 0.06 4 8.92
(8.70-9.14)
6
Methysergide 8.35 ± 0.10 3 8.52
(8.32-8.72)
5
Phentolamine 6.25 ± 0.05 4 6.37
(5.88-6.86)
6
Buspirone 6.05 ± 0.11 3 <7 5
Pindolol <5 3 <5 5
values are the mean (95% confidence limits) or mean ± 
s.e.mean
*pA values determined by S MacLennon and taken from 
2
Brown. MacLennon and McGrath (1987).
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Membranes were incubated with [ I]-LSD (0.2nM) and a 
range of concentrations of the competing ligand in Tris 
buffer (50mM Tris HC1 containing 5.7mM ascorbate, 4mM 
CaCl , 10/un pargyline; pH 7.4) for 60min at 37 C in a final 
volume of 250/xl. Nsb was defined using 2/un methysergide.
174
Table 4.11 Inhibition of 5HT-induced platelet aggregation
IC (M)
50
-8
ketanserin 8.0 x 10
-7
compound X 1.5 x 10
-7
methysergide 2.0 x 10
cyproheptadine 7.5 x 10 ^
yohimbine 2,°5X 10
prazosin >10
Platelet aggregation was carried out in response to 5HT 
(10/xm) and collagen (160nM) in the absence or presence of 
increasing concentrations of the competing ligands.
175
4.4 Discussion
The studies performed in this section were designed to
characterise the binding of [ H]-ketanserin to rat and
gerbil brain membranes and to examine the influence of
experimental conditions. Investigations of peripheral
[ H]-ketanserin binding were also undertaken and the
results compared with functional studies of the 5HT
receptors. 2
3
The results obtained confirmed that [ H]-ketanserin is
an effective radioligand for the study of 5HT receptor
2
binding sites, showing both high affinity for the site and 
only a low percentage of non-specific binding 
(approximately 25% around the Kd of the ligand) . The slow 
dissociation rate of the ligand-receptor complex means that 
bound radioactivity can be separated from free by vacuum 
filtration.
3
The kinetics of [ H]-ketanserin binding were consistent 
with it binding to a single population of sites up to 5 nM. 
However, above this concentration a second component to the 
binding was identified in both total and specific binding 
isotherms. This second component also showed relatively 
high affinity and low capacity. It was assumed to be 
binding to a second neurotransmitter site as 
ketanserin has been shown to have nanomolar affinity for 
ce -adrenoceptors and histamine receptors (Leysen and 
Laduron, 1977). Therefore studies of 5HT2 receptor binding 
sites were performed at concentrations less than 5nM.
[ H]-Ketanserin has been shown to label a^-adrenoceptors in 
human and pig brain membranes (Hoyer et al, 1987c). This 
probably explains the reports in earlier studies that some 
antagonists show biphasic inhibition curves for 
[ H]-ketanserin binding in the pig cortex (Hoyer et al, 
1985b).
Difficulty was encountered in finding a drug to define 
nsb. Ketanserin itself was found to displace nsb, probably 
due to its high lipophilic nature. The structurally 
unrelated antagonist methysergide (2x10 M) was chosen.
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Several compounds including 5HT, showed a plateau at the 
same level of specific binding as methysergide which 
suggests that the specific binding is accurately defined 
and that interaction with other receptor sites or with 
chemical recognition sites of the ketanserin structure 
'ketanserin binding site' is not involved. Compounds of the 
same chemical structure to the radioligand have previously 
been shown to displace nsb (see Burt, 1985) . 
[ H]-ketanserin has been shown to label displaceable 
non-serotonergic sites in striatal membranes and on 
platelets (Leysen 1985), which were found to be selectively 
inhibited by tetrabenazine and proposed to be involved in 
the release of mainly oxidized metabolites of 
catecholamines and 5HT (Leysen et al, 1987).
There were considerable differences in the binding of
[ H]-ketanserin under various conditions. When included in
the assay to prevent oxidation of indolamine ligands,
ascorbate caused a reduction in both the affinity and
number (although not significant in this study) of 5HT2
binding sites. This has previously been shown by
Muakkassah-Kelly et al, (1982) for the binding of 
3 .
[ H]-spiperone and Leysen et al, (1982a) for the binding of
[ H]-ketanserin. The reduction in binding in the presence
of ascorbate could be cause by lipid peroxidation induced
by ascorbate (Muakkassah-Kelly et al, 1982). This phenomena
was described at some length in the discussion to chapter 3
and therefore will not be repeated here.
In a physiological buffer a significant decrease in 
affinity and a decrease in Bmax^ although not significant 
was found for the binding of [ H]-ketanserin. This was 
suggested by Leysen et al, (1982a) to be due to an 
increase in the dissociation rate of the [ H]-ketanserin 
receptor complex in physiological compared with Tris HC1 
buffers. Monovalent ions have been shown^to have very 
little effect on the specific binding of [ H]-ketanserin. 
Sodium which is usually the most potent monovalent ion in 
shifting agonist curves (Limbird, 1981) has little effect 
on agonist inhibition of [ H]-ketanserin binding. However, 
Battaglia et al, (1983) showed that Li was 10 fold more
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potent in reducing the apparent affinity of 5HT for 
[ H]-ketanserin.
GTP was found to cause a rightward shift in agonist
concentration response curves, similar to those reported
for receptors coupled to adenylate cyclase. However, Conn
and Sanders-Bush (1985, 1986) showed a good correlation
between the 5HT^ binding affinity in the rat frontal cortex
and the inhibition of PI turnover. Therefore, as suggested
by Rodbell (1980) , it would appear that not only sites
linked to adenylate cyclase are influenced by GTP. The
involvement of a guanine nucleotide binding protein in the
coupling of the 5HT binding site to its effector systems
2
has been proposed (Berridge and Irvine, 1984).
3
The site labelled by [ H]-ketanserin in the gerbil
frontal cortex would appear to be 5HT^ specific as adjudged
by the moderate affinity of 5HT and high affinity of 5HT
antagonists but low affinity of NA, dopamine, isoprenaline
and histamine and of prazosin, domperidone, propranolol and
triprolidine. Although only a limited study of the
distribution of 5HT binding sites in the gerbil brain was
2 . . .  
undertaken. The highest density of binding sites was seen
in the frontal cortex as in the rat (this study, Leysen and
Laduron, 1977) and guinea-pig (Leysen et al, 1982b). In
human brain a high density of 5HT^ binding sites is found
in layers 111 and V of several cortical areas including the
frontal cortex (Pazos et al, 1987). No significant binding
was seen in the cerebellum. This is similar to that
observed in the rat but in contrast with that reported for
the guinea-pig (Leysen et al, 1982b). The distribution of
5HT binding sites markedly differs from the distribution
of 5HT binding sites in the gerbil, see section 3.2.6.
1
3 . . .
A high affinity, saturable [ H]-LSD binding site was
identified on human platelet membranes, with drug
affinities comparable to the 5HT2 binding site in rat
frontal cortex membranes. The characterisation of this site
was similar to the site described by McBride et al (1983)
for the binding of [3H]-spiperone to intact human platelets
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and by Geaney et al, (1984) for the binding of [3H]-LSD. 
[ H]-5HT also labels a 5HT site on human platelets with 
relatively high affinity (20nM) and high capacity 
(800fmol/mg protein) which has been shown to be the 5HT 
uptake site (Pletscher and Affolter, 1983). The affinity 
values of a number of antagonists, for the human platelet 
5HT^ binding site were found to correlate with their 
ablility to inhibit 5HT-induced platelet aggregation. 
Therefore this could provide a useful functional test for 
5HT^ antagonists. This information would be especially 
useful as changes in platelet aggregation are implicated in 
the aetiology of many vascular disorders.
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A high affinity, saturable [ I]-LSD binding site was 
identified for the first time on human umbilical artery 
membranes. Binding was displaced potently by 5HT
2
antagonists with affinities comparable to the rat brain and
not by 5HT ligands. The failure to identify 5HT^ binding
sites on PCA using [ H]-ketanserin was probably due to the
low specific activity of the radioligand. Studies of 
125
[ I]-LSD to PCA showed only limited success because of 
the difficulties encountered in the membrane preparation, 
the tissue was very fibrous and at the time of these 
studies only a relatively low spin speed was available. 
However, these problems were overcome in the HUA studies 
and the binding methods used here may prove useful for the 
further characterisation of human vascular 5HT^ receptors. 
They also show a useful integration of binding and 
functional techniques.
Compound X, using in vitro binding assays, was found to 
bind with high affinity to 5HT^ receptor sites; however the 
competition curves showed low Hill slopes. A shallow Hill 
slope can indicate negative co-operativity. The binding of 
compound X lessens the apparent affinity that the rest of 
the binding sites display for the competing drug, i.e. 
there is an allosteric modulation on the binding of the 
compound. This observation prompted a more thorough 
investigation of the type of inhibition caused by compound
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3
X on [ H]—ketanserin binding to 5HT sites on rat frontal 
cortex. 2
Compound X was shown to have no intrinsic agonist
activity on 'in ^vitro1 smooth muscle preparations.
Displacement of [ H]-ketanserin binding to rat frontal
cortex membranes by compound X was unaffected by lmM GTP,
unlike 5HT and bufotenine, therefore it is unlikely to
have agonist activity.
Interestingly, the experiments indicated that compound X
was non-competitive at 5HT binding sites in the rat
frontal cortex. Frenkel and Kaumann, (1985) suggested a
model for allosterically controlled 5HT receptors.
2
According to the model 5HT and ketanserin compete for the 
5HT^ receptor in the active R state whereas methysergide 
and ritanserin (Frenkel and Kaumann 1987) favour
isomerization of the receptor towards the less active R' 
state. Ketanserin competes not only with 5HT for the 5HT
2
receptor in the R state but also competes with methysergide
for the allosteric site thus causing R' - R. When the 5HT2
receptor is in the R' state, 5HT at high micromolar
concentrations can evoke merely a residual low-sensitivity
component of contraction.
Therefore, functional experiments suggest that ketanserin
binds with high affinity to both the 5HT2 receptor and an
allosteric site, whereas methysergide and ritanserin bind
apparently only to the allosteric site. This would imply 
3
that [ H]-ketanserin should label both sites and that
ritanserin and methysergide should bind only to the
allosteric site. Ritanserin and methysergide therefore
should only partially remove ketanserin from specific
sites. However, this does not hold true for the binding of 
3
[ H]-ketanserin to rat frontal cortex. Methysergide appears 
to be a competitive antagonist which displaces the same 
percentage of specific binding as 5HT. The extra binding 
displaced by cold ketanserin has been attributed to a 
'ketanserin binding site' i.e. displaceble nsb.
Following preincubation with InM ritanserin (Leysen et 
al, 1985) or lOnM compound X [ H]-ketanserin binding is 
reduced. Conceivably these compounds, by allosterically
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favouring the^R1 state of the 5HT receptor prevents the
access of [ H]-ketanserin to both the allosteric site (by
competition) and to the R state of the 5HT receptor (by
2
allostensm) . However, the non-competitive inhibition by
ritanserin has been ascribed to the slow dissociation of
the compound from 5HT^ sites in the rat frontal cortex
(Leysen et al, 1985). This cannot explain the apparent
non-competitive inhibition by compound X, as it rapidly
dissociates from 5HT binding sites, (MacLennan, 1986).
2
A further complication is that compound X appears to be 
competitive in PCA and HUA preparations (MacLennan, 1986) . 
It would be useful to examine the binding kinetics of these 
compounds in tissues where they have been shown to be 
non-competitive in functional studies, in order to further 
examine the proposed 'states' of the receptor.
Compound X may well prove a useful tool in these studies.
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Chapter 5: THE EFFECT OF CEREBRAL ISCHAEMIA ON 5HT
NEUROPHARMACOLOGY IN THE MONGOLIAN GERBIL
5. THE EFFECT OF CEREBRAL ISCHAEMIA ON 5HT 
NEUROPHARMACOLOGY IN THE MONGOLIAN GERBIL
5.1 Introduction
A marked reduction in the supply of oxygen or glucose to 
the brain leads to a cascade of events that proceed from 
neuronal dysfunction to cell death depending on the
severity and duration of the insult. Although cerebral 
ischaemia is generally related to disturbances within the 
circulation, its impact on the tissue is determined by 
neurochemical events at the cellular and subcellular level. 
The absence of all blood supply results in an immediate 
reduction in high energy phosphates and glucose (Goldberg 
et al, 1966) with a reciprocal increase in lactate 
(Rehncrona et al, 1981) and free fatty acids (Bazan, 1970). 
If a critical period of ischaemia is reached then 
uncontrolled entry of calcium occurs leading to cell death 
(Hass, 1983).
In addition to changes in cellular metabolism, cerebral 
ischaemia alters the level of the monoamines, noradrenaline 
(NA) dopamine (DA) and 5HT; neurotransmitter release could 
be associated with calcium entry. Cerebral infarction in 
the Mongolian gerbil, Meriones unguiculatus, reduces the 
level of DA in the neostriatum, hippocampus and 
hypothalamus (Zervas et al, 1974) and corpus striatum (Alps 
et al, 1984), and 5HT in the cerebral cortex (Welch et al, 
1977; Harrison et al, 1979) and striatum (Alps et al, 
1985) . Low levels of 5HT have also been reported in human 
cerebral infarcts cit autopsy (Jellinger et al, 1978). The 
reduction in DA and 5HT has been attributed to their 
release from neurons situated in the penumbra of the 
ischaemic insult (Lavyne et al, 1975a; Welch et al, 1972). 
The increased level of extraneuronal 5HT has been suggested 
as a contributing factor in the pathogenesis of progressive 
cerebral ischaemia (Welch et al, 1972; 1973), possibly 
leading to secondary deleterious effects on cerebral blood 
flow and metabolism (Wurtman and Zervas, 1974) .
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In order to investigate further the effects of cerebral
ischaemia on the 5HT system, studies were carried out in
the gerbil, using a number of models of ischaemia.
Although it is known that certain types of neurons are
selectively vulnerable to ischaemia, such as the
hippocampus pyramidal cells in the CA1 subfield (Kirino,
1982) ,. very few studies have focused on the alterations in
the receptor populations following ischaemia. This section
describes the effect that ischaemia has on 5HT binding
sites in the gerbil, namely 5HT sites in the frontal
2
cortex, 5HT sites in the striatum and 5HT sites in the 
IB 1A
hippocampus. The latter population are particularly
interesting as they are located on the pyramidal cells
(Pazos and Palacios, 1985). The effect of cerebral
ischaemia on the level of 5HT in various regions of the
brain was also examined to determine, if possible, its
relation to the alterations in the receptor populations.
Finally, preliminary studies were undertaken to examine
the functional relevance of the changes observed.
The figures and tables are included at the end of the
results section.
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5.2 RESULTS
5.2.1 Identification of stroke-prone animals
Initial studies into the effects of cerebral ischaemia 
on 5HT binding sites were undertaken using the 3h 
unilateral non-recovery model of ischaemia described in 
section 2.3.1a. One disadvantage to the model is the low 
yield of ischaemic animals. The Mongolian gerbil was 
introduced as a stroke model because of its incomplete 
circulus arteriosus; unilateral carotid ligation produces 
ischaemia in 30-40% of the gerbils. The failure to induce 
cerebral ischaemia in all animals made it necessary to 
select out the stroke-prone from stroke-resistant animals. 
Selective breeding in some laboratories has increased the 
yield of stroke-prone animals. Selection is most commonly 
achieved using an assessment of clinical signs, circling 
behaviour, extreme rotation of hind limb, eyes fixed open, 
ptosis, paucity of movements and piloerection-tremor. 
However, this is only possible in recovery models of 
ischaemia and therefore could not be used in these 
studies. A method for rapidly assessing the anatomical 
defects in the circulus arteriosus was devised for 
determining stroke-prone animals.
5.2.1a Anatomical determination of stroke-prone animals
A schematic representation of the circulus arteriosus in 
the Mongolian gerbil is shown in fig. 5.1.
The observation by Levine and Payan, (1966) that 
unilateral carotid ligation in the Mongolian gerbil caused 
a 20% mortality rate after 48h was suggested to be due to 
some inadequacy of the cerebral anastomotic circulation. 
Anatomical investigation by Levine and Sohn, (1969) 
established that in the gerbil, posterior communicating 
arteries between the carotid and vertebro-basilar 
circulatory systems were often absent. This finding was 
confirmed by Kahn, (1972) and was extended by Harrison et 
al, (1973) who also reported a variable anatomy of the 
anterior cerebral arteries.
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GERBIL CEREBRAL VASCULATURE
Anterior cerebral a.
Middle cerebral a.
Internal carotid a.
Posterior cerebral a. 
Post communicating a.
External carotid a. 
Basilar a.
Common carotid a. 
Vertebral a.
Pig. 5.1 Diagramatic representation of the gerbil cerebral 
vasculature, showing the arteries making up the ci 
arteriosus. a=artery.
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Initial results in this study indicated that
determination of whether an animal succumbed to unilateral 
carotid ligation was independent of the lack of anastomosis 
between the carotid and vertebro-basilar circulation as the
majority of the animals failed to show anastomosis. The
significant feature of the blood supply was the degree of 
anastomosis between the anterior cerebral arteries. Thus, 
the anterior neurovasculature could be used to predict the 
outcome of the surgical procedure.
On the basis of the anterior vasculature arrangement a 
method for identifying stroke-prone and stroke-resistant 
animals was established. From a detailed microscopic 
examination of the anterior cerebral arteries of 500
animals, the following classification was devised:-
Group 1 - No anterior cerebral anastomosis. The two
anterior cerebral arteries continued as separate 
vessels to a point where they could no longer be 
traced beyond the olfactory bulbs.
Aproximately 5-10% of animals 
Group 2 - Small, probably insignificant, branch between
the two anterior cerebral arteries which again remain 
separate. This connecting branch is distal to the 
optic chiasma.
Aproximately 25-30% of animals 
In groups 1 and 2 the critical point for effective 
anastomotic supply to the opposite anterior and middle 
cerebral arteries has been passed. Together they form the 
stroke-prone group of animals.
Group 3 - The anterior cerebral arteries fuse to form a 
single vessel close to the optic chiasma. The blood 
supply is greatest from the unligated side.
Group 4 - The anterior cerebral arteries fuse close to the 
optic chiasma and form many collaterals. The blood 
supply is even from both sides. Often a communicating 
artery was found between the anterior and posterior 
circulation.
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Groups 3 and 4 make up the stroke-resistant group of 
gerbils which is >60% of the total number of animals. A 
diagrammatical representation of the four groups is shown 
in fig 5.2.
TYPES OF ANTERIOR CEREBRAL ANASTOMOSES
S T R O K E - P R O N E
S T R O K E - R E S I S T A N T
Pig. 5.2 Diagramatic representation of the possible types 
of anastomoses between the anterior cerebral arteries in 
stroke-prone and stroke-resistant gerbils.
The anterior cerebral vasculature of stroke-prone and
stroke-resistant animals, stained with black ink, can be 
seen in photographs 5.1 and 5.2.
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5.2.1b EEG determination of stroke-prone animals
A second method of determining stroke-prone animals 
was investigated, namely examination of the 
electroencephalogram (EEG) of the animal. Animals were 
anaesthetised with halothane. No change in the magnitude of 
the signal was apparent before or after surgery. Following 
unilateral occlusion of the right common carotid artery the 
EEG became isoelectric. On removal of the occlusion normal 
EEG activity returned indicating the reversible nature of 
the effect. Animals showing ipsilateral or bilateral 
isoelectric EEGs within 10s of unilateral occlusion of the 
right common carotid artery were designated 
stroke-prone (fig 5.3). Anatomical investigation of the 
cerebral vasculature of these animals indicated an 
incomplete circulus arteriosus and poor collateral 
circulation. This suggested that a correlation existed 
between neurovascular anatomical defficiency and the 
occurence of an isoelectric EEG. However, only a 
subpopulation of animals described as stroke-prone in 
anatomical studies developed isoelectric EEGs. This 
subpopulation (8%) was shown to correspond to the group 1 
stroke-prone animals showing severe vascular insufficiency. 
Bilateral EEG flattening in many of these animals 
emphasised that the poor blood flow was unable to support 
any electrical activity. Stroke-resistant animals were not 
susceptible to unilateral occlusion and showed no EEG 
flattening (fig. 5.3).
The use of EEG flattening to determine stroke-prone 
animals was rapid and less invasive than the anatomical 
examination of the circulus arteriosus. However, this 
method indentified only a subpopulation of the previously 
designated stroke-prone animals. Interestingly all animals 
under pentobarbital anaesthesia showed some degree of EEG 
flattening. However, pentobarbital was used in unilateral 
ligation studies because gaseous anaesthesia was 
impractical for large numbers of animals.
In the following studies stroke-prone animals were 
identified for an anatomical assessment of the circulus 
arteriosus.
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EEG RECORDINGS
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Fig. 5.3 EEG recordings from a stroke-prone and stroke- 
resistant animal pre and post-ligation. The electrodes 
were postioned subcutaneously in the left cortex, right 
cortex and hindbrain areas, roughly equivalent to EEG 
positions 13,14 & 2 0 in the human. Recordings were made 
from left hemisphere to hindbrain, right hemisphere to 
hindbrain and left to right hemisphere. A flattening of the 
EEG recording can be seen post—ligation in the stroke—prone 
gerbil.
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5.2.2 Effect of cerebral ischaemia on 5HT levels
5.2.2a Determination of 5HT levels in the left and right 
corpus striatum following 3h unilateral ligation
Examination of stroke-prone animals, Groups 1 and 2, 
showed that in sham—operated animals there was no 
difference between the 5HT levels in the left and right 
striatum; whereas in ligated animals a fall in 5HT was 
observed. This reduction in tissue 5HT was only 
statistically significant in the occluded hemisphere 
(table 5.1).
In animals classified as stroke-resistant, Groups 3 and 
4, ligation of one common carotid artery did not result in 
a statistically significant decrease in the level of 5HT in 
either the left or right hemisphere of the corpus striatum, 
(table 5.1).
Table 5.2 shows the percentage change in corpus striatal 
5HT in the occluded relative to the non-occluded hemisphere 
for both experimental groups. The data for each individual 
animal is represented in fig 5.4.
5.2.2b Determination of 5HT levels in the left and right 
corpus striatum following 30 and 60min unilateral ligation
The fall in 5HT was dependent upon the duration of the 
ischaemic insult, a decrease in the 5HT level in the 
ligated hemisphere was seen at 30min and 60min (fig 5.5), 
however, it was not significant until 3h.
5.2.2c Determination of 5HT and 5HIAA in the frontal 
cortex following 3h unilateral ligation
In stroke-prone animals a significant decrease in the 
level of 5HT was observed in the ischaemic hemisphere of 
the frontal cortex (table 5.3). The alteration in the level 
of 5HT as a result of global ischaemia is therefore not 
restricted to the corpus striatum. A corresponding 
increase, although not significant, in the level of 5HIAA 
was found in the ischaemic hemisphere.
5.2.2d Determination of 5HT and 5HIAA levels in the
frontal cortex following 5min bilateral ischaemia
A significant decrease in 5HT levels was seen in the 
frontal cortex following 5min bilateral ischaemia (table
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5.4). A slight although not significant decrease in 
5-hydroxyindole acetic acid (5H1AA) was also found.
An example of the chromatograph (fig 5 .6) shows the 
separation of 5HT and internal standard produced under 
conditions used in this study.
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Pig. 5.6 A standard chromatogram for NA (2ng/100/il) , DA 
(2ng/l00/il) , 5HT (2ng/100/zl) and the internal standard DHB 
(lng/100/il) . Analysis by HPLC was performed as described in 
methods.
Thus global unilateral ischaemia (up to 3h) and brief 
bilateral ischaemia have pronounced effects upon the level 
of 5HT in at least two areas of the gerbil brain (frontal 
cortex and corpus striatum).
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5*2.3 Effect of cerebral ischaemia on 5HT binding sites
5.2.3a Effect of ischaemia on 5HT binding site parameters
The binding of [ H]—ketanserin to membranes of gerbil 
frontal cortex was saturable, reversible and of high 
affinity. Iterative non-linear analysis of the binding 
isotherms demonstrated a single class of high affinity 
sites with a Kd of 0.4810.03nM and a Bmax of 206120 fmol/mg 
protein (see section 4.2.6).
3
The effect of ischaemia on [ H]-ketanserin binding in 
the non-recovery model is shown in table 5.5. Ligation of
the right common carotid artery for 3h without reperfusion
caused significant reduction in [ H] -ketanserin binding to 
the right hemisphere of the frontal cortex. The binding of 
[ H]-ketanserin to the left hemisphere was unaffected by 
unilateral ligation. Iterative non-linear analysis of the 
binding isotherms indicated that the change in 
[ H]-ketanserin binding to the right hemisphere was due to 
a decrease in the density of binding sites and not a change
in affinity. Also see fig 5.7.
[ H] -Ketanserin binding was also affected in the less
severe model of cerebral ischaemia. Analysis of the
3 . . .
saturation isotherms for [ H]-ketanserin binding to frontal
cortical membranes prepared from animals 3 days after a
5min period of cerebral ischaemia revealed a significant
decrease in the total number of [ H]—ketanserin binding
sites without an apparent change in affinity (table 5.6).
[ H]-ketanserin binding to ischaemic frontal cortex 
membranes showed a similar pharmacological profile to 
non-ischaemic tissue. In competition studies affinity 
values were determined for ketanserin (pKi 8.6), 
methysergide (pKi 7.9) and 5HT (pKi 5.4), which are similar 
to the affinities determined for the binding of these 
compounds to non-ischaemic (control) gerbil cortex (see 
table 4.7).
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5.2.3b The effect of different methods of inducing death 
on the ^^^2 binding site parameters after 3h
The 3h unilateral ligation of the right common carotid 
artery is a very severe model of cerebral ischaemia. 
Therefore, in order to provide additional evidence that 
cerebral ischaemia does selectively alter the binding 
parameters of the ^ ^ 2  binding site, a comparative study 
was carried out to assess 3h hemispheric ischaemia and 3h 
postmortem changes.
In this study all animals were anaesthetised with 6mg
pentobarbital, and then killed by decapitation, air
embolism or cervical dislocation. The brains were left 'in
o
situ' for 3h and the animals maintained at 37 C, for direct 
comparison with the 3h ischaemia model. Membranes were then 
prepared and assays performed as described in section 
2.1.1.
3
The binding of [ H]-ketanserin to membranes prepared 3h 
after death was found to be highly variable (table 5.7). 
Death by cervical dislocation resulted in animals showing 
either 'normal' binding characteristics, ischaemia-like 
binding characteristics (i.e. decrease in Bmax without a 
change in Kd) or minimal specific binding. Death by 
decapitation resulted in ischaemia-like binding 
characteristics or in most animals no detectable specific 
binding. Death induced by air embolism again resulted in 
the loss of specific binding in most of the animals tested. 
It is possible that cervical dislocation does not
immediately stop all blood flow to the brain, unlike the 
other two methods. However, no dose-dependent inhibition of 
[ H]-ketanserin binding by methysergide could be measured 
in membranes from 3h postmortem tissue. Therefore any 
binding detected in saturation studies is probably nsb. The 
results of this study suggest that 5HT2 binding sites in 
the gerbil frontal cortex are destroyed 3h postmortem and 
are selectivly vulnerable to 3h hemispheric ischaemia.
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5.2.3c Effect of ischaemia on 5HT binding site parameters
1A 3
Preliminary experiments carried out using [ H]-5HT
(table 5.8), showed an increase in the number of 5HT
1
binding sites. The increase was not seen immediately 
following lOmin bilateral ligation but was apparent after 
2h reperfusion (p<0.02). A significant decrease in affinity 
was also found (p<0.05).
3
The binding site labelled by [ H]-8-OH-DPAT in the 
gerbil hippocampal membranes is characteristic of the 5HT
1A
binding site, having high affinity for 5HT, 8-OH-DPAT,
buspirone and WB4101 and low affinity for the 5HT
2
antagonist ketanserin or the selective 5HT /5HT
1C 2
compound mesulergine (see section 3.2.6).
Iterative non-linear analysis of the saturation
isotherms indicated that transient ischaemia followed by
72h recovery resulted in a significant increase in the
density of 5HT binding sites in the hippocampus (table
1A
5.9). This increase in 5HT binding sites was not
1A 3
accompanied by a change in the affinity of [ H]-8-OH-DPAT
for the binding site.
Similar results were obtained using the 5HT ligand 
3 1A
[ H]-WB4101. An increase was found in the number of 5HT
1A
binding sites in the hippocampus without an apparent change 
in affinity (table 5.10).
5.2.3d 5HT binding site 
IB
In contrast to the ischaemia-induced increase m  5HT
1A
binding sites in the hippocampus and decrease in 5HT2
binding sites in the frontal cortex, 3h unilateral
ischaemia had no significant effect upon 5HT binding
125 ( 1J3
sites labelled by [ I]-CYP in the corpus striatum, (table
5.11). A slight but not significant increase in affinity
was noted.
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5.2.4 Functional correlates for changes in 5HT binding
5.2.4a The effect of the 5min bilateral ligation followed 
by 72h recovery on the number of quipazine-induced 
head shakes
Agonist interactions at 5HT binding sites induce a head
twitch behaviour in mice and rats which can be inhibited by
5HT^ antagonists (Ortmann et al, 1982; Green et al, 1983?
Green and Heal, 1985). In these studies the 5HT agonist
2
quipazine was also shown to induce head shakes in the 
gerbil.
The number of quipazine-induced head shakes seen pre- 
and post-ischaemia is shown in table 5.12. No significant 
change in the number of head shakes in the sham-operated or 
ligated groups of animals was seen 24 or 72h following 
ischaemia. This could be as a result of the low number of 
head shakes recorded for the gerbil, 13±3/group of three 
animals /15min, or the degree of interanimal variability. 
Simiarly no significant change was seen in the locomotor 
activity of the sham-operated or ligated animals following 
ischaemia (table 5.13).
5.2.3b Autoradiographic location of 5HT binding sites in 
the gerbil
The localisation of 5HT binding sites labelled by 
125 2
[ I]-LSD in coronal sections through the frontal cortex
area of the gerbil brain can be seen in photograph 5.3. The
binding was assessed to be specific for the 5 H T 2 binding
site as in it could be displaced by 2/liM methysergide
leaving only non-specific binding (photograph 5.4). These
results indicate a high density of 5HT binding sites in
2
the frontal cortex of the gerbil brain as shown in the 
binding studies, section 4.2.6.
Unfortunately no method of quantifying the density of 
binding was available, therefore it was difficult in these 
studies to assess the effect of ischaemia. However, this 
could be a very useful technique for future studies.
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Photograph 5.3 Autoradiograph of total [ H]-ketanserin 
binding to a section through the gerbil frontal cortex.
3
Photograph 5.4 Autoradiograph of nsb [ H]-ketanserin 
binding to a section through the gerbil frontal cortex.
5.2.3c Behavioural observations
Ipsilateral rotational behaviour was observed in some of
the recovered animals undergoing unilateral ligation, these
animals were later assessed as stroke-prone by anatomical
investigation of the circulus arteriosus. However, this
rotational behaviour is unlikely to be associated with the
release of 5HT. In the rat, rotational behaviour induced
by 5HT agonists has been shown to act via 5HT receptors,
1
probably located m  the substantia nigra, an area not 
affected in this model, and the rotation is contralateral 
to the lesion (Blackburn et al, 1984) . The release of large 
amounts of DA has been suggested to be the cause of 
ipsilateral rotational behaviour in stroked gerbils (Lavyne 
et al, 1975b), a phenomenon which in rats is also related 
to asymmetric DA release (Anden et al, 1966) .
A few animals recovering from bilateral ligation showed 
flat body posture. However, other 5HT behavioural signs 
described for the rat (Tricklebank, 1984a?b) such as head 
weaves, front paw treading and head shakes were not 
observed.
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The effect on Corpus Striatal 5HT levels of unilateral ligation 
of the oatmeal carotid artery
120
inn
,60
Sham-operated Ligated
i
Stroke prone animals
Sham-operated Ligated
Stroke resistant animals
Fig. 5.4 Diagramatic representation of the results 
presented in table 5 .2 , showing the individual data points. 
The results are expressed as the % change in 5HT levels in 
the ligated relative to the unligated hemisphere.
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THE EFFECT OF 3 0 , 6 0  & 1 80  MINUTES UNILATERAL LIGATION ON SHT LEVELS IN 
THE CORPUS STRIATUM
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3 0
Fig. 5.5 Ischaemia was induced by unilateral ligation of 
the right common carotid artery for periods of 30-180min. A 
statistically significant decrease in the level of 5HT was 
seen in the right ligated hemisphere after 3h, *p<0.05.
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Fig. 5.7 Saturation experiments were carried out on the 
left or right frontal cortical membranes (2 cortex/membrane 
preparation) from ischaemic and non-ischaemic brains. 
Unilateral ischaemia was induced by a 3h ligation of the 
right common carotid artery. The data describes a 
single experiment in each group.
2 0 1
Table 5.1 The effect of unilateral ligation on 5HT levels
in the corpus striatum
A. Stroke-prone gerbils
experimental 5HT (/zg/g wet weight)
group n left hemishere right hemisphere
--------------------- ----------------------- (1 igated)____
Sham-operated 5 0.414 ± 0.049 0.464 ± 0.053
Ligated 7 0.392 ± 0.040 0.261 ± 0.043
5HT was measured by HPLC as described under methods. 
Unilateral ischaemia was induced by a 3h ligation of the 
right common carotid artery.
^Statistical significance
p<0.05 relative to left hemisphere
p<0.02 relative to sham-operated right hemisphere
B. Stroke-resistant gerbils
experimental 5HT (Mg/g wet weight)
group n left hemishere right hemisphere
___________________ (ligated)__
Sham-operated 8 .0.435 ± 0.025 0.422 ± 0.036
Ligated 8 0.392 ± 0.045 0.347 ± 0.072
5HT was measured by HPLC as described under methods. 
Unilateral ischaemia was induced by a 3h ligation of the 
right common carotid artery.
No significance difference between any group
2 0 2
Table 5.2 Percentage change in 5HT levels in the corpus 
striatum
right (ligated) hemisphere 
experimental Stroke-resistant Stroke-prone
group animals animals
Sham-operated 97.0 ± 5.1 (8) 112.2 ± 10.8 (5)
* (3
Ligated 88.4 ± 3.8 (8) 66.6 ± 5.8 (7)
^Statistical significance
p<0.01 relative to stroke-prone sham-operated
@ ,
p<0.01 relative to stroke-resistant ligated
number of animals/group shown in brackets
Percentage change in 5HT levels in the right (ligated) 
hemisphere, following 3h unilateral ischaemia. Data are 
derived from the absolute values shown in table 5.1.
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Table 5.3 The effect of unilateral ligation on 5HT levels
in the frontal cortex
(Mg/g wet weight) 
left hemishere right hemisphere
--------------------- :__   (ligated)______
5HT 0.89 + 0.05 0.38 ± 0.05
5HIAA 5.63 ± 0.07 6.19 ± 0.05
5HT and 5HIAA were measured by HPLC as described under
methods. Unilateral ischaemia was induced by a 3h ligation
of the right common carotid artery. Each value represents
the mean ± s.e.m. of twelve seperate determinations.
Significant difference from the non-ischaemic hemisphere 
*
p<0.001.
Table 5.4 The effect of bilateral ligation on 5HT levels 
in the frontal cortex
(Mg/g wet weight)
Sham-operated Ligated
5HT 0.93 ± 0.22 0.40 ± 0.11
5HIAA 6.78 ± 0.52 6.33 ± 0.27
5HT and 5HIAA were measured by HPLC as described under 
methods. Ischaemia was induced by a 5min ligation of the 
left and right common carotid arteries. Each value 
represents the meanis.e.m. of 16 separate determinations. 
Significant difference from the non-ischaemic sham-operated
animals.
*
p<0.05.
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Table 5.5 Effect of unilateral cerebral ischaemia on 5HT
• • 2 
binding sites in gerbil frontal cortex labelled
by [ H]-ketanserin
Left hemisphere Right hemisphere
Kd Bmax Kd Bmax
nM fmol/mg protein nM fmol/mg protein
NON-ISCHAEMIC CORTEX
0.48 ± 0.03 203 ± 10.4 0.47 ± 0.03 209.4 ± 18.9
ISCHAEMIC CORTEX
0.51 ± 0.03 218.4 ± 7.0 0.45 ± 0.02
*
95.5 ± 10.0
Saturation experiments were carried out on the left and
right frontal cortical membranes (2 cortex/membrane
preparation) from ischaemic and non-ischaemic brains.
Unilateral ischaemia was induced by a 3h ligation of the
right common carotid artery. Each value represents the mean
± s.e.m. of five seperate determinations. Significant
difference from the non-ischaemic sham-operated animals 
*
p<0.001.
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Table 5.6 The effect of bilateral cerebral ischaemia on 
5HT^ binding sites in gerbil frontal cortex 
labelled with [ H]-ketanserin
Kd Bmax 
fmol/mg proteinnM
NON-ISCHAEMIC 0.42 ± 0.06 192.9 ± 9.8
*
ISCHAEMIC 0.51 ± 0.06 136.6 ± 18.9
Saturation experiments were carried out on frontal cortex 
membranes prepared from ischaemic and non-ischaemic brains. 
Ischaemia was induced by a 5min ligation of the left and 
right common carotid arteries followed by 72h recovery. 
Each value represehts the meants.e.m. of 7 separate 
determinations. Significant difference from the 
non-ischaemic sham-operated animals p<0.01.
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Table 5.7 3h ischaemic or 3h postmortem changes
in binding sites on gerbil frontal cortex
Kd Bmax
nM fmol/mg protein
Control 0.47 ± 0.03 209.4 ± 18.9
*
Control hemisphere 0.51 ± 0.03 218.4 ± 7.0
(3h hemisheric
ischaemia)
ligated hemisphere 0.45 ± 0.02 95.5 ± 10.0
(3h hemispheric 
ischaemia)
Decapitation 
(3h global 
ischaemia)
3h death 
(air embolism)
3h death 
(cervical 
dislocation)
o
all experiments at 37 C 
left hemisphere 
n=4. or individual results are shown.
[ H]-Ketanserin binding parameters were determined in 
membranes from 3h ischaemic or 3h postmortem tissue as 
described in methods.
0.54 86.9
no detectable specific binding 
no detectable specific binding 
no detectable specific binding
0.28 98.4
no detectable specific binding 
no detectable specific binding 
no detectable specific binding
0.23 70.2
1.65 16.6
0.45 222.0
0.37 118.5
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Table 5.8 The effect of cerebral ischaemia on 5HT binding
1A 3
sites in gerbil hippocampus labelled by [ H]-5HT
Kd
nM
Bmax 
fmol/mg protein
non-ischaemic
hippocampus
6.12 ± 1.5 600 ± 120
ischaemic
hippocampus
5.18 ± 0.8 570 ± 80
ischaemia + 
lh reperfusion
ischaemia +
2h reperfusion
6.02 ± 1.0
11.80 ± 1.2
650 ± 60
**
1110 ± 50
Saturation experiments were carried out on hippocampal 
membranes prepared from ischaemic and non-ischaemic brains. 
Ischaemia was induced by a lOmin ligation of the left and 
right common carotid arteries. Each value represents the 
meanls.e.m. of 3 separate determinations.
*P<0.05 relative to non-ischaemic hippocampus 
**P<0.02 relative to non-ischaemic hippocampus
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Table 5.9 The effect of cerebral ischaemia on 5HT bindincx
3 1A
sites m  gerbil hippocampus labelled by [ H]-8-OH-DPAT.
Kd Bmax
nM fmol/mg protein
non-ischaemic 4.49 ± 0.89 458 ± 16
hippocampus
*
ischaemic 4.49 ± 0.20 636 ± 27
hippocampus
* p<0.01
Saturation experiments were carried out on hippocampal 
membranes prepared from ischaemic and non-ischaemic brains. 
Ischaemia was induced by a 5min ligation of the left and 
right common carotid arteries followed by 72h recovery. 
Each value represents the meanis.e.m. of 4 separate 
determinations.
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Table 5.10 The effect of cerebral ischaemia on 5HT
binding sites in gerbil hippocampus labelledMoy 
[ H]-WB4101.
Kd Bmax
nM fmol/mg protein
non-ischaemic 1.43 ± 0.22 347 ± 43
hippocampus
ischaemic 1.21 ± 0.07
*
538 ± 62
hippocampus
* p<0.05
Saturation experiments were carried out on hippocampal 
membranes prepared from ischaemic and non-ischaemic brains. 
Ischaemia was induced by a 5min ligation of the left and 
right common carotid arteries followed by 72h recovery. 
Each value represents the mean±s.e.m. of 4 separate 
determinations.
2 1 0
Table 5.11 The effect of cerebral ischaemia on 5HT
IB
binding sites in gerbil corpus striatum labelled 
by [ I]-CYP
.Kd Bmax
pM fmol/mg protein
Sham-operated
Stroke prone
left 77 + 21 310 ± 20
right 87 ± 20 314 ± 20
Stroke resistant
left 69 + 25 309 ± 12
right 65 ± 19 325 ± 10
Ligated
Stroke prone
left 37 + 14 378 ± 21
right .35 + 11 360 ± 15
Stroke resistant
left 31 + 11 350 ± 24
right 35 + 15 338 ± 12
Saturation experiments were carried out on left and right 
frontal cortex membranes prepared from ischaemic and 
non-ischaemic brains. Ischaemia was induced by a 3h 
ligation of the right common carotid artery. Each value 
represents the meanis.e.m. of 3 separate determinations.
2 1 1
Table 5.12 Headshakes pre- and post-ischaemia
HEADSHAKES
1 day 3 day
Pre-ischaemia post-ischaemia post-ischaemia
Sham-operated
group 1 8 10 14
group 3 14 5 4
group 5 16 7 5
ligated
group 2 7 1 6
group 4 7 2 1
group 6 26 18 21
Ischaemia was induced by a 5min ligation of the left and
right common carotid arteries followed by 72h recovery. 
Pre-ischaemia, 24 and 72h post-ischaemia the gerbils 
(3/group) were given quipazine (25mg/kg s.c.) and 30min 
later the number of headshakes determined over a I5min 
period.
2 1 2
Table 5.13 Locomotor activity pre- and post-ischaemia
ACTIVITY
1 day 3 day
Pre-ischaemia post-ischaemia post-ischaemia
Sham-operated
group 1 2849 2732 2876
group 3 3072 3046 3152
group 5 2830 2962 2881
ligated
group 2 3013 3068 3026
group 4 3414 3304 3398
group 6 3497 . 3608 3820
Ischaemia was induced by a 5min ligation of the left and
right common carotid arteries followed by 72h recovery. 
Pre-ischaemia, 24 and 72h post-ischaemia the gerbils 
(3/group) were given quipazine (25mg/kg s.c.) and 30min 
later their activity monitored over a 15min period.
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5.3 Discussion
The use of the gerbil as an animal model of cerebral 
ischaemia is dependent on the identification of 
stroke-prone animals by anatomical investigation of the 
circulus arteriosus. Ligation of one common carotid artery 
produces cerebral ischaemia in 30-40% of animals (Kahn, 
1972) whereas bilateral common carotid artery ligation 
produces ischaemia in 60% of animals (Levy and Brierley, 
1974) . In contrast ligation of both common carotids in the 
rat causes little morbidity and unilateral ligation is 
practically ineffective (Payan et al, 1965).
The absence of a significant posterior communicating 
artery has been suggested to account for the succeptibility 
of the gerbil (Levine and Sohn, 1969; Kahn, 1972). However, 
in this study the determination of whether the animals 
succumbed was apparently independent of the lack of 
anastomosis between the anterior and posterior circulation, 
as most of the animals failed to show any such anastomosis. 
This finding is in agreement with studies by Harrison et 
al, (1973). The significant feature of the blood supply 
appeared to be the degree of anastomosis between the 
anterior cerebral arteries. Microscopic examination of the 
anterior vasculature proved to be rapid, reliable and 
highly predictive.
EEG recordings can also be used to identify a 
subpopulation of stroke-prone animals equivalent to the 
Group 1 stroke-prone animals with severe vascular 
deficiencies. These animals showed an isoelectric EEG 
(often bilateral) following unilateral ligation. This 
assessment could only be used in halothane anaesthetised 
animals, pentobarbital was found to cause a degree of 
flattening in all animals. Barbiturate treated animals have 
been shown to lose corneal reflexes (Levy and Brierley 
1979) and have been shown to be protected against stroke 
(see review by Smith, 1977). The incidence of stroke in 
pentobarbital anaesthetised gerbils following unilateral 
ligation has been reported to be less (Lightfoote et al, 
1977) or the same (Harrison et al, 1973; and this study) as
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using ketamine (Berry et al, 1975), ether (Levine and 
Payan, 1966) or halothane (Levy et al, 1975) anaesthesia.
Measurement of the common carotid artery pressure can 
also be useful, the lower threshold of the arterial blood 
pressure for the development of brain infarcts ranges from 
22-25mm Hg (Laas, 1984). Recently occular fundus 
examination with direct ophthalmoscopy has been suggested 
as a suitable method to select stroke-prone gerbils 
(Delbarre et al, 1988).
The metabolism of 5HT appears particularly sensitive to 
the effects of even minimal ischaemia. The levels of 5HT 
were reduced in the ligated hemisphere, as early as 3 0min 
after unilateral ligation, which reached significance after 
3h. The early reduction of 5HT may be a factor contributing 
to the development of seizure-like activity in Mongolian 
gerbils undergoing carotid artery ligation. Depletion or 
elevation of brain 5HT by pharmacological means 
respectively facilitates or decreases susceptibility to 
seizures in several animal models (Maynert et al, 1975). 
However, Welch et al, (1978) have suggested that DA and NA 
levels fall only in animals that develop seizures whereas 
5HT falls in ischaemic tissue in the absence or presence of 
seizures. Further study is needed to establish if the 
change in 5HT associated with ischaemia-induced seizures is 
primary or secondary to the seizure activity itself. In 
should be added that pentobarbital has also been shown to 
significantly reduce seizure activity (Goldblatt et al, 
1971).
Unilateral carotid artery occlusion resulted in a 44% 
decrease in the level of 5HT in the striatum and a 57% 
decrease in the level of 5HT in the frontal cortex after 
3h. This is in good agreement with Welch et al, (1977) and 
Harrison et al, (1979); they reported decreases of 44% and 
38% respectively. Both these studies were performed using 
cerebral cortex, where control levels of 5HT were reported 
to be between 0.3 5 and 0.45 MU/U wet weight, which is 
similar to the levels reported in this study, 0.46+0.05 
jug/g wet weight in the corpus striatum and 0.89+0.06 ng/g
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wet weight in the frontal cortex.
The exact cause of the reduction in 5HT is unknown. 
Neuronal release of monoamines early after the onset of 
ischaemia has also been reported in the baboon (Welch et 
al, 1972) and in patients suffering from stroke (Meyer et 
al, 1974). Release Of 5HT could be attributed to membrane 
depolarization with ionic shifts and/or mitochondrial 
dysfunction (Lee and Yatsu, 1974). Other factors which 
would cause eventual intraneuronal monoamine depletion are 
failure of energy dependent synaptosomal reuptake (a 16% 
decrease in 5HT reuptake was found in this laboratory 
following 5min bilateral ligation) and synthesis 
impairment (Lavyne et al, 1975a). Inhibition of tryptophan 
hydroxylase activity prior to ischaemia, by PCPA treatment, 
results in an even greater depletion of 5HT than in 
untreated animals. The reduction in tissue 5HT is likely 
to be due in part to synthesis impairment (Welch et al, 
1977) .
The relationship between ischaemia-induced alteration in
5HT, changes in 5HT binding site characteristics or
compounds affecting these parameters is likely to be
complex. The experiments outlined in chapters 3 and 4
demonstrated the existence of 5HT binding sites in the
brain of the Mongolian gerbil. The 5HT2 binding site in the
frontal cortex and the 5HT site in the hippocampus were
1A
characterised pre- and post-ischaemia. Ischaemia changed 
the Bmax but not the Kd of high affinity 5HT binding sites. 
However, the binding sites showed the same pharmacological 
profile as non-ischaemic (normal) membrane preparations, 
which suggests they maintain their specificity.
Cerebral ischaemia resulted in a significant decrease in
the number of 5HT binding sites in the ipsilateral frontal
2
cortex following 3h unilateral ligation with no apparent 
change in affinity. The precise mechanism is not known. It 
would appear not to depend on reperfusion, which is 
associated in other models with ischaemic changes, as the 
artery ygg occluded for the duration of the experiment. 
Long periods of reperfusion have been shown to increase
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a<^ renoceP^or density in the ischaemic cat myocardium 
(Corr et al, 1981).
The decrease in the density of 5HT binding sites may be 
as a consequence of a general disruption of neuronal 
membranes. Histological damage to the gerbil cortex has 
been shown to occur in severe models of ischaemia such as 
unilateral occlusion for periods in excess of lh (Klatzo, 
1975; Ito et al, 1975). The severity of this model was 
questioned. However, specific 5HT binding was lost in 3h 
postmortem tissue unlike 3h ischaemic tissue. There is a 
general increase in proteolysis in postmortem brains. 
Therefore it may be interesting to see what effect 
incubation with protease inhibitors e.g. PMSF, has on 5HT
2
binding after ischaemia.
Ischaemia-induced changes in the number of 5HT binding
2
sites could result from a sudden non-physiological release 
of 5HT which could, through excessive stimulation, alter 
the 5HT binding protein to such an extent that it cannot 
recover later when 5HT levels decrease; prehaps they are 
internalised and degraded. In vivo dialysis measurement of 
DA release has shown there is a sevenfold increase in DA 
release in the ischaemic hemisphere 15min after carotid 
ligation (Brannan et al, 1987). As yet similar studies to 
determine the extent of 5HT release have not been 
published. However, post-ischaemia changes in 5HT levels 
suggests that 5HT release could occur earlier and take the 
tissue level of 5HT longer to recover than DA.
Alternatively the changes observed could be specific and 
selective. Alterations in the 5HT system may be one of the 
factors exacerbating ischaemic damage.
To investigate further the possible selective effects of 
ischaemia on the 5HT sites a second ischaemic model was 
used, a 5min bilateral occlusion with 72h recovery. This 
eliminated some of the problems associated with the 3h 
unilateral model, i.e. it is less severe and relies less on 
a wasteful, subjective anatomical assessment for stroke 
-prone animals. In addition, this model allows a greater 
control over the anaesthesia used. However, even in this
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model 40-s of gerbils are resistant to bilateral ischaemia 
(Levy and Brierley, 1974). Therefore, flattening of the EEG 
recording was used to determine susceptibility to 
ischaemia.
A decrease in the density of 5HT sites in the gerbil 
frontal cortex with no apparent change in affinity was 
also found in this less severe model of ischaemia. Brief 
bilateral carotid artery occlusion does not produce the 'no 
reflow' phenomenon in the gerbil after removal of the clips 
(Levy et al, 1975) suggesting that a lack of blood flow to 
the cortex during the recovery phase of the bilateral model 
is unlikely to give rise to the reduction in 5HT binding
site density. However reperfusion following the insult
could expose the 'injured' cells to damaging oxy-radicals 
leading to increased lipid peroxidation and proteolysis 
etc. The ischaemic period is therefore very different from 
the the unilateral model. The long periods of reperfusion 
associated with bilateral ligation may cause physical 
disruption of the membrane. In this model histological
changes have been shown to be restricted to the hippocampus 
(Suzuki et al, 1983; Kirino and Sano, 1984), and although 
spontaneous neuronal activity in the cortex and hippocampus 
ceases within 60sec of the ischaemic insult, it then
returns to normal in the cortex (Suzuki et al, 1983). 
Therefore it is unlikely that the decrease in density of 
5HT binding sites was due to a general disruption of 
membranes within the cortex but may represent an example of 
selective vulnerability of neurons containing the
binding sites.
There is evidence to suggest that the 5HT system may be 
selectively vulnerable to cerebral ischaemia.
Cyproheptadine and LSD, compounds with high affinity for 
5HT binding sites, have been shown to exert a beneficial 
protective effect in a rabbit spinal cord ischaemia model 
which could be reversed by the 5HT agonist bufotenine 
(Zivin, 1985).
At present the functional significance of the decrease
in 5HT binding sites in the gerbil cortex is unknown, It 
2
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has been suggested that alterations in the density of 5HT 
binding sites may play a role in the aetiology of 
depression (Blackshear and Saunders-Bush, 1982). A decrease 
in the density of binding sites has also been reported
in the hippocampus of depressed suicide victims (Cheetham 
et al, 1986). In contrast Stanley and Mann, (1983) reproted 
increased 5HT^ binding in the frontal cortex of suicide 
victims. This may reflect heterogeneity in the nature of 
the psychiatric illness. Chronic administration of the 
5HT^ antagonists ritanserin (Leysen et al, 1986) mianserin 
and ketanserin (Blackshear et al, 1983) and the 5HT
2
antagonists/5HT reuptake blockers, zimelidine (Green,
1984) and amytriptyline (Peroutka and Snyder, 1980)
apparently decrease the density of cortical 5HT binding
2
sites. Agonist interactions at 5HT binding sites in mice
2
induce a head twitch behaviour which can be inhibited by
5HT antagonists (Ortmann et al, 1982; Green et al, 1983). 
2
This behaviour has been used to investigate both acute and 
longer term effects of antidepressant drugs on 5HT 
function. Several antidepressant treatments have been shown 
to inhibit the head twitch response both acutely and 
chronically (Friedman et al, 1984; Goodwin et al, 1984).
This study showed that quipazine head shakes can be 
observed in the gerbil, which seem to resemble the rat 
rather than the mouse in frequency of responses. However, 
a significant correlation between the decrease in receptor 
binding sites and the decrease in head shakes could not be 
made.
As discussed above the 5min bilateral carotid artery 
occlusion reduces blood flow and suppresses EEG activity 
in the hippocampus of the gerbil (Suzuki et al, 1983) ;
after 3 days severe destruction of neurons within the
hippocampus is observed (Suzuki et al 1983; Kirino and 
Sano, 1984) . Therefore further investigations into effect 
of ischaemia on 5HT binding sites were carried out in the
gerbil hippocampus, an area shown in this study to be rich
in 5HT binding sites.
Although there was no change in the affinity of the
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5HT1A binding sites for the ligand, the number of binding
sites was increased following ischaemia. The finding that
the number of sites increases in a brain area where death
of selectively vulnerable cells occurs, suggests that the
5HT^^ sites are not located on vulnerable cells. However,
it is well established that the CA1 pyramidal cells in the
hippocampus are particularly vulnerable in this model of
ischaemia (Kirino, 1982; Kirino and Sano, 1984) and it has
been shown that the CA1 region is rich in 5HT bindinq
1A
sites which are located on the pyramidal cells (Pazos and
Palacios, 1985); Hall et al, 1985). These receptors
mediate 5HT-induced hyperpolarisations and are directly
+
coupled via a G protein to a K channel (Andrade et al,
1986).
Cerebral ischaemia has been reported to alter adenosine
receptors and GABA binding sites in a 15min bilateral model
of ischaemia in the gerbil. Adenosine (A ) receptors, also
1
located on the pyramidal cells, are markedly reduced but
not until 27 days post-ischaemia (Onodera and Kogure,
1985) . GABA binding, located on GABAergic interneurons
A . . . .
m  the CA1 region, showed a significant increase 3 days
after ischaemia and decreased after 27 days (Onodera et al,
1987). It is possible that there are several different
populations of 5HT sites in the hippocampus and that the
1A
5HT sites influenced by ischaemia do not reside on the 
1A
pyramidal cells. 5HT sites have been suggested to be
1A
located both pre- and post-synaptically and have been 
linked to different second messenger systems in the 
hippocampus; adenylate cyclase (Shenker et al, 1985) and 
possibly PI metabolism (Janowsky et al, 1985).
Therefore the increase in the density of 5HT^ binding 
sites is probably a compensatory change in response to the 
maturation of neuronal damage. In this respect destruction 
of the serotonergic raphe system with 5,7 dihydroxy- 
tryptamine increases the number of 5HTia sites in the 
hippocampus (Wang et al, 1985) .
The affinity and number of sites on a membrane is 
variable according to the physiological state of the
2 2 0
tissue. The nature of a proteinaceous binding site is 
likely to be influenced by its microenvironment. The 
microviscosity of the membrane can influence the number of 
available and non-available (cryptic) sites to the ligand. 
For the 5HT system it has been calculated that 50-90% of 
the binding sites are not available to the agonist (Heron 
et al, 1980) . Phospholipids, cholesterol and cytoskeletal
components all contribute to the nature of the 
microenvironment which will be altered during ischaemia. 
The microviscosity of the membrane is controlled by the 
phospholipid composition and the composition of other 
membrane lipids. Early studies by Bazan, (1970) suggested 
that energy failure in the cell led to a sharp rise in free 
fatty acids which could be correlated with the duration 
and severity of ischaemia. If the liberated FFAs arise from 
membrane phospholipids, then it is probable that brain 
ischaemia results in marked changes in the viscosity of the 
cell membranes. Therefore it is possible that the change in 
number of 5HT binding sites could be a consequence of a 
change in membrane viscosity. The dependence of 5HT binding 
sites on phospholipid composition could be further studied 
by examining 5HT binding in membrane preparations where the 
phospholipid environment has been altered, e.g. treatment 
with phospholipase.
The changes in binding site density is unlikely to be 
due to endogenous 5HT in the membrane preparation. Analysis 
by HPLC of the membrane preparation failed to detect 5HT. 
However, endogenous inhibitors or activators for the 5HT 
binding site that are induced or removed during the 
ischaemic process could influence the number of available 
sites. The effect of divalent ions and other modulators on 
ischaemic membranes should be further studied. In the 
present studies Ca2+ or Mg were always added back to the 
membrane preparation.
These findings encourage further study of the effects 
of ischaemia on all aspects of serotonergic function. It 
will be important to establish whether the changes in 5HT 
binding sites are related to functional changes which might
2 2 1
well be a contributing factor in the pathology of
ischaemia. This could be achieved by further behavioural
studies, preliminary results were presented here, or by
biochemical assessment of functional response, i.e.
inhibition of adenylate cyclase by 5HT sites or
1A
hydrolysis of phosphatidyl inositol by 5HT receptors.
Finally it will be important to show that these effects 
were not exclusive to the gerbil, and study the possible 
protective effects, if any, of selective 5HT compounds.
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Chapter 6: 5HT/NA INTERACTIONS IN THE BRAIN AND
ALPHA -ADRENOCEPTOR SUBTYPES 
2
5HT/NA INTERACTIONS IN THE BRAIN AND a -ADRENOCEPTOR 
SUBTYPES 2
6.1 Introduction
The morphological organisation of monoamine systems in 
the brain and psychopharmacological studies have long 
suggested a functional linkage between noradrenergic and 
5HT neuronal systems.
The 5HT neurons in the midbrain raphe nuclei receive one 
of the greatest noradrenergic innervations in the brain. 
This input has been demonstrated by histofluorescence 
(Fuxe, 1965) and by immunocytochemical (Grzanna and 
Molliver, 1980; Baraban and Aghajanian, 1981), biochemical 
(Levitt and Moore, 1979) and electrophysiological 
techniques (Baraban and Aghajanian, 1980) . It has been 
suggested that the noradrenergic innervation plays an 
important role in maintaining the tonic firing activity and 
the transmitter release of 5HT neurons. Interruption of 
noradrenergic transmission by application of 
a-adrenoceptor antagonists suppresses 5HT nerve firing
(Baraban and Aghajanian, 1980) and 5HT metabolism (Reinhard 
and Roth, 1982). Administration of the ^-adrenergic
agonists has been shown to increase 5HT synthesis and
metabolism in several brain areas (Waldmeier, 1981) and to
potentiate the behavioural syndrome elicited by
5-hydroxy tryptophan (Ortmann et al, 1981) .
Midbrain 5HT neurons have been reported to contain 
/3-adrenoceptors coupled to adenylate cyclase (Dolphin et 
al, 1979) and cAMP-dependent protein kinase (Sawada et al,
1985) and it has been suggested that the activity of 
tryptophan hydroxylase is linked to a /3-adrenoceptor 
related mechanism probably via an intracellular
cAMP-dependent process. a-ftdrenoceptor agonists, such as 
the imidazoline clonidine, have no effect on tryptophan 
hydroxylase activity. However, antagonists of the yohimbine
type reduce it to 78% (Sawada and Nagatsu, 1986) .
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cortex, where from an anatomical point of view nothing is 
known about the NA/5HT interaction, two stereochemically 
different subtypes of adrenoceptors can be found which 
regulate NA and 5HT release and are located, respectively, 
on NA and 5HT presynaptic nerve terminals. Schlicker et al, 
(1987) suggested that the 5HT nerve terminals in the rat 
brain cortex are endowed with an adenylate cyclase, which 
is negatively coupled to the presynaptic a -adrenoceptors, 
but is not linked to the presynaptic 5HT autoreceptors.
Recent studies with antidepressants have provided new 
evidence for a 5HT/NA link in the brain, at the level of 
the /3-adrenoceptor coupled adenylate cyclase system. Most 
antidepressant treatments, on repeated administration, 
decrease the number of (3-adrenoceptors in the cortex, a 
change that requires an intact 5HT neuronal input, 
suggesting that 5HT neurons play a pivotal role in the 
change, and high-lighting the complex neurotransmitter 
interactions that are present (Manier et al, 1987) . Later 
studies have shown NA to regulate the population of 
/3-adrenoceptors in the agonist high affinity state and 5HT 
to regulate those in the low affinity conformation 
(Gillespie et al, 1988). The subtype of 5HT receptor 
involved in this response has so far not been identified.
A number of compounds show high affinity for both 5HT 
receptors and a-adrenoceptors. These include: LSD,
mianserin, the yohimbine series and dibenzyline, which 
historically was the first compound used to define 
('D') receptors in guinea-pig ileum (Gaddum and Picarelli, 
1957) , but has since been shown to be a very potent 
a-adrenoceptor antagonist (Drew, 1976). The specificity and
selectivity of a wide range of structurally different
compounds for both classes of receptors are examined in 
this chapter.
The hippocampus was shown to be rich in 5HT^ binding 
sites (see chapter 3) but found in the present studies to 
have low numbers of'a —adrenoceptor binding sites labelled 
by [3H]-yohimbine. The ratio of S H T ^ : ^  -adrenoceptor
binding sites was found to be 6:1. The hippocampus is an
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important mood control center and maybe an important site
of action of new 5H^2a anxi°lytic compounds such as
buspirone and ipsapirone. These compounds have been shown
to be effective anxiolytics in man (Goa and Ward, 1986).
Interestingly they have a common active metabolite
1— (2—pyrimidinyl)—piperazine a compound with appreciable
a -adrenoceptor affinity but devoid of 5HT affinity. This 
2 t
study undertook to investigate if the a —adrenoceptor in
the hippocampus is atypical or if some allosteric coupling
exists between the a -adrenoceptor and 5HT receptor 
, , _. , , 2 t 1A
binding sites m  the hippocampus, such coupling might be
important for the mechanism of action of these new
anxiolytic compounds.
[ H]-Yohimbine is routinely used in many laboratories to
label -adrenoceptors. However the binding data produced
is often both diverse and complex. It has been suggested to
be both monophasic (Cheung et al, 1982) and biphasic (Diop
et al, 1983) in rat cortical membranes. Michel and Whiting,
(1984) reported shallow antagonist displacements of
[ H]-yohimbine binding which indicates an even more
complex binding isotherm. This study undertook a careful
investigation of the binding characteristics of
[ H]-yohimbine in three tissues; rat cortex, rat
hippocampus and human platelets. Displacement curves for a
wide range of a and 5HT ligands were examined.
Some interesting differences were observed between the
ct -adrenoceptor populations in the three tissues.
Therefore further studies were undertaken to study possible
ct —adrenoceptor subtypes. The -adrenoceptor populations
in rat cortex, rat hippocampus and human platelets were
compared and contrasted using [ H]-yohimbine and
[ H]-idazoxan radiolabels.
Brief history of a—adrenoceptor subtype binding assays
Early attempts to directly label a-adrenoceptors (May et 
al, 1967) were unsuccessful due mainly to the low affinity 
and specific activity of the radioligand employed and to 
the high levels of non-specific binding. The early use of 
[3H]-catecholamines was also largely unsucessful (Lefkowitz
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et al, 1973) as these studies failed to demonstrate the
normal characteristics of ligand-receptor interactions.
The availability of high affinity ligands which could be
labelled to high specific activity enabled direct
labelling of a—adrenoceptors (Williams and Lefkowitz, 1976;
Greenberg et al, 1976). Investigations in several
laboratories led to the conclusion that ct —adrenoceptors
and -adrenoceptor subtypes were present in the CNS
(U'Prichard et al, 1979; U'Prichard and Snyder, 1979;
Tanaka and Starke, 1980).
Following the widespread acceptance of a-adrenoceptor
subtypes, a range of selective radioligands has been
introduced (see review: Bylund and U'Prichard, 1983) .
[ H]-prazosin (Greengrass and Bremner, 1979; Hornung
et al, 1979) is regarded as the ligand of choice for
3
the study of a -adrenoceptors. [ H]-yohimbine (Diaguji et 
3 1
al, 1981), [ H]-rauwolscine (Perry and U'Prichard, 1981)
3 3
and [ H]-RX 781094 ([ H]-idazoxan) (Pimoule et al, 1983)
have been used as antagonist radioligands for the study of
ct -adrenoceptors.
Evidence for further divisions of a -adrenoceptor subtypes
2
Bylund, (1981) provided a basis for further
differentation of a -adrenoceptors by showing that the
3 2 3 . . . .
densities of [ H]-yohimbine and [ H]-clonidme binding
sites varied considerably across several tissues and
species. Since then a number of laboratories have
demonstrated heterogeneity of a^—adrenoceptors between
species (Cheung et al, 1982; Feller and Bylund 1984;
Neylon and Summers 1985; Kawahara and Bylund 1985;
Dickinson et al, 1986). A classification of
ct -adrenoceptor binding site heterogeneity has been
developed based on the differences in affinity and rank
order of potency of a variety of compounds to inhibit
3H-antagonist binding (Nahorski et al 1985, Bylund 1985)
and H-agonist binding (Randall et al 1983).
A number of clear differences between rodent and
non-rodent a -isoreceptors have been demonstrated; the
affinity of 2yohimbine and oxymetazoline is higher in
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non-rodent species as compared with rodents whereas the 
a^-adrenoceptor antagonists prazosin and indoramin show 
relatively high affinity for rodent a —adrenoceptors and 
low affinity for non-rodents. A study in kidney membranes 
from five different species reported marked differences 
not only between species but also in the rank order of
potency of antagonists. The species potency series for 
yohimbine is man > rat > mouse > rabbit > dog and for 
idazoxan is rat > man > dog > rabbit > mouse (Neylon and 
Summers 1985), demonstrating that a rodent and non-rodent 
classification is clearly oversimplified. Other groups have 
also shown heterogeneity within the same species; rat
(Bylund, 1985), human (Summers et al, 1983; Petrash and 
Bylund, 1986).
Further biochemical evidence that the rat brain contains
two subtypes of a -adrenoceptor is based on the observation
that (-)-mianserin acts as an antagonist at the
-adrenoceptor (heteroreceptor) which mediates 5HT release
but is without effect on the a -adrenoceptor (autoreceptor)
2
which mediates presynaptic regulation of NA release
(Raiteri et al, 1983). This also suggests heterogeneity
between a -adrenoceptors in different anatomical locations. 
One interesting development in support of this is the
introduction of SK & F 104078 which is a compound claimed
to be inactive at pre—junctional -adrenoceptors but with 
approximately lOOnM affinity for post-junctional
a —adrenoceptors and platelet -adrenoceptor binding sites 
(Ruffolo et al, 1987).
There is evidence to suggest that o;^ —adrenoceptor
-mediated responses are dependent on the physical
environment. The a -adrenoceptor can exist in different
2
conformational states depending on tissue or species,
according to the presence of co—factors in the immediate 
vicinity of the receptor. However, the heterogeneities 
between human platelets and rat cerebral cortex (Karahara 
and Bylund 1985) and human and rabbit spleen (McKernan et 
al 1986) are maintained upon solubilisation, which favours 
the suggestion that the differences between
227
-adrenoceptors arise from heterogeneities in the
molecular architecture of the receptor. In soluble
preparations agonists cannot induce high affinity states of
the receptor. Therefore this technique argues against
heterogeneous binding due to different agonist affinity
states and suggests absolute conformational differences
may exist between different a -adrenoceptor subtypes.
McKernan and colleagues (1986) have shown that thiol groups
are not involved in the structural differences but that
there are some differences in the carbohydrate portion of
the receptor, although it is not clear to what extent the
carbohydrate portion of the molecule is involved in ligand
binding. This is nevertheless interesting because the
subdivision of a-adrenoceptors will probably be ultimately
based on their primary structure. The possibility exists
therefore that a -adrenoceptors could differ sufficiently
2
to allow the identification of antagonists which could be 
targeted to different tissue or different -subtypes.
The figures and tables are presented at the end of the 
results section.
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6.2 Results
6.2.1 Receptor binding assays 
SHT^binding assays
[ H]—5HT was found to label a 5HT binding site on rat
cortex membranes (Kd 4.95nM; Bmax 132fmol/mg protein),
similarly [ H]-8-0H-DPAT was found to label a 5HT bindinq
1A
site m  the rat cortex (Kd 1.3nM; Bmax 102fmol/mg protein) 
and rat hippocampus (Kd l.lnM; Bmax 534fmol/mg protein) see 
chapter 3. [ H]-Ketanserin was found to label a 5HT
2
binding site in the rat frontal cortex with high affinity
(Kd 0.42nM) and Bmax, 240fmol/mg protein, see chapter 4.
These assays were used to determine the 5HT binding
affinity of compounds used in the following studies.
a^-adrenoceptor binding assay
[ H]-Prazosin was found to bind to a single population
of high affinity sites (Kd 0.2nM; Bmax 98fmol/mg protein)
(fig. 6.1) on the rat cerebral cortex membranes which was
characteristic of the a -adrenoceptor showing high affinity
1
for WB4101 (0.9nM) and prazosin (0.3nM) and low affinity
for yohimbine (398nM) and imiloxan (>10,000nM). This assay 
was used to determine the a^-adrenoceptor binding 
affinities in the following studies.
A more detailed description of the a^-adrenoceptor 
binding assay is given below.
6.2.2 A correlation of the affinities of standard
compounds for a—adrenoceptor and 5HT bindinq—sites 
Rat cortex
Table 6.1 shows the affinity values, determined in the 
rat cerebral cortex, for a wide variety of compounds for 
the a -adrenergic, ct -adrenergic, 5HT and 5HT^ binding 
sites. The compounds represent those available at the start 
of this thesis. The 5HT antagonists cyproheptadine, 
mianserin, methysergide and ketanserin showed moderate to 
high affinity for the ct —adrenoceptor binding site. 
Yohimbine showed moderate affinity for the 5HT1A binding 
site.
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Rat hippocampus
Table 6.2 shows the affinity values for selected ligands
for the a -adrenergic and 5HT binding sites in the rat 
• , , 1A
hippocampus. Yohimbine, rauwolscine and WY26703 showed
moderately high affinity for the 5HT binding site on rat
hippocampal membranes. Idazoxan and imiloxan were inactive
at the 5HT site, as was the buspirone metabolite, MJ 
1A '
13653. The very selective 5HT ligand DP-5CT was inactive
at the -adrenoceptor binding site as was 5CT.
Interestingly the 5HT ligands buspirone, 8-OH-DPAT
methysergide and RU24969, which are all proposed to be
agonists or at least partial agonists at the 5HT site,
1A
showed moderate affinity for the a -adrenoceptor binding
site (pIC^ 6.5-7.14). However, all the compounds inhibited
[ H]-yohimbine binding with Hill slopes less than unity.
Therefore it was decided to further investigate the
interaction of these compounds with the a -adrenoceptor
binding site and examine the possibility of agonist action, 
3
multiple [ H]-yohimbine binding sites or an allosteric 
interaction.
6.2.3 -adrenoceptor binding assays 
3
1.  ^ H]-Yohimbine binding to rat cerebrocortical membranes
[ H]-Yohimbine was found to bind to a single population 
of high affinity sites (Kd 5.2±0.9nM; Bmax 121±10fmol/mg
protein) over the concentration range of 0.1-15nM. At 1.5nM 
[ H]—yohimbine specific binding represented 60—65% of the 
total binding.
Table 6.3 shows the affinity values for inhibition of
3
[ H]—yohimbine binding to rat cortex. Rauwolscine was found 
to have a significantly higher affinity than yohimbine 
(p<0.01). BDF6143 was the most potent imidazoline tested
(0.6nM). Whereas idazoxan showed similar affinity to 
yohimbine. Prazosin and oxymetazoline produced biphasic 
displacement curves which could be statistically best
described using a two site model. Prazosin showed high 
affinity (50nM) for approximately 50% of [ H]-yohimbine 
binding (fig. 6.2). The rank order of potency for the
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adrenergic compounds was rauwolscine > yohimbine > 
oxymetazoline >> prazosin = WB4101 >>> indoramin. Except
for prazosin and oxymetazoline all these ligands showed 
Hill slopes not significantly different from unity.
5HT was shown to be inactive. However, the four 5HT
ligands tested, buspirone, methysergide, RU24969 and
8-OH-DPAT, all showed biphasic displacement curves with a
greater than two log order difference in affinity between
the two sites. The rank order of potency for the high
affinity site was methysergide > RU24969 > buspirone >
8-OH-DPAT. A representative inhibition curve for RU24969 is
shown in fig. 6.3, methysergide in fig. 6.4 and 8-OH-DPAT
in fi<^ . 6.5. Figure 6.4 also shows that in the presence of
1x10 M prazosin the high affinity site for methysergide is
-7
blocked. Similarly, in the presence of 1x10 M prazosin the 
high affinity component of buspirone, 8-OH-DPAT and RU24969 
binding is abolished, which suggest that the site showing 
high affinity for prazosin and the 5HT1A ligands is the 
same site. This site will now be referred to as site A and 
it represents approximately 40% of the total binding in the 
cortex. In contrast in the presence of lxl03 M prazosin 
oxymetazoline still shows high affinity for [ H]-yohimbine 
binding.
2. [3H]-Yohimbine binding to rat hippocampal membranes
Similarly, over a concentration range of 0.1-15nM,
[ H]-yohimbine was found to bind to a single population of 
high affinity a -adrenoceptor binding sites (Kd 5.8±0.7nM) 
with a low receptor number (Bmax 72±6fmol/mg protein) on 
rat hippocampal membranes. At 1.5nM [ H]-yohimbine specific 
binding represented 55-60% of total binding.
Table 6.4 shows the Ki values for inhibition of 
3 •[ H]—yohimbine binding to rat hippocampus. Yohimbine and
rauwolscine show equal affinity for this site. Whereas
idazoxan and imiloxan showed lower affinity than in the
cortex. Prazosin produced biphasic displacement curves
which could be statistically best fitted to two sites
revealing a very high affinity component (7.9nM).
Oxymetazoline also showed biphasic displacement curves
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(fig. 6.6). The rank order of potency of the adrenergic 
compounds was prazosin > rauwolscine = yohimbine = 
oxymetazoline > WB4101 » >  indoramin.
The inhibition by the 5HT compounds was biphasic as seen 
in the cortex. The order of potency for the high affinity 
site was RU24969 > methysergide > 8-OH-DPAT. Buspirone
showed very high affinity (39.8nM) (fig. 6.7) and 
selectivity 310 fold siteA/siteB. The ratio of site A to 
site B is approximately 30:70*/in the hippocampus.
33 •  ^H]-Yohimbine binding to human platelet membranes
[ H]-Yohimbine was found to bind to only one site on 
human platelet membranes with very high affinity (Kd 
0.66±0.07nM; Bmax 152±10fmol/mg protein). At 1.5nM 
[ H]-yohimbine specific binding represented 80-85% of total 
binding.
Table 6.5 shows the Ki values for inhibition of
3
[ H]-yohimbine binding to human platelets by a series of 
a-adrenergic and 5HT compounds. Yohimbine was the most 
potent compound tested (0.79nM) with a slightly higher 
affinity than its stereoisomer rauwolscine (1.04nM). Both 
showed almost a log order higher affinity than in the rat 
brain. Oxymetazoline showed high affinity (3.9nM) whereas 
prazosin was relatively weak (871nM) ; both were best fitted 
to a one site fit. The rank order of potency for the 
adrenergic compounds was yohimbine > rauwolscine > 
oxymetazoline = WB4101 » >  prazosin > indoramin (fig. 6.8).
5HT was inactive at the site. However RU249 69 and 
methysergide showed moderate potency, 76nM and 89nM 
respectively. 8-OH-DPAT was less active (217nM) and 
buspirone was relatively weak (603nM) (fig. 6.8). The Hill 
slopes were determined for each curve and were found to be 
not significantly different from unity (table 6.5). The 
values determined for 8-OH-DPAT, RU24969 and^methysergide 
were similar to their high affinity site for [ H]—yohimbine 
binding in the rat cortex and hippocampus. However, 
buspirone was less active than would be predicted from its 
affinity in the rat brain.
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6,2,4 ^3 comPar^son— Qf the bindinq characteristics of
SI -yohimbine in the rat cortex, rat hippocampus 
and human platelet
Saturation curves for rat cortex, rat hippocampus and 
human platelets membranes labelled by [ H]—yohimbine are 
shown in fig. 6.9 (also see table 6.9), along with the 
Scatchard plot for each curve. The experiments were 
analysed using the. non-linear curve fitting programme 
'Ligand' (Munson and Rodbard, 1980) and indicated a high 
affinity site for each tissue over the concentration range 
0.l-15nM.
A good correlation can be drawn between the Ki values
determined in the rat cortex and rat hippocampus site B (r=
0.724) (fig. 6.10). Similarly a correlation can be drawn
between the two tissues using site A (r=0.991). This
suggests that the [ H]-yohimbine binding is similar in both
tissues. Standard a -adrenoceptor antagonists yohimbine,
2
rauwolscine, WY26703 and BDF6143 show approximately equal 
affinity in the rat cortex and rat hippocampus. Rauwolscine 
shows higher affinity than yohimbine in the cortex but 
equal affinity to yohimbine in the hippocampus. However, 
the imidazoline compounds imiloxan and idazoxan show 
greater affinity in the cortex than the hippocampus.
Yohimbine and rauwolscine showed a ten fold higher 
affinity for the platelet a -adrenoceptor binding site, as 
did methysergide, RU24969 and 8-OH-DPAT.
5HT/NA interaction
The 5HT ligands showed higher affinity for site A in 
1A
the hippocampus. The anxiolytic buspirone showed markedly 
higher affinity for the hippocampus site A than for the 
platelet. Therefore a further study was undertaken to 
investigate if any indication of an interaction between 
a -adrenoceptors and 5HT receptors could be found in the 
rat hippocampus. 5HT has no direct affinity for the binding 
of [ H]—yohimbine to rat hippocampus at concentrations up 
to 1x10 M. To investigate if 5HT acts as an allosteric 
modulator saturation assays were performed as described in 
section 2.1.6b, in the presence or absence of 1 or lOnM
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5HT. No significant change was found in Kd or Bmax (table 
6 .6).
alternative explanation for the two site nature of
prazosin, oxymetazoline and the 5HT compounds could be that
they act as agonists at one or both of the cl —adrenoceptor
sites. Therefore the inhibition curves were repeated in the
presence of O.lmM GTP. While in parallel experiments GTP
increased the 1C values of noradrenaline and adrenaline
50
in all three tissues it failed to alter the inhibition 
curves of prazosin, 8-OH-DPAT, RU24969 and methysergide 
(table 6.7). However GTP was found to induce a small but 
significant shift in the IC value determined for
а. 50buspirone in the hippocampus (table 6.7). Prazosin and the
other compounds, with perhaps the exception of buspirone,
are probably antagonists at the a -adrenoceptor sites.
2
Finally to investigate if any structural differences 
could be determined between the -adrenoceptor binding 
site in the cortex or hippocampus, a study on the effect of 
chemical modifying agents was undertaken.
б.2.5 The effect of chemical modifying agents on a -
2
adrenoceptor binding sites
In order to further study the heterogeneity revealed by 
competition studies, the effects of the modifying agents 
N-ethylmaleimide (NEM; selective for the -SH group of 
cysteine) and phenylglyoxal (PGL; selective for the 
guanidino group of arginine) on -adrenoceptors in rat 
cortex and hippocampus was investigated (fig* 6.11 & 6.12; 
table 6.8).
Prior incubation with NEM results in alkylation of a 
thiol group preventing binding of [ H]-yohimbine to the 
cl -adrenoceptor in the rat cortex as reported by Mattens 
et al (1984) and now shown also to occur in the 
hippocampus. Similarly preincubation with PGL causes a 
concentration-dependent decrease in receptor number in the
hippocampus and cortex.
Scatchard transformations of the binding data in the 
present of either compound were best fitted to a one site 
fit suggesting that both [ H ] -yohimbine binding sites are
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effected. Therefore for both populations of a -
adrenoceptors there is evidence of arginine and cysteine 
residues at or near the binding site of [3H]-yohimbine, and 
there is no evidence to suggest that there is any variation 
in the position or accessibility of these chemical moieties 
between the cortex and the hippocampal a -adrenoceptor 
binding sites. 2
3
It begins to appear that [ H]-yohimbine labels two 
distinct populations of binding sites in the rat cortex and 
hippocampus which can be differentiated by prazosin,
oxymetazoline and the 5HT ligands, methysergide, RU24969 
and 8-OH-DPAT (which accounts for the low Hill slopes in 
table 6.2). Different proportions of the two sites exist in 
different brain regions which probably best explains the 
differences between the cortex and hippocampus a
2
-adrenoceptors. No evidence for an atypical a -adrenoceptor
2
m  the hippocampus was found. Similarly no evidence for a
a^/5HT link in the hippocampus was seen, except that the
unusually high a -adrenoceptor affinity for buspirone
2
merits further investigation. However, evidence for 
a -adrenoceptor heterogeneity was found. Therefore a 
further study of the characteristics of -adrenoceptor 
binding sites in the rat brain was made using [ H]-idazoxan 
as radioligand.
3
6.2.6 A comparison of the bindinq of r H]-idazoxan in the 
rat cortex, rat hippocampus
3
1. [ H]-Idazoxan binding to rat cerebral cortex membranes
In a Tris EDTA buffer system [ H]-idazoxan over the 
concentration range l-12nM bound to a single population of 
high affinity sites (Kd 4.1±0.9nM; 87±8fmol/mg protein), 
fig. 6.13. At 2nM [ H]-idazoxan specific binding
represented 65-70% of total binding.
2. [3H]-Idazoxan binding to rat hippocampal membranes
Similarly under the same conditions [ H]-idazoxan labels 
a single population of sites with high affinity (Kd 
3 . 5±0.5nM) and a low receptor number (Bmax 36±6fmol/mg
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protein) in the hippocampus (fig. 6.13). At 2nM
[ H]-idazoxan specific binding represented 60-65% of total 
binding.
. . 3
Competition experiments with [ H]-idazoxan to rat cortex
showed the imidazolines were more potent than the
yohimbine-like compounds. BDF6143, idazoxan and WY26703
showed slightly higher affinity in the hippocampus than the
cortex whereas prazosin showed a 6 fold higher affinity in
the hippocampus. The 5HT ligands showed similar affinities
in the cortex and hippocampus. Interestingly buspirone was
devoid of affinity in both the cortex and hippocampus (pKi
<5) . The results are presented in table 6.9. The Hill
slopes were determined for each curve and were found not to
be significantly different from unity (table 6.9). Fig.
6.14 shows the inhibition curves for [ H]-idazoxan binding
in the rat hippocampus. Idazoxan itself was found to
displace nsb, determined in displacement studies using
boiled membranes as described in section 4.2.Id for
3
displacement of [ H]-ketanserin nsb by cold ketanserin.
8-OH-DPAT was also found to displace the nsb unlike in the 
3
[ H]-yohimbine binding assays where its biphasic 
displacement curves could not be explained by the 
displacement of nsb.
3
6.2.7 A Comparison of bindinq of r H]-yohimbine _and 
~5 ~~
X HI-idazoxan
Significant differences were observed between the
maximum number of [ H]-yohimbine and [ H]-idazoxan binding
sites in the rat cortex and hippocampus, (table 6.10). The
density of ct -adrenoceptors was significantly higher using 
3 2
[ H]-yohimbine in both tissues. Kd values for each ligand 
were not however significantly different in either tissue.
[ H]-yohimbine showed higher affinity for the human
platelet a -adrenoceptor. 3
Affinity values for the displacement of [ H] yohimbine 
and [3H]-idazoxan from rat cortex and rat hippocampus 
membranes are shown in tables 6.3,6.4 and 6.9. 
Noradrenaline and adrenaline displaced the binding to both
ligands with IC values in the nanomolar range and Hill 
50
236
coefficents <1. The affinity values were markedly 
attenuated in the presence of O.lmM GTP with nH values 
brought closer to unity (see table 6.7).
Affinity values for yohimbine, rauwolscine and WY26703
determined in cortex and hippocampus for
displacement of [ H]-yohimbine were higher than for
displacment of [ H]-idazoxan. In contrast the imidazoline
structures idazoxan, imiloxan and BDF6143 (except in the
cortex) show higher affinities for the site labelled by
[ H]-idazoxan. The 5HT compounds show higher affinities for
a site labelled by [ H]-yohimbine; buspirone is inactive at
the idazoxan site and methysergide is 100 fold weaker.
A good correlation could be made between the binding to
[ H]-yohimbine site B and the [ H]-idazoxan binding
site, r=0.845;p<0.001, (fig. 6.15). In contrast a poor
correlation is made with site A, r=0.456 (fig. 6.16).
Similarly in the rat hippocampus a significant correlation
3
could be made between the binding to [ H]-yohimbine site B
and [H]-idazoxan binding site, r=0.803;p<0.001, (fig. 6.17)
but not for site A, r=0.304, (fig. 6.18). Therefore these
3
results suggest that [ H]-yohimbine labels two populations
of binding sites in rat brain both of which would appear to
be a —adrenoceptor subtypes, from competition studies with 
2 . . .  . 
antagonists, from comparison with -adrenoceptors in other
tissues and from the use of other a -adrenoceptor
2
radioligands. Additional studies were performed using 
pharmacological tools to selectively block one of the sites 
in order to determine the affinity of NA for the two 
sites.
3
Agonist affinities for the [ H]-yohimbine binding studies
Prazosin at a concentration of 1x10 M (see fig. 6.2)
3 . . . . .
was chosen to block the [ H] -yohimbine binding site A in
the rat cortex. This method proved to be ^highly
reproducable. Idazoxan at a concentration of 1x10 M was
chosen to block the [ H ] -yohimbine site B. However,
idazoxan did not prove a reliable tool giving varible
specific binding. Nevertheless agonist inhibition curves
were generated in the presence of absence of O.lmM GTP. The
results are shown in table 6.11). NA showed higher affinity
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for the site B, similar to its affinity for the total 
binding. However, NA was less potent at site A. UK14304 
showed high affinity for the site B but low affinity for 
site A. 5HT was inactive at both sites. A further 
investigation of the site A was undertaken. Rauwolscine 
showed high affinity for [ H]-yohimbine binding to site A 
(pKi 20nM) , although not as high as its affinity value 
determined for total binding (pKi 7.1nM; table 6.3). The 
finding indicates that this site is probably also an 
a^-adrenoceptor binding site.
3
6.2.8 Effect of assay buffer constituents on [ H]-yoh-imh-in<> 
and r~H1-idazoxan bindinq
In the above studies, assays were performed under 
identical conditions. Preliminary studies were undertaken 
to examine the influence of buffer ions on the specific 
binding of the two ligands.
In the physiological incubation medium (physiological
o
buffer pH 7.4 at 25 C containing (mM) : NaCl, 118; KC1, 4.8;
CaCl , 1.3; KH PO , 1.2; MgSO , 1.2; NaHCO , 25; glucose
2 2 4 4 o 3
5.5; equilibrated with 95% 0 /5% CO^ at 25 C before use)
[ H]-idazoxan over the range l-12nM bound to a single 
population of high affinity sites in rat cortex with
similar affinity 4.7±0.8nM to assays performed in Tris HC1 
buffer. A higher, although not significantly higher,
number of binding sites (107±12fmol/mg protein) was
labelled. No significant difference was found in the Kd or 
Bmax determined for [ H]-idazoxan binding to rat 
hippocampus. Similarly in a physiological buffer 
[ H]-yohimbine was found to label a slightly higher number 
of binding sites (130±llfmol/mg protein). Competition 
experiments showed that pKi values determined with 
[3H]-yohimbine (1.5nM) were not significantly different in 
Tris HC1 or physiological buffer. Antagonist inhibition of 
[3H]-idazoxan at a fixed concentration of 2nM produced 
slightly higher affinity values in the physiological 
buffer.
The influence of divalent ions on the binding of the two 
ligands was also examined. Assays performed in a Tris HC1
238
o 2 +
buffer pH 7.4 at 25 C containing 2 . 6mM Ca resulted in a
significant decrease in the percentage binding of both
ligands, particularly the [ H]-yohimbine. Similarly assays
performed in Tris HC1 buffer pH 7.4 at 25°C containing 5mM
Mg caused a decrease in the specific binding of both
ligands and a decrease in the affinity values obtained with
[ H]-yohimbine.
3
6.2,9 [ H]-Idazoxan binding to human platelet membranes
Preliminary investigations were undertaken to establish
3
the binding characteristics of [ H]-idazoxan to human
platelets which might help investigations of
a -adrenoceptor subtypes. However, difficulty was 
2
encountered in obtaining specific binding, only 3 0%
3
specific binding at 2nM [ H]-idazoxan. Platelet membranes
were prepared as described in methods section 2.1.1a, and
incubated with [ H]-idazoxan in a Tris EDTA buffer (50mM
o
Tris HC1, 0.5mM EDTA; pH 7.4) for 30min at 15 C. Under
3
these conditions [ H]-idazoxan labelled a small number of 
binding sites (Bmax 52fmol/mg protein) with high affinity 
(Kd 6. 5nM) .
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[ 3H ]-P R A ZO S IN  BINDING TO RAT CEREBROCORTICAL MEMBRANES
to ta l
20tt
nsb
specific
[ 3tO -p razo s in  concentration (nM)
Fig. 6.1 Relationship between total, nsb and specific
binding and ligand concentration. [ H]-prazosin
concentrations of 0.1-8.9nM were incubated with washed rat
o . . .
cerebrocortical membranes at 25 C for 30mm m  Tris HC1
buffer (50mM Tris HC1, 0.5mM EDTA; pH 7.4). Non-specific
binding was determined in the presence of 10/im
phentolamine.
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PRAZOSIN INHIBITION OF [ 3H ]—YOHIMBINE BINDING
TO RAT CEREBROCORTICAL MEMBRANES
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Fig. 6.2 Inhibition studies of [ H]-yohimbine to rat
cerebrocortical membranes were conducted over a
-10 -4
concentration range of 1x10 -1x10 M prazosin.
Incubations were performed for 30min at 25 C in a Tris HC1 
buffer (50mM Tris HCl/ 0.5mM EDTA; pH 7.4). Non-specific 
binding was determined in the presence of lOjxm
phentolamine. The data describes a single experiment 
performed in duplicate. Computer-assisted curve fitting 
procedures showed a two site fit was significantly 
better than a one site fit, p<0.001. (1 site, ssmin
62882, DF 11; 2 site, ssmin 2965, DF 9; F value 91.1)
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INHIBITION OF SPECIFIC [ 3H]-Y0HIMBINE BINDING
TO RAT CEREBROCORTICAL MEMBRANES RU24969
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Fig. 6.3 Inhibition studies of [ H]-yohimbine to rat
cerebrocortical membranes were conducted over a
-10 -4
concentration range of 3x10 -1x10 M RU24969.
Incubations were performed for 30min at 25 C in a Tris HC1 
buffer (50mM Tris HOI, 0.5mM EDTA; pH 7.4). Non-specific 
binding was determined in the presence of 10/zm
phentolamine. The data describes a single experiment 
performed in duplicate. Computer-assisted curve fitting 
procedures showed a two site fit . was significantly 
better than a one site fit, p<0.001.
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METHYSERGIDE INHIBITION OF [ 3 H]-YOHIMBINE BINDING 
TO RAT CEREBROCORTICAL MEMBRANES
a control
1655
5 09
-7  -6  -5  -4
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3
Fig. 6 . 4 a  Inhibition studies of [ H]-yohimbine to rat
cerebrocortical membranes were conducted over a
-10 -4
concentration range of 3x10 -3x10 M methysergide.
o
Incubations were performed for 30min at 25 C in a Tris HC1 
buffer (50mM Tris HC1, 0.5mM EDTA; pH 7.4). Non-specific 
binding was determined in the presence of 10/xm 
phentolamine. The data describes a single experiment 
performed in duplicate. Computer-assisted curve fitting 
procedures showed a two site fit was significantly 
better than a one site fit, p<0.01.
-7
b in the presence of 10 M prazosin
1 1 5 0 r
5 0 9
- 9  -8  -7  ■”6 -5  -4
log methysergide concantratlon (M)
Fig. 6 . 4 b  shows the inhibition of [ H ] -yohimbine binding in
_7
the presence of 1x10 M prazosin which blocks 44% of the
3 . , .
specifically bound [ H]-yohimbine.
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8-O H -D P A T INHIBITION OF [ 3H]-YOHIM BINE BINDING
TO RAT HIPPOCAMPAL MEMBRANES
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3
Pig. 6.5 Inhibition studies of [ H]-yohimbine to rat
cerebrocortical membranes were conducted over a
-9 -3
concentration range of 3x10 -1x10 M 8-OH-DPAT.
o
Incubations were performed for 30min at 25 C in a Tris HC1 
buffer (50mM Tris HC1, 0.5mM EDTA; pH 7.4). Non-specific 
binding was determined in the presence of lOfim 
phentolamine. The data describes a single experiment 
performed in duplicate. Computer—assisted curve fitting 
procedures showed a two site fit was significantly better 
than a one site fit, p<0.01.
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OXYMETAZOLINE INHIBITION OF [ 3H]-YOHIMBINE BINDING
TO RAT HIPPOCAMPAL MEMBRANES
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Fig. 6.6 Inhibition studies of [ H]-yohimbine to rat 
hippocampal membranes were conducted over a concentration
” 1 0  " 4  , • _  l- X- •range of 3x10 -1x10 M oxymetazoline. Incubations were
performed for 30min at 25°C in a Tris HCl buffer (50mM Tris 
HC1, 0.5mM EDTA; pH 7.4). Non-specific binding was
determined in the presence of 10/um phentolamine. The 
data describes a single experiment performed in duplicate. 
Computer—assisted curve fitting procedures showed a two 
site fit was significantly better than a one site
fit, pco.001.
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BUSPIRONE INHIBITION OF [ 3H]-YOHIM BINE BINDING
TO RAT HIPPOCAMPAL MEMBRANES
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Fig. 6.7 Inhibition studies of [ H]-yohimbine to rat
hippocampal membranes were conducted over a concentration
“9 - 4  . , ^ .
range of 1x10 -3x10 M buspirone. Incubations were
o
performed for 30min at 25 C in a Tris HC1 buffer (50mM Tris 
HC1, 0.5mM EDTA? pH7.4). Non-specific binding was
determined in the presence of 10/xm phentolamine. The data 
represents a single experiment performed in duplicate. 
Computer—assisted curve fitting procedures showed a two 
site fit was significantly better than a one site
fit, pco.Ol.
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INHIBITION OF SPECIFIC [ 3H]-YOHIMBINE BINDING
TO HUMAN PLATELET MEMBRANES
100
SHTjQ
o SO
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[ndoramin
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□ prazosin 
■ RU24969
3
Fig. 6.8 Inhibition of specific bound [ H]-yohimbine to
human platelet membranes by yohimbine, oxymetazoline,
methysergide, 8-OH-DPAT, RU24969, prazosin, indoramin,
buspirone and 5HT. Incubations were performed at
3 °
approximately 1.5nM [ H]-yohimbine for 30mm at 25 C m  a
Tris HC1 buffer (50mM Tris HCl, 0.5mM EDTA; pH 7.4).
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S P E C IF IC  B IN D IN G  OF [ 3H > Y 0 H IM B 1 N E  TO RAT BRAIN A HUMAN PLATELET MEMBRANES
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Pig. 6.9 Specific binding of [ H]-yohimbine to rat cerebral
cortex, rat hippocampus and human platelet membranes.
Specific binding is defined as that binding displaced by
10/im phentolaraine, and the data describes a single
experiment performed in duplicate in each tissue.
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pKI VALUES FOR [ 3H>YOHIMBINE BINDING
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Fig. 6.10 Correlation between binding affinities of 
compounds for [ H] -yohimbine binding to rat cortex and rat 
hippocampal membranes, (site B).
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Fig. 6.11 Scatchard plots of [ H]-yohimbine saturation
binding to rat cerebrocortical membranes: • control; ■
o
pretreated for 20min at 37 C with 1 or lOmM NEM or 20min 
with lmM PGL.
[ 3H ]-Y 0H IM B IN E  BINDING TO RAT HIPPOCAMPUS
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Fig. 6.12 Scatchard plots of ( H]-yohimbine saturation 
binding to rat hippocampal membranes: • control; ■
pretreated for 20min at 37 C with 1 or lOmM NEM or lmM PGL.
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SPECIFIC  BINOING OF [ 3H ]-ID A ZO XA N  TO RAT CORTEX & HIPPOCAMPUS MEMBRANES
■ rat cortax
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Fig. 6.13 Specific binding of [ H]-idazoxan to rat cerebral 
cortex and rat hippocampus. Specific binding is defined as 
that binding displaced by 3/xM phentolamine, and the data 
describes a single experiment performed in duplicate in 
each tissue.
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INHIBITION OF SPECIFIC [ 3H]-IDAZOXAN BINDING TO RAT HIPPOCAMPAL MEMBRANES
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Fxg. 6.14 Inhibition of specific binding of [ H]-idazoxan
binding to rat hippocampal membranes by idazoxan, BDF6143,
WY26703, 8-OH-DPAT, RU24969 and buspirone. Incubations were
performed at approximately InM [ H]-idazoxan for 30min at 
o
25 C in a Tris HCl buffer (50mM Tris HC1, 0.5mM EDTA; pH 
7.4). Non-specific binding was defined using 3^M 
phentolamine.
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Fig. 6.15 Correlation between binding affinities of
3 3
compounds for [ H]-yohimbine site B and [ H]-idazoxan
binding to rat cerebrocortical membranes.
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Fig. 6.16 Correlation between binding affinities of
3 3
compounds for [ H]-yohimbine site A and [ H]-idazoxan
binding to rat cerebrocortical membranes.
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pKI VALUES FOR [»H ]-Y O H IM B IN E  SITE B A [*H ]-IO A ZO X A N  BINDING TO RAT HIPPOCAMPUS 
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Fig. 6.17 Correlation between binding affinities of 
compounds for [ H]-yohimbine site B and [3H]-idazoxan 
binding to rat hippocampal membranes.
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Fig. 6.18 Correlation between binding affinities of 
compounds for [3H]-yohimbine site A and [ H]-idazoxan 
binding to rat hippocampal membranes.
254
Table 6.1 Affinity values for alpha-adrenergic and 5HT
binding sites on rat cortex
5HT 5HT
1A 2
Ki (nM)
5HT antagonists
ketanserin 18 + 1.3 1259 ± 105 900 + 60 2 + 0.9
methysergide 186 + 35 447 ± 76 125 + 16 10 + 0.7
cyproheptadine 175 + .42 501 ± 77 1000 + 75 6 + 0.7
mianserin 89 + 14 63 + 9 1995 ± 115 11 + 0.9
Dopamine antagonists
spiperone 35 ± 10 355 ± 51 180 + 30 1,. 6 ± 1
a-Adrenoceptor antagonists
prazosin 0.6 ± 0.08 389 + 45* >10000 1259 + 85
phentolamine 7 ± 1.1 3 ± 0.8 >10000 1000 + 80
yohimbine 398 ± 15 13 ± 1 125 + 20 200 + 25
imiloxan >10000 79 ± 19 >10000 >10000
Agonists IC
50
83*
(nM))
noradrenaline 8912 ± 980* 758 ± >10000 >10000
adrenaline 4467 ± 340* 178 ± 46* >10000 >10000
5HT >10000 >10000 20 ± 2 501 ± 36
dopamine >10000 >10000 >10000 >10000
histamine >10000 >10000 >10000 >10000
The affinity values were obtained for specific binding of 
[ H]-prazosin to rat cerebral cortex (alpha^), 
[ H]-yohimbine binding to rat cerebral cortex (alpha^), 
[ H] -5HT binding to rat cerebral cortex (5HT ) and 
[ H]-ketanserin binding to rat frontal cortex (5HT^). The 
concentration of drug to inhibit binding by 50% was 
obtained graphically and converted to a Ki value when the 
hill slopes were not significantly different from unity by 
the Cheng Prusoff equation. Values shown are the mean ± 
s.e.m. of at least three experiments performed in
duplicate.
*nH<l
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Table 6.2 Affinity values for a -adrenergic and 5HT
binding sites in rat hippocampus
compound a
2
pIC
50
5HT
1A
yohimbine 7.9 ± 0.06 6.9 ± 0.2
rauwolscine 7.9 ±0.09 7.1 ± 0.09
WY26703 8.05 ± 0.07 6.5 ± 0.2
idazoxan 7.65 ± 0.1 5.5 ± 0.3
imiloxan 7.20 ± 0.1 <5
MJ 13653 7.0 ±0.2 <5
buspirone 6.85* ± 0.09 7.95 ± 0.1
8-OH-DPAT 6.80* ± 0.09 8.52 ± 0.07
TFMPP 6.5* ± 0.2 6.90 ± 0.2
methysergide 7.02* ± 0.1 7.15 ± 0.1
RU24969 7.14* ± 0.1 8.01 ± 0.08
5CT 5.8 9.13 ± 0.1
DP-5CT <5 9.25 ± 0.1
The affinity values were obtained for specific binding of 
[ H]-yohimbine (alpha ) and [ H]-8-OH-DPAT (5HT_^) to rat 
hippocampal membranes. The results are presented as IC5Q 
values corrected of free ligand concentration as some of 
the compounds showed Hill slopes <1 (*) . Values shown are 
the mean ±s.e.m. of at least three experiments performed in 
duplicate.
256
3Table 6.3 Inhibition of [ H]-yohimbine binding to rat
cortex
Ki (nM) selectivity %
site A site B ratio A:B
A/B
Yohimbine 12.6 ± 0.9
Rauwolseine 7.1 ± 1.3
WY26703 9.1 ± 1.6
Idazoxan 9.1 ± 0.9
Imiloxan 79.4 ± 19
BDF6143 0.6 ± 0.1
Prazosin 50 + 14 999 + 320 20 50:50
WB4101 57.5 ± 11
Indoramin 8128 ± 540
Oxymetazoline 120 + 40 5.6 + 5.3 0.05 40:60
5HT >100, 000
Buspirone 269 ± 43 19498 + 1200 72 40:60
8-OH-DPAT 371 ± 34 10715 + 898 29 40:60
RU24969 199 ± 26 6309 ± 721 32 40:60
Methysergide 67.6 + 14 4467 ± 1203 66 40:60
The affinity values were obtained for specific
3
[ H]-yohimbine binding to rat cortex. Experiments were
performed using l-2nM [ H]-yohimbine and the concentration
of drug that inhibited specific binding by 50% (IC ) was
50
obtained graphically and converted to a Ki value using the 
relationship Ki =IC /(l+[L]/Kd), where [L] represents the 
free ligand concentration and Kd = the equilibrium 
dissociation constant of the radioligand. Values shown are 
the mean Ki ±s.e.m. of at least three experiment performed 
in duplicate. Results were evaluated by computer-assisted 
curve fitting procedures described under methods. A two 
site fit was accepted only if it was statistically better 
than a one site fit. Determination of the affinity for site 
B was also carried out in the presence of 1x10 M prazosin 
to distinguish site B from site A.
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Table 6.4 Inhibition of [ H]-yohimbine binding to rat 
hippocampus
Ki (nM) selectivity %
site A site B ratio A:B
---------------------—-----------------------.----------------- ---------- A / R
Yohimbine 13.4 ± 2.3
Rauwolseine 13.8 ± 1.8
WY26703 11.5 ± 1.9
Idazoxan 21.4 ± 3.1
Imiloxan 457 ± 56
BDF6143 1.1 ± 0.1
Prazosin 7.9 ± 12 1148 + 221 145 50:50
WB4101 57.5 ± 11
Indoramin 10233 ± 2100
Oxymetazoline 1380 + 173 13.7 + 3.9 0.1 31: 69
5HT 51286
Buspirone 39.8 + 7 12303 + 1360 309 30:70
8-OH-DPAT 209 + 42 16281 ± 2500 78 30:70
RU24969 31.6 ± 11 7413 ± 1250 234 40: 60
Methysergide 70.7 + 8 20417 + 1555 288 40:60
The affinity values were obtained for specific 
3
[ H]-yohimbine binding to rat hippocampus. Experiments were
3
performed using l-2nM [ H]-yohimbine and the concentration
of drug that inhibited specific binding by 50% (IC ) was
50
obtained graphically and converted to a Ki value using the
relationship Ki =IC /(1+[L]/Kd), where [L] represents the
50
free ligand concentration and Kd = the eguilibnum 
dissociation constant of the radioligand. Values shown are 
the mean Ki is.e.m. of at least three experiment performed 
in duplicate. Results were evaluated by computer-assisted 
curve fitting procedures described in methods. A two site 
fit was accepted only if it was significantly better than a 
one site fit. Determination of the affinity for site B was 
also carried out in the presence of 1x10 M prazosin to 
distinguish site B from site A.
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Table 6.5 Inhibition of [ H]-Yohimbine binding to Human 
platelets
Ki (nM) nH
Yohimbine 0.79 ± 0.14 1.03
Rauwolscine 1.04 + 0.07 1.08
Idazoxan 4.98 + 0.10 0.94
Imiloxan 366 ± 36 0.99
BDF6143 1.09 ± 0.15 1.00
Prazosin 871 + 145 0.93
WB4101 4.0 ± 0.4 1.01
Indoramin 1259 ± 89 1.11
Oxymetazoline 3.9 + 0.3 1.03
5HT >50000 -
Buspirone 603 + 93 0.94
8-OH-DPAT 217 ± 32 0.97
RU24969 76 ± 16 0.97
Methysergide 89 ± 23 0.95
The affinity values were obtained for specific 
[3H]-yohimbine binding to human platelets. Experiments were 
performed using l-2nM [ H] -yohimbine and the concentration 
of drug that inhibited specific binding by 50% (ICgQ) was 
obtained graphically and converted to a Ki value using the 
relationship Ki =IC /(1+[L]/Kd), where [L] represents the 
free ligand concentration and Kd = the equilibrium 
dissociation constant of the radioligand. Values shown are 
the mean Ki is.e.m. of at least three experiment performed 
in duplicate. The hill slopes were also determined and were 
not significantly different from unity.
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Table 6*6 Effect of 5HT in vitro on rat hippocampal 
-adrenoceptor binding sites
Kd Bmax 
fmol/mg proteinnM
control 5.8 ± 0.7 72 ± 6
+ InM 5HT 5.6 ± 0.8 75 ± 8
+ lOnM 5HT 5.4 ± 1.0 73 ± 10
Scatchard analysis were performed as described under
methods, in the absence or presence of InM or lOnM 5HT. The
results represent the mean ± s.e.m of at least three
experiments performed in duplicate. No significant
difference was found between the groups
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Table 6.7 Efect of GTP on affinity values for a -
2
adrenoceptor binding sites in the rat hippocampus
-GTP +GTP
adrenaline 7.12
noradrenaline 6.65
prazosin 6.9
8-OH-DPAT 6.8
RU24969 7.14
methysergide 7.02
buspirone 6.85
+ 0.05 5.83 + 0.06**
+ 0.07 5.60 + 0.05**
± 0.1 6.85 + 0.1
± 0.09 6.7 + 0.08
± 0.1 7.22 + 0.06
± 0.1 6.9 ± 0.1
± 0.1 6.26 ± 0. 06*
The affinity values were obtained for specific
3 .[ H]-yohimbine binding to rat hippocampus in the presence
or absence of O.lmM GTP. The results are presented as IC
DU
values corrected of free ligand concentration as some of 
the compounds showed Hill slopes <1 (*) • Values shown are 
the mean ±s.e.m. of at least three experiments performed in
duplicate.
Statistical significance (*p<0.01; **P<0.001) from the
corresponding value determined in the absence of GTP.
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Table 6.8 The effect of pretreatment with NEM or PGL on
-adrenoceptor binding sites
Kd Bmax
nM fmol/mg protein
RAT CORTEX
control 5.2 ± 0.9 121 + 10
+ 1 mM NEM 5.1 ± 0.7 90 + 8
+ 10 mM NEM No appreciable binding
+ 1 mM PGL 5.3 ± 0.7 64 + 10*
RAT HIPPOCAMPUS
control 5.8 ± 0.7 72 + 6
+ 1 mM NEM 6.4 ± 1.0 74 + 5
+ 10 mM NEM 7.1 ± 1.2 35 ± 5*
+ 1 mM PGL 6.7 ± 1.0 36 + 10*
Scatchard analysis were performed as described under 
methods, with membranes for 20min at 37 C in the 
absence or presence of
N-ethylmaleimide (NEM) or phenylglyoxal (PGL) . The 
results represent the mean ± s.e.m of at least three 
experiments performed in duplicate.
**Statistical significance (p<0.05) from the corresponding 
value determined in the absence of NEM or PGL.
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Table 6.9 Inhibition of [3H]-Idazoxan binding
Ki (nM)
compound Cortex Hippocampus
Yohimbine 56.2 ± 10 51.7 ± 8
Rauwolseine 81.3 ± 13 69.5 ± 12
WY26703 29.5 ± 0.8 19.9 ± 1.7
Idazoxan 7.6 ± 0.8 2.0 ± 0.2
BDF6143 2.2 ± 0.1 0.3 ± 0.05
Prazosin 195 ± 32 1259 ± 354
Buspirone 25119 ± 900 19952 ± 260
8-OH-DPAT 851 ± 165 931 ± 98
RU24969 955 ± 81 903 ± 150
Methysergide 7413 ± 890 11000 ± 700
The affinity values were obtained for specific 
[ H]-idazoxan binding to rat cortex and hippocampus. 
Experiments were performed using approximately 2nM 
[ H]-idazoxan and the concentration of drug that inhibited 
specific binding by 50% (IC ) was obtained graphically and 
converted to a Ki value using the relationship Ki 
=IC / (1+ [L]/Kd) , where [L] representes the free ligand 
concentration and Kd = the equilibrium dissociation 
constant of the radioligand. Values shown are the mean Ki 
±s.e.m. of at least three experiment performed in 
duplicate. The hill slopes were also determined and were 
not significantly different from unity.
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Table 6.10 Specific binding of [ H]-yohimbine and 
[ H]—idazoxan to human platelets, rat cerebral cortex and 
rat hippocampus membranes
3 . 3
[ H]-yohimbine [ H]-idazoxan
Kd Bmax Kd Bmax
Platelets 0.66 ± 0.07 152 ± 10 -
cortex 5.2 ± 0.9 121 ±10 4.1 ± 0.9 87 ± 8
Hippocampus 5 .8±0.7 72 ± 6  3.5±0.5 3 6 ± 6
Specific binding of [ H]-yohimbine and [ H]-idazoxan to 
human platelets, rat cortex and rat hippocampus membranes. 
Values shown were obtained using the non-linear itterative 
curve programme 'Ligand' (Munson & Rodbard, 1980) , and are 
the mean ± s.e.m. of at least three experiments.
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Table 6.11 Agonist affinity values for [ H]-yohimbine
binding sites
pIC (nH)
-7 50 -7
Control 1x10 M idazoxan 1x10 M prazosin
-GTP +GTP
(site A) 
-GTP +GTP
(site
-GTP
B)
+GTP
NA 6.81 (0.47) 6.12(1.02) 5.73 <5 6.58(0.8) 5.95(1.2
UK* 7.63 (0.82) 7.53(0.97) <5 <5 7.89(1.14) 7.85(1.1
5HT <5 <5 <5 <5 <5 <5
Affinity values for agonists were determined in the
presence or absence of O.lmM GTP for [ H]-yohimbine
binding. Assays were performed in the absence or presence
of 1x10 idazoxan and 1x10 prazosin to distinguish the
3
two populations of [ H]-yohimbine binding sites. Values
shown are the pIC (nH) of at least 3 experiments performed
50 .
in duplicate. All standard errors fall within 5% of the
mean.
*UK represents UK 14304
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6.3 Discussion
These results provide further evidence for heterogeneity 
°f -adrenoceptor binding sites. Differences were
observed in the pharmacological profile of ot. —adrenoceptors 
in the rat brain and human platelet, which is consistent 
with a previous report suggesting a possible
heterogeneity of -adrenoceptors binding sites in the 
human platelet and rat cortex (Cheung et al, 1982) . The 
non-rodent and rodent -adrenoceptors have been classified 
as a-2A and a-2B respectively (a-2A yohombine=rauwolseine 
> »  prazosin; a-2B rauwolscine>yohimbine>prazosin, Nahorski 
et al, 1985). Bylund, (1985) extended this classification 
to include oxymetazoline which shows higher affinity for 
the rodent than the non-rodent subtype. However, a 
comparison of rat brain and human platelet a -adrenceptors 
must now take into account the possible heterogenous 
nature of a -adrenoceptors in the rat cortex and 
hippocampus as shown by the biphasic curves for prazosin, 
oxymetazoline (Bylund, 1985; this study) and 8-OH-DPAT, 
RU24969 and methysergide (this study). The human platelet 
appears to consist of a single population of 
cl -adrenoceptors (Cheung et al, 1982; this study) whereas 
the human brain has been shown to consist of a 
heterogeneous population of -adrenoceptors (Petrash and
Bylund, 1986).
[ H]-Yohimbine labels more than one -adrenoceptor 
subtype in the rat brain. However, neither subtype can be 
immediately classified as an a-2A subtype similar to that 
seen in the human platelet since the affinity of yohimbine 
and rauwolscine at both of the sites is 10 fold less than 
for the platelet a-2A subtype. It is also difficult to 
use selectivity of yohimbine/rauwolscine as an index for 
classification of the two subtypes, as in the original 
classification (Nahorski et al, 1985), because a less than 
10 fold difference in affinity for the two sites is not 
sufficient to significantly resolve the data from 
saturation or competition assays.
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Prazosin and oxymetazoline were found to inhibit the 
binding of [ H]-yohimbine in a biphasic manner (site A:B) 
in the cortex (40:60) and hippocampus (30:70). Furthermore 
the affinities of prazosin for its lower affinity site 
(site B) was similar to that found in the human platelet, 
i.e. the a—2A subtype. Similar affinity values have been 
reported for prazosin at the a—2A subtype described in rat 
cortex (Bylund, 1985) human brain (Petrash and Bylund,
1986) and human platelet (Cheung et al, 1982) .
In this study a number of other compounds,
methysergide, RU24969, 8-OH-DPAT and buspirone were found 
3
to inhibit [ H]-yohimbine binding in a biphasic manner 
which could be statistically best fitted to a two site 
model. However, in this case the higher affinity site (site 
A) for these compounds was found to be similar to the 
platelet a-2A subtype.
An alternative explanation for the two site nature of 
these compounds is that they act as agonists at one or both 
of the 0! -adrenoceptor binding sites. However O.lmM GTP 
failed to alter the inhibition curves of these compounds, 
except for buspirone, while in parallel experiments, GTP 
decreased the affinity of noradrenaline by 5 fold for site 
A and 2 fold for site B. These results indicate that 
agonist activity of these compounds does not account for 
the two site inhibition data and therefore supports the 
conclusion of receptor subtypes. Bylund, (1985) concluded 
that the biphasic inhibition shown by prazosin in the
cortex and hippocampus could not be explained by negative 
cooperativity or different affinity states of a single 
receptor.
The pharmacological profile of both sites indicates that 
it is most unlikely (under these assay ^conditions) that 
there is a significant interaction of [ H]-yohimbine with 
other receptor systems. Broadhurst and Wyllie, (1986) 
suggested that [3H]-rauwolscine labels a saturable, low
affinity, spiperone-sensitive site on rat cortical
membranes which they postulate is a 5HT2 binding site. A
similar low affinity component has been suggested for 
[3H]-yohimbine binding (Michel and Whiting, 1984). They
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concluded that it most resembled a low affinity
0!2_adrenOCeptor bindin<3 site. However, the later study was 
carried out using concentrations in excess of 2 0nM to label 
the low affinity site. In the present study competition 
experiments were carried out using 1.5nM [3H]-yohimbine, 
therefore it is unlikely that any of the binding was to the 
low affinity site.
The site showing high affinity for 8-OH-DPAT, RU24969, 
methysergide and buspirone is not related to the 5HT
1A
receptor binding site since all these compounds have >10
fold higher affinity for the 5HT binding site. 5HT, 5CT
1Aand DP-5CT were inactive at this site, whereas all show 
nanomolar affinity for the 5HT binding site. Similarly
Petrash and Bylund, (1986) showed that the a. -adrenoceptor
2
subtype with very high affinity for prazosin is not related 
to the a -adrenoceptor which has 250 times higher affinity 
for jDrazosin.
[ H]-Yohimbine did not label a 5HT binding site, at
concentrations up to 15nM in the rat brain. Interestingly
yohimbine has been shown to have high affinity (50nM) for
the 5HT binding site of human and bovine brain membranes 
ID .
(Hoyer et al, 1987a; Heuring and Peroutka, 1987), and it is
possible to speculate that low affinity [ H]-yohimbine 
binding, especially in these tissues may be related to a 
5HT binding site (see chapter 3) . However, no direct 
labelling of a 5HT binding site was found in the present 
study and no evidence of a 5HT /ct -adrenergic 
receptor/receptor interaction was found in the hippocampus 
where both are present. 5HT had no modulatory effect on the 
3 -adrenoceptor binding in the hippocampus, although the 
unusually high affinity of buspirone for a binding site 
labelled by [3H]-yohimbine in the hippocampus, which was 
significantly higher than in the cortex, merits further 
investigation. NA has been shown to act as a modulator of 
5HT release in the rat hippocampus (Feuerstein et al, 
1985).
No evidence of an atypical -adrenoceptor in the 
hippocampus was found, except perhaps the high affinity of 
buspirone. No variation in the position or accessibility of
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the chemical moieties, arginine and cysteine, between the
calf cortex, human platlet and human uterus (Matten et al,
1984), or rat cortex and rat hippocampus (this study) was
seen. Jacobs et al, (1982) showed that a -adrenoceptors in
the human platelet are not sensitive2to dithiothreitol
(DTT) , which suggests the lack of essential disulphide
bonds in the binding unlike the ^-adrenoceptor which does
contain an essential disulphide bond (Guellaen and Hanoune,
1979) . Similarly Mckernan et al (1986) showed DTT to be
ineffective against solubilized rabbit spleen and human
spleen a -adrenoceptors. The effect of DTT in the rat 
2
brain should therefore be investigated. The same group were 
unable to show any differences between human and rabbit 
spleen -adrenoceptors using sulfhydryl agents. However
they did find some differences in the carbohydrate portion 
of the receptor. Therefore the study of physiochemical 
properties of the receptors could be a useful method for 
investigating possible receptor heterogeneity.
Further investigations of a -adrenoceptor heterogeneity
were undertaken in this study using [ H]-idazoxan. Initial
studies in rat cortex and hippocampus membranes showed that
the Ki values for displacing [ H]-yohimbine or
3 . . .
[ H]—idazoxan binding differed between the yohimbine-like
and imidazoline ct -adrenoceptor antagonists. The
2 . . 
yohimbine-like compounds showed higher affinity for
[3H]-yohimbine binding whereas the imidazolines showed
higher affinity for [3H]-idazoxan binding which suggests
differences in the a -adrenoceptor populations labelled by
2
the two radioligands.
The density of a -adrenoceptor binding sites in the rat 
cortex reported i A h e  literature is wide (90-242fmol/mg 
protein) as a result of different incubation media and of 
membrane preparations being purified to different extents. 
For comparison of the binding of [ H] -yohimbine and 
[3H]-idazoxan in this thesis identical methodology was used 
for preparation of tissue membranes and binding assays. 
Under the present conditions (crude membrane preparation 
and Tris HC1 buffer system: 50mM Tris HC1, O.SmM EDTA; pH
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7.4 at 25 C) the specific binding of the a -adrenoceptor
3 2 3
antagonists [ H]-yohimbine (l-15nM) and [ H]-idazoxan
(l-12nM) to membranes from rat cerebrum and human platelets
was rapid, reversible, saturable and of high affinity.
Extensive washing of the membrane preparation with EDTA was
2+
used to remove endogenous Mg and other divalent cations 
which can reduce the affinity of the radioligand and 
complicate analysis of displacement curves generated by
competing drugs (Cheung et al, 1982).
The a^-adrenoceptor has been shown to exist in different
affinity states modulated by the presence of mono- and
3
divalent cations and guanine nucleotides. H-Agonist
3
radioligands are affected whereas H-antagonist binding is 
generally little affected by these modulators. Lane et al
(1983) suggested that the binding of the antagonist
[ H]-idazoxan is markedly increased in the presence of a 
high concentration of sodium ions (physiological buffer 
containing 119.2mM Na ). However, they used a crude 
synaptosomal P2-fraction prepared in sucrose followed by 
resuspension in physiological buffer. Apparent maximal 
[ H]-yohimbine binding to cortex membranes prepared in a
similar manner is also increased in the presence of Na 
ions (Woodcock and Murley, 1982). Further investigation of 
this membrane preparation (Cheung et al, 1984) revealed it 
to be comprised of a high proportion of intact synaptosomes 
containing endogenous NA, which could interfere with the 
subsequent a -adrenoceptor binding assay; these effects 
could be reversed by Na ions. This is not as marked with 
membranes prepared in hypotonic buffers.
In this study [ H]-idazoxan binding showed a slight but 
not significant increase when assays were performed using a
high Na concentration favours binding to an imidazoline 
binding site (see below).
Early models of a -adrenoceptor binding suggested the
2 . . .  
antagonists yohimbine and rauwolscme selectively bind to
the free receptor, thus destabilizing receptor-guanine
+
ical buffer, it is tempting to speculate that a
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nucleotide protein complexes; this is based on the 
modulatory effects of buffer ions and GTP on ^-antagonist 
binding (Bylund and U 1Prichard, 1983; Woodcock and Murley, 
1982; Salama et al, 1982). In terms of binding kinetics 
this^ would predict that there are two affinity components 
of [ H]-yohimbine and [ H]-rauwolscine binding. However, as 
described above, this is most probably related to the 
insufficiently washed membrane preparation. Further 
evidence against this hypothesis has come from studies of 
solubilised a2-adrenoceptor preparations, which by 
definition must contain the free receptor protein, the 
affinity values for yohimbine and rauwolscine are equal to 
their affinity for membrane preparations (Kawahara and 
Bylund, 1985). Therefore the two binding sites labelled by 
[ H]-yohimbine in this study shown by the biphasis curves 
to prazosin, methysergide, 8-OH-DPAT and RU24969, is 
unlikely to be due to different affinity states. It remains 
to be seen if they act at an allosteric binding site.
Under the assay conditions described for this study, Ki 
3
values for [ H]-idazoxan binding to the rat cortex and 
hippocampus were consistent with binding to an 
a -adrenoceptor binding site and were similar to those 
described for a rat P2 cerebral membrane (Lane et al, 
1983). All the competing antagonists showed monophasic 
inhibition with Hill slopes not significantly different 
from unity, including prazosin, oxymetazoline,
methysergide, 8-OH-DPAT and RU24969, which all showed low 
affinity. Saturation studies showed that [ H]-idazoxan 
labelled fewer binding sites in the rat cortex and 
hippocampus. Since neither of these two compounds have been 
reported to have a -adrenoceptor agonist activity, the 
total binding (Bmax) provides evidence of a difference in 
the population of a -adrenoceptors labelled by the two 
ligands. As discussed above a^number of compounds showed 
biphasic inhibition curves for [ H]-yohimbine binding. The 
affinities of these compounds for inhibition of 
[3H]-idazoxan binding showed a good correlation with 
[3H]-yohimbine site B. Similarly in the rabbit cerebral
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cortex [ H]-yohimbine has been reported to label almost 
twice as many binding sites as does [3H]-idazoxan, and both 
ligands are reported to label an a -adrenoceptor binding 
site (Hamilton et al, 1988). 2
In contrast recent autoradiographical and 
pharmacological evidence has been presented suggesting that 
[ H]—idazoxan labels two distinct a —adrenoceptor 
populations in the rat brain with high affinity, only one 
of which is labelled by [ H]-rauwolscine (Boyajian et al, 
1987; Boyajian and Leslie, 1987). These studies were 
carried out using a Na /K buffer system. One possibility 
which could account for the the large percentage of 
[ H]-idazoxan binding is that, under these conditions, 
idazoxan binds preferentially to the proposed imidazoline 
site (Ernsberger et al, 1987) . There is evidence from 
functional studies that many central actions of imidazoline 
-adrenoceptor agonists, such as clonidine, may be 
mediated by an imidazoline receptor (Bousquet and Feldman,
1987) . There is even some evidence of an endogenous 
imidazoline agonist, a clonidine displacement substance 
(Atlas et al, 1987).
The a -adrenoceptor binding site on human platelets 
2 3
labelled by [ H]-yohimbine appeared to be a hybrid of the
sites A and B described for rat brain membranes.
3
Unfortunately binding of [ H]-idazoxan to the human 
platelet was not able to resolve this because of the 
failure to achieve sufficient specific binding. This may be 
related to the procedures used resulting in degradation of 
either the ligand or the ct^ -adrenoceptor binding site. 
However, this is unlikely since under identical conditions 
[ H]-yohimbine binding was entirely consistent with binding 
to an ol -adrenoceptor. McLaughlin et al, (1987) reported 
specific binding of [ H]-idazoxan to human platelets to be 
saturable and to a single population of high affinity sites 
(Kd 1..43nM; Bmax 240fmol/mg protein). The assays were 
performed under similar conditions, platelet membranes were 
incubated with [3H]-idazoxan (0 .25-8nM) for 20min at 22 C 
in a Tris EDTA buffer system (50mM Tris HCl, 0.5mM EDTA) at
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pH 7.2. However, they do not indicate the level of nsb 
which was determined in the presence of IOjxM idazoxan. In 
the present study idazoxan was found to displace nsb at 
this concentration.
In conclusion, evidence suggests that a -adrenoceptor 
binding sites are not homogeneous. [ H]-Yohimbine labels 
two sites in the rat brain both of which have the overall 
profile of an -adrenoceptor, although a number of
significant differences between the two sites have arisen.
3
Site B correlates with the binding of [ H]-idazoxan, a 
similar pharmacological profile is seen for both sites; 
moderately high affinity of NA, high affinity for the 
a^-adrenoceptor antagonists, yohimbine, rauwolscine and the 
imidazolines, idazoxan and imiloxan but low affinity for 
prazosin, 8-OH-DPAT, RU24969 and methysergide.
The second binding site labelled by [ H]-yohimbine, site 
A, shows lower affinity for NA although this is still a 
higher affinity than for any other agonist tested. It also 
shows high affinity for a -adrenoceptor antagonists, 
yohimbine and rauwolscine. It is distinguished by high 
affinity of prazosin, 8-OH-DPAT, RU24969 and methysergide. 
The latter four compounds also show moderately high 
affinity for the a -adrenoceptor binding site on human 
platelets. Recently 8-OH-DPAT has been shown to be a 
post-synaptic c l -adrenoceptor antagonist (Crist and 
Surprenant, 1987;2 PA2 6.9-7.2). Therefore this site also
appears to be an a -adrenoceptor binding site.
In view of the. differences in [ H]-yohimbine and 
[ H]-idazoxan binding it seems neither ligand should be 
considered the ligand of choice for the study of
cl -adrenoceptors.
Further investigations of the properties of 
a -adrenoceptor subtypes in both membrane and soluble 
populations are needed. It will also be important to 
establish whether the above differences m  
-adrenoceptors are reflected by appropriate functional
responses.
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7. GENERAL DISCUSSION
In each of the preceding chapters a detailed discussion 
of the experimental results has been provided, and it is 
therefore the purpose of the general discussion to
concentrate on the significance of the results and 
prospects for future research.
In this study a number of high affinity 5HT and 
-adrenoceptor binding sites have been described, in
different tissues and species. However, before claiming new 
receptor types two important questions have to be
answered:- 1. When are high affinity binding sites
sufficently different to suggest heterogeneity? 2. When can 
a high affinity binding site be called a receptor?
Classification of receptors on a pharmacological basis 
requires reliable methods for the quantitative assessment 
of agonist and antagonist affinities for putative receptor 
subtypes (Furchgott 1972, Kenakin, 1984). In radioligand 
binding studies the affinity constants of antagonists 
provide the critical evidence for receptor classification. 
However, binding studies on their own cannot be taken as 
the sole criterion for receptor classification. High 
affinity binding sites are usually considered to be 
receptors when it has been shown that the occupation of the 
site by an agonist elicits a pharmacological response, 
(e.g. contraction of a tissue) or biochemical response 
(e.g. increase in adenylate cyclase), and the 
pharmacological characteristics of the binding site relate 
to those of the response. However, if by definition a 
receptor is coupled to a response, then it is difficult to 
classify binding sites which represent 'receptor' sites 
that have become uncoupled from the response, either during 
development or evolution, but have the same properties as 
those coupled to a functional response.
Therefore one of the major difficulties in the early 
stages of any binding study is to know which binding sites 
actually represent receptors which lead to known effects on 
the cell. The use of a selective and high affinity
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radioligand is the most important tool for ligand binding
studies. Evidence of 5HT receptor subtypes in this study is
drawn from a high degree of uniformity across many
different tissues and species with respect to the binding
affinity of the individual 5HT subtype radioligands. A
number of 5HT receptors were studied, 5HT , 5HT , 5HT
1A IB 1C*
C5HT ) and 5HT^ (where binding and functional studies were 
performed in the same tissue) . For each of these there is 
literature evidence of second messengers and functional 
responses. In addition there is functional and preliminary 
binding evidence for a 5HT receptor, which was not studied 
in the thesis.
Although a receptor requires a response a fully 
characterised binding site showing a pharmacologically 
distinct profile, possibly with its own selective ligands, 
should not be ignored. Central 5HT binding sites were all 
defined before a functional correlate was available. Many 
potentially useful pharmacological systems with specific 
binding/receptor sites may await identification and 
therapeutic exploitation.
Evidence for heterogeneity must be carefully assessed as 
receptors which mediate the same response in the same way 
and respond similarly to known antagonists, may still be 
different in different cells or different tissues, in 
different environments or biochemical or pathological 
states, in different species or different individuals at 
different stages of development. After all, receptors are 
proteins made up of a number of subunits. Haemoglobin, 
used by A.J.Clark (1937) in his brilliant discussion of 
the reaction between proteins and drugs, has now been shown 
to consist of at least 7 tetramers as well as the normal 
adult a //? haemoglobin. Under certain conditions some 
tetramers behave lik6 models of functional receptors. Under 
other conditions they may bind a ligand without giving a 
response. Although haemoglobin is not a typical protein it 
suggests the possibility that all pharmacological receptors 
(proteins) of a particular 'type' may not be identical.
Molecular biology techniques which are increasingly
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being used to study receptor heterogeneity, have shown that 
nicotinic receptors have different molecular weights and 
different, but homologous, amino acid sequences in 
different tissues and species (Conti-Tronconi et al, 1985; 
Momoi and Lennon, 1986).
3In this study [ H]-Yohimbine was found to label two 
binding sites in rat cortex and hippocampus with high 
affinity, both of which appear to be a -adrenoceptor-like 
showing high affinity for a^-adrenoceptor antagonists (site 
A showed some affinity for NA whereas other endogenous 
agonists tested were inactive). A number of compounds 
(prazosin, methysergide, oxymetazoline, 8-OH-DPAT and 
RU24969) showed selectivity for the two sites. The 
heterogeneity was unlikely to be due to different affinity 
states as yohimbine has no agonist activity and GTP had no 
effect on the affinity of the selective compounds or other 
a -adrenoceptor antagonists. It remains to be seen if site 
A (high affinity for prazosin) is an allosteric binding 
site.
Further characterisation of the two sites must await the
development of selective ligands. However, there are some
leads. For example Site B correlates well with the 
3
[ H]-idazoxan binding site on the rat cortex and rat 
hippocampus, since both of these ligands, yohimbine and 
idazoxan, are antagonists at the -adrenoceptor 
autoreceptor, which may be a functional correlate for this 
site. However, one drawback of binding to crude membrane 
preparations, as used in these studies, is the diversity of 
the possible binding site locations and most of the binding 
in crude membrane preparations is to post-synaptic 
ot —adrenoceptors as shown in lesioning studies (see Bylund 
and U*Prichard, 1983). A functional correlate for site A 
awaits further study. It is interesting to speculate that 
site A may be an a -heteroceptor perhaps on 5HT neurons, 
where an a -adrenoceptor mediating 5HT release has been 
proposed (Raiteri et al, 1983) or on other non-adrenergic 
neurons. The answers to these questions await the results 
of selective lesioning studies and release studies.
276
The strength of ligand binding lies in the ability to
study the receptor directly, not only to determine the
affinity of compounds but also to study the influence of
modulators, e.g. nucleotides and metal ions, which have
been implicated in functional studies as participants in
the agonist-receptor interactions and in the subsequent
reactions which couple the receptors to effector responses.
The binding of [ H]-5HT was found to be complex and
influenced by GTP and mono/divalent ions. However, the
complex binding curves produced were best described by
3
5HT^ subtypes. [ H]-8-OH-DPAT binding was also influenced
by GTP and divalent ions; but the confirmation of multiple
5HT affinity states must await the introduction of 
1A
antagonist ligands. The reason for the complex
interactions of agonist binding with the 5HT binding site
are at present unknown. There is however evidence from
binding studies to implicate the involvement of a guanine
nucleotide binding protein in agonist interactions with the
5HT binding site in the rat brain. The involvement of a 
2 . . .  
guanine nucleotide binding protein m  the coupling of the
5HT binding site to its effector systems has been proposed 
2
(Berridge and Irvine 1984). Antagonist binding to 5HT2
bindinq site or a -adrenoceptor binding sites labelled by 
3 2
[ H]-yohimbin e was not influenced by GTP. In contrast
guanipe nucleotides have been shown to increase the
affinity of some antagonists at receptors (Wreggett and
De Lean, 1984) and 0 -adrenoceptor sites (Lang and Lemmer,
1985), which suggests that the affinity of certain
antagonists can be influenced by receptors interacting with
G proteins.
A useful technique for further studies of 5HT and 
a -adrenoceptor subtypes would be to perform binding assays 
on intact cells. Internalisation and other regulatory 
processes can also be studied using this technique.
However, the use of intact systems in direct binding 
studies is not without its problems as has been highlighted 
in studies on the 0 -adrenoceptor (Pittman and Molmoff,
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1980) . In these studies a considerable degree of cellular
accumulation of lipophilic radioligands, together with the
identification of internalised or sequestered binding sites
has been reported. While the resolution of these problems
in studies on the /3—adrenoceptor has been greatly
facilitated by the availability of a suitable high
affinity, hydrophilic radioligand, [ H]-CGP-12177
(Staehelin and Hertal, 1983), the low affinity
(particularly of d^-radioligands) and high degree of
lipophilicity (5HT and a -adrenoceptor radioligands) may
2
necessitate the development of antagonist ligands of higher 
affinity and reduced lipophilicity before accurate studies 
on these receptors in intact cells can be performed 
successfully.
The current classification of 5HT receptors and
a -adrenoceptors was both verified and extended in this
2 . thesis, by the study of different tissues and species.
Information on receptor subclassification has been useful
in the development of novel drugs which will in turn be
useful in the treatment of a number of psychiatric
disorders in which 5HT has been implicated, such as
schizophrenia, anxiety and depression, where it now appears
that rather than being independent of the NA, the two
systems are probably linked. In addition these studies also
showed that 5HT may have a role to play in cerebral
ischaemia.
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Appendix l
Theoretical basis for identification of receptors using 
direct radioligand binding techniques
Ligand-receptor interactions may be expressed in terms 
of the following generalised reaction for the simplest case 
of a single ligand interacting with a homogeneous receptor 
population. K
1
[R] + [L] ^  [RL] equation 1
K
-1
Where [R], [L] and [RL] represent the equilibrium
concentration of free receptor, free ligand and receptor 
ligand complex, respectively. K and K are rate constants 
describing the opposing association and dissociation
reactions. The equilibrium binding constant of the
radioligand for the receptor can be defined as either the 
association binding constant (Ka) or the dissociation
binding constant (Kd).
K
1
[RL]
Association constant (Ka)  -----------    equation 2
K [R][L]
K
’1 [R][L]
Dissociation constant (Kd) = ---  —   equation 3
K [RL]
The Kd may be calculated either directly from equilibrium 
saturation binding experiments or indirectly by 
determination of the rate constants K^ and
Direct measurement of Kd and receptor number (Bmax)
Another property of ligand-receptor interactions is 
saturability. The maximun number of specific receptor sites 
(Bmax) is represented by the equation:-
[RL] + [R] = Bmax equation 4
multiple by [L]
[RL][L] + [R][L] = Bmax[L]
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[RL][L] + ----[R][L] = Bmax[L]
[RL]
from equation 3
[RL]([L] + Kd) = Bmax[L]
Bmax[L] 
[L] + Kd
equation 5
Define:- [L] = free ligand concentration, F
[RL] = concentration of bound ligand, B 
then equation 5 can be written as
BmaxF
B  ------- e<
F + Kd
This is the hyperbolic relationship of equation 1
ax
y = b + x
shown graphically:-
y
at CO,y e Bmax
bound
radioligand
Bmax
2
JL
Kd0 radioligand concentration
Bmax
Kd = [L] leading to [B] = — ~~
Bmax is attained only at infinite [F]
The form of the Scatchard plot which is most frequently 
applied to the analysis of radioligand binding data is the 
plot of B/F on the ordinate versus B on the abscissa.
From equation 6
BF + BKd = BmaxF
Divide by F
B + B/FKd = Bmax
or
Bmax -B
B/F  ------- equation 7
Kd
y = mx + c B/F = -1/KdxB + Bmax/Kd
The Hill plot is another transformation of saturation 
binding data, which is often used to determine the nature 
of more complex ligand-receptor interactions. The Hill 
equation (equation 6) can be transformed into a logarithmic 
form for convenience in plotting.
BxKd + B[F]n = Bmax[F]n
n
BxKd = (Bmax -B)[F]
B n
 Kd = [F]
(Bmax-B)
B
(Bmax-B) 
Taking log of both sides
n
[F]
Kd
logB/(Bmax-B) = nlog[F]-logKd equation 8
A Hill plot is constructed where the y axis is 
logB/(Bmax-B) and the x axis is log [F]. The abscissa value 
when logB/(Bmax-B)=0 is the affinity. This only equals 
the Kd value when the slope of the Hill plot, nH, is equal 
to l. nH>l indicates positive cooperativity. nH<l 
indicates, negative cooperativity, multiple, non 
interacting binding site or multiple interconvertible
affinity states.
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As shown above, when bound radioactivity represents 
binding to a saturable receptor population, pocessing a 
single affinity, Kd, for the ligand, the plot of bound 
versus free will yield a rectangular hyperbola. 
Consequently the determination of the binding parameters, 
Kd and Bmax, is complex. Numerous methods have been 
developed for analysis of experimental data. They fall into 
three main categories, graphical, linear regression 
analyses of transformed data and direct analysis using non­
linear regression analyses.
Each of these methods has both its advantages and 
disadvantages. The graphical approach is highly predictive 
since most binding models are described in terms of their 
graphical appearance. However, this method of analysis is 
purely subjective with best fits been adjusted by eye and 
has no statistical basis. A second pseudo-graphical method 
is often employed in which data are transformed using a 
linearising transformation (eg Scatchard, 1949) thereby 
enabling a regression analysis by least squares to be 
performed, from which estimates of slope and intercept are 
easily obtained. This method also introduces a degree of 
statistical validity. The major disadvantage of these 
linear regression analyses on transformed data is that the 
transforms used are often prone to magnify errors (eg at 
very low concentrations of radioligand where accurate
determination of bound is difficult) . Insuffient saturation 
concentrations of free radioligand may lead to inaccuate 
extrapolation to determine Bmax. Because of the 
inequalities in variance of the measured varibles
complicated weighting functions often have to be 
introduced. For a linear transformation to mainfest a
single slope a single ligand must be interacting in a fully 
reversible manner with a homogeneous population of
non-interacting sites. Deviations from linearity occur when 
complex models of binding operate.
The use of non-linear regression analysis has proved 
highly sucessful when applied to the analysis of ligand 
binding data, having widespread applicability. This method 
can be used to analyse binding of one or more ligands to
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several species of interacting or non-interacting sites.
Affinity values for the receptor can also be determined
in competition studies. A plot of bound on the y axis
versus log [drug] on the x axis (a log scale is used as
saturability is easier to obtain for cold drugs) , can be
used to assess the the concentration of drug inhibiting
50% of the specific binding (IC ). As described above the 
. . 50
nH coefficient indicates the complexity of the reaction.
The equilibrium dissociation constant for the competitor
can be determined from the IC using the Cheng Prusoff
50
equation, if nH=l. (see data analysis section 2.1.1k).
Determination of association rate constant
From equation 1 it can be seen that the association of a 
ligand with a receptor is a second order (bimolecular) 
reaction. The simple rate equation for bimolecular 
association is
d[RL]
----- = Ka[L][R] 
dt
when intergrated
2.303 R[L-x]
Ka  ------log------ equation 9
t[L-R] L[R-x]
with' R and L equal to the unoccupied receptor and free
ligand respectively, at time t , and x is the amount of
consumed L and R at time t. Theor^lcally equation 9
enables the calculation of Ka for any bimolecular reaction
when L, R, and x are known. In practice bound ligand is
assayed at various time intervals up to the steady-state
level (B ) . Ln[B /(B -Bt)] is plotted versus time, where
B is the amount^ of specifically bound ligand at time t.
The slope of the line (K ) is calculated, from which K 
c obs 1
can be derived using equation 10.
However, estimation of K by this method requires 
knowledge of the dissociation rate constant.
Determination of dissociation rate constant
The half life (t ) for loss of specifically bound
radioligand is determined from a plot of log[B]/[B]
o
versus time, where [B] is the bound at any time t and
[B] is bound at time =0. The K is calculated 
o -1
as 0.693/t . Alternatively, the slope of log[B]
versus time multiplied by -2.303 yields K
When binding of L to R represents binding to a single 
class of receptors binding L in a reversible fashion with a 
fixed affinity, then it is expected that the Kd determined 
from saturation experiments should be equivalent to the Kd 
calculated from kinetic data.
-1
K min 
-1
Kd    = Molar
-1 -1 
K min M 
1
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